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Abstract 
Introduction: Individuals practicing unprotected receptive anal intercourse 
are at particularly high risk of HIV infection. Men who have sex with men in 
the developed and developing world continue to have disproportionate and 
increasing levels of HIV infection. The last few years have seen important 
progress in demonstrating the efficacy of oral pre-exposure prophylaxis, 
vaginal microbicides, and treatment as prevention but there has also been 
significant progress in the development of rectal microbicides. The purpose 
of this thesis is to summarise the status of rectal microbicide research, to 
identify opportunities, challenges, and future directions in this important field 
of HIV prevention, and to describe the results of a recently completed Phase 
1 rectal microbicide study (MTN-007). 
Methods: MTN-007, a Phase 1, randomised, partially blinded, rectal safety 
study was undertaken to determine whether a reduced glycerin formulation 
of tenofovir 1% gel was safe and acceptable to men and women with a 
history of practicing receptive anal intercourse. The study was conducted at 
three clinical trial sites in the United States (Pittsburgh, Pennsylvania; 
Boston, Massachusetts; and Birmingham, Alabama). Study participants were 
randomized to one of three gel arms (tenofovir gel, a hydroxyethyl cellulose 
placebo gel, or a 2% Nonoxynol gel) or a no treatment arm and received a 
total of eight rectal daily doses of the study product.  In addition to collecting 
conventional clinical safety and acceptability data, the study also included 
extensive mucosal safety assays to determine whether product 
administration was associated with changes in mucosal biology that might 
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predispose to increased risk of HIV acquisition associated with unprotected 
receptive anal intercourse.  
 
Results: Sixty-five participants (45 men and 20 women) were recruited into 
the study. There were no significant differences between the numbers of ≥ 
Grade 2 adverse events across the arms of the study. Likelihood of future 
product use (acceptability) was 87% (reduced glycerin formulation of 
tenofovir 1% gel), 93% (hydroxyethyl cellulose placebo gel), and 63% 
(Nonoxynol-9 gel). Fecal calprotectin, rectal microflora, and epithelial 
sloughing, did not differ by treatment arms during the study. Suggestive 
evidence of differences was seen in histology, mucosal gene expression, 
protein expression, and T cell phenotype. These changes were mostly 
confined to comparisons between the Nonoxynol-9 gel and other study 
arms. Microarray analysis of the mucosal transcriptome provided preliminary 
evidence that topical application of tenofovir 1% gel was associated with 
decreased mitochondrial function within the rectal mucosa. 
 
Conclusions: The MTN-007 study demonstrated that, using conventional 
criteria, tenofovir gel is safe and acceptable and should be advanced to 
Phase 2 development as a potential rectal microbicide. However, microarray 
analysis of mucosal tissue suggested that use of tenofovir gel may modulate 
mucosal mitochondrial function. This observation will require further 
evaluation in future studies.  
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Rectal Microbicide Development 
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1 Rectal microbicide development 
1.1 Introduction 
The first cases of human immunodeficiency virus (HIV) infection / acquired 
immunodeficiency syndrome (AIDS) were recognised in 1981 among men 
who have sex with men (MSM) living in North American urban centres 
including New York, Los Angeles, and San Francisco (1981). Subsequently, 
cases of AIDS were recognized in Sub-Saharan Africa (Serwadda et al., 
1985) and the global HIV pandemic began to gather momentum. Over the 
last three decades the global epidemiology of HIV/AIDS has evolved. 
Incidence rates in certain populations have stabilized or even fallen. 
However, as can be seen in Figure 1-1, the number of new HIV diagnoses in 
men who have sex with men (MSM) in the United Kingdom (UK) appears to 
be stable or possibly increasing. Similar trends in HIV infection have been 
reported among MSM in most countries where data are available (Beyrer et 
al., 2010; Beyrer et al., 2012). A recent development is the recognition that 
populations of MSM with high incidence and prevalence of HIV infection can 
be found in most Sub-Saharan countries (Baral et al., 2009). The failure to 
decrease contemporary rates of HIV infection in MSM has many possible 
explanations. Unprotected receptive anal intercourse (URAI) between 
serodiscordant partners is the most efficient way to transmit HIV infection. 
The per contact probability of acquiring HIV infection from URAI has been 
estimated to be 1.4% (Jin et al., 2010; Baggaley, White, & Boily, 2010) which 
is approximately 18-fold higher than the risk associated with unprotected 
penile-vaginal intercourse (Boily et al., 2009). Unfortunately, a significant 
proportion of MSM are unwilling or unable to use condoms consistently 
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(Boily et al., 2009; Varghese, Maher, Peterman, Branson, & Steketee, 2002). 
However, these estimates are quite variable due to the factors discussed 
above (Baggaley et al., 2010). 
 
The gastrointestinal tract is a rich source of HIV-1 target cells. Isolated 
lymphoid follicles, which serve as inductive sites for immune responses, are 
located throughout the colon (Koboziev, Karlsson, & Grisham, 2010). The 
number of follicles generally increases toward the anus with the greatest 
numbers found in the rectum (Langman & Rowland, 1986; Langman & 
Rowland, 1992). Antigen presenting cells (macrophage and dendritic cells) 
along with effector and regulatory T cells are found within the follicles. These 
cells are generally activated and express HIV-1 co-receptors, CCR5 and 
CXCR4, as well as soluble immune mediators (Anton et al., 2000; Poles, 
Elliott, Taing, Anton, & Chen, 2001; Zhang et al., 1998; McGowan et al., 
2004) thus creating the perfect environment primed for HIV-1 infection.  
 
HIV-1 can reach these activated immune cells in several ways. While micro-
tears in the epithelium can occur during coitus, the envelope of HIV-1, 
gp120, has been shown to increase the permeability of the epithelium 
allowing HIV-1 enhanced access to the lamina propria (Nazli et al., 2010). 
Even with an intact mucosa, epithelial cells can bind and transfer HIV-1 
either through active transport, transcytosis (Bomsel, 1997), or non-
specifically (Dezzutti et al., 2001; Meng et al., 2002; Wu, Chen, & Phillips, 
2003). Finally, dendritic cells extend dendrites through the tight-junctions of 
the epithelium to sample the luminal environment (Rescigno et al., 2001). 
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HIV-1 can take advantage of this by binding to Dendritic Cell-Specific 
Intercellular adhesion molecule-3-Grabbing Non-integrin (DC-SIGN) and 
subsequently infect activated lymphocytes (Gurney et al., 2005). Once past 
the epithelium, HIV-1 preferentially infects local lymphocytes expressing 
CCR5 (Anton et al., 2000; Meng et al., 2000). Cell-free and cell-associated 
virus are both present in the ejaculate and so it is still not clear which form of 
the virus is responsible for initiating mucosal infection (Anderson et al., 
2010). However, recent sequence analysis of viral RNA and integrated 
proviral DNA suggests that cell-free virus contributes the most to mucosal 
transmission (Butler et al., 2010). These early infection events are known to 
initiate from a single founder virus in heterosexual transmission (Keele et al., 
2008; Sagar et al., 2009), but RAI is associated with a more diverse founder 
virus population (Li et al., 2010) likely due to direct access to underlying 
immune cells. This information suggests that an ideal rectal microbicide 
should protect the epithelium and be active against a swarm of viruses. 
 
Ribeiro dos Santos et al. have reported the results of a non-human primate 
(NHP) rectal challenge study in which they used a combination of 
immunohistochemistry, laser capture microdissection, and a suite of 
molecular techniques to characterize the virological events that occurred 
after rectal challenge with SIVmac231 in rhesus macaques (Ribeiro Dos et 
al., 2011). The macaques were sacrificed at four, sixteen, and twenty four 
hours and two, three, and four days following rectal challenge with 7.31 log 
copies / mL of viral RNA. A key finding from the study was the demonstration 
that by four hours SIV could be identified in the rectal mucosal, and perhaps 
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more importantly, could also be found in the para-colic lymph nodes. The 
authors commented that this process of viral dissemination is faster than that 
seen with oral and vaginal NHP challenge studies. These findings clearly 
have implications for microbicide and vaccine development. A successful 
rectal microbicide will have to prevent this early viral dissemination and a 
vaccine would have to induce protective immunity both within the rectal 
mucosa and the draining lymph nodes. 
1.3 Pre-exposure prophylaxis of HIV infection 
In 2010 Grant et al. reported the results of the iPrEx trial that demonstrated 
that oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate 
(TDF)/emtricitabine (FTC) (Truvada®, Gilead Sciences Inc., Foster City, 
California, USA) by MSM and transgender women was associated with a 
44% reduction (95% confidence interval (CI), 15 to 63; P = 0.005) in the 
incidence of HIV infection (Grant et al., 2010). This important study clearly 
identified the potential promise of oral PrEP for HIV prevention but also 
identified a key challenge; among the participants randomized to receive 
Truvada, drug was detected in 3 of 34 participants with HIV infection (9%) 
and 22 of 43 seronegative controls (51%). Ideally, drug would have been 
detected in all the participants randomized to receive Truvada and these 
data suggest that in this study adherence to oral Truvada was suboptimal. 
The iPrEx open label extension or iPrEx OLE study will provide important 
data as to whether adherence patterns improve when study participants 
know that they are receiving active drug. Meanwhile other modalities of HIV 
prevention including rectal microbicides are being explored for individuals at 
risk of HIV infection associated with URAI.  
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1.4 Microbicides 
Microbicides are topical products that are designed to be applied to the 
vaginal or rectal mucosa with the intent of preventing, or at least significantly 
reducing, the acquisition of sexually transmitted infections (STIs) including 
HIV (McGowan, 2010). The original impetus for vaginal microbicide 
development was to provide women with options for HIV prevention in 
settings where their partners were unwilling or unable to use condoms. In 
1990, Zena Stein proposed the development of a “topical virucide” whose 
desirable properties would include the product being non-irritant, non-toxic, 
low-priced, and efficacious (Stein, 1990). Microbicides have been formulated 
as gels, creams, intravaginal rings, films, and fast dissolving tablets (Rohan 
& Sassi, 2009; Garg et al., 2010) (Figure 1-2). 
 
Figure 1-2 Microbicide formulations 
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Vaginal microbicides that have been evaluated in clinical trials can be 
categorized by their primary mechanism of action (Figure 1-3) and are 
discussed below. 
1.4.1 Vaginal defense enhancers 
The vaginal flora has evolved to provide a hostile environment for potential 
pathogens such as STIs, including HIV. A key feature of this environment is 
the capacity of resident lactobacilli to maintain an acidic pH. Unfortunately, in 
conditions such as bacterial vaginosis, lactobacilli diminish, vaginal pH rises, 
and these changes appear to result in increased susceptibility to acquisition 
of HIV infection (Myer et al., 2005). A more transient vulnerability occurs 
when seminal fluid, which has an alkaline pH, is deposited in the vagina. To 
circumvent these problems, microbicides were developed that could 
maintain an acidic pH (BufferGel and Acidform) or that delivered 
lactobacilli genetically modified to release antiviral peptides such as 
cyanovirin (Mayer et al., 2001; van de Wijgert et al., 2001; Amaral et al., 
2006; Liu et al., 2006). 
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Figure 1-3 Mechanism of action for microbicide candidates 
 
McGowan, I Biologicals 2006 (McGowan, 2006) 
1.4.2 Surfactants 
Surfactants such as nonoxynol-9 (N9) were some of the first microbicides to 
be evaluated in human studies (Stafford et al., 1998). They were cheap, 
readily available, and in the case of N9 had a long history of use as 
spermicidal agents. Other surfactant microbicides evaluated in clinical trials 
included C31G (Savvy™) (Corner, Dolan, Yankell, & Malamud, 1988; 
Ballagh, Baker, Henry, & Archer, 2002), and sodium lauryl sulphate (Trottier 
et al., 2007; Omar et al., 2008) However, surfactant microbicides are 
detergents and their mechanism of action is through disruption of cell 
membranes (Hillier et al., 2005). Unfortunately, they do not discriminate 
between mammalian and viral membranes, which led to significant toxicity 
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issues and effectively stopped the clinical development of N9 as a vaginal 
microbicide.  
1.4.3 Entry/fusion inhibitors 
At a cellular level, HIV transmission follows an orderly process. The three 
steps required for cell infection are (i) attachment of virus to host cells, (ii) 
interaction of virus with receptors and co-receptors, and (iii) fusion of virus 
and host cell membranes (Shattock & Moore, 2003).  
 
First generation anionic polymer fusion inhibitors worked by interfering with 
the binding of the HIV-1 V3 loop of gp120 to the CD4 receptor. Examples 
that have been evaluated in clinical trials include PRO-2000 (Mayer et al., 
2003), dextrin sulphate (Low-Beer et al., 2002), cellulose sulfate (Malonza et 
al., 2005), Carraguard® (van de Wijgert et al., 2007), cellulose acetate 
phthalate (Lacey et al., 2010), and SPL7013 (VivaGel®) (O'Loughlin et al., 
2010; McGowan et al., 2011).  Small molecule agents that target the CC 
chemokine receptor type 5 (CCR5) HIV co-receptor have been developed 
and licensed for the treatment of chronic HIV infection (Maraviroc) and are 
being evaluated as candidate microbicides including an intravaginal ring 
(MTN-013; http://clinicaltrials.gov/: NCT01363037).  PSC-RANTES is a 
synthetic CCR5 antagonist that has shown efficacy in an non-human primate 
vaginal challenge model (Lederman et al., 2004) and additional analogues 
have also shown efficacy in the NHP model (Veazey et al., 2009).  
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1.4.4 Replication inhibitors 
Reverse transcriptase (RT) inhibitors provide the cornerstone of antiretroviral 
(ARV) regimens for the treatment of chronic HIV infection.   
 
ARV microbicides act by inhibiting HIV-1 viral RT, a critical enzyme needed 
to convert viral RNA into DNA before integration into the host genome. In the 
presence of RT inhibitors this process is suppressed resulting in quantitative 
reductions in viral replication. ARVs are also being evaluated for oral and 
topical HIV-1 prevention.  ARV microbicides that have been evaluated in 
clinical trials include tenofovir (TFV), UC781, and dapivirine (TMC-120).  
1.4.4.1 Tenofovir  
TFV (Gilead Sciences Inc., Foster City, CA, USA) is an adenosine 
nucleoside monophosphate (nucleotide) analog belonging to the class of 
acyclic phosphonomethylether nucleosides. The prodrug of TFV (Tenofovir 
disoproxil fumarate; TDF) is licensed for the treatment of chronic HIV 
infection (Viread®). Activation of TFV is dependent upon anabolic 
phosphorylation by intracellular nucleoside kinases, whose activity and 
availability are dependent upon the activation state of the cell. Consequently, 
it is unknown how long it will take lymphocytes, dendritic cells, and 
monocyte/macrophages in mucosal surfaces to convert TFV to its active 
diphosphorylated antiviral metabolite.   It is possible that the absolute rate of 
TFV activation will depend upon a wide range of factors including the 
presence or absence of mucosal inflammation.  
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1.4.4.2 UC781 
UC781 is a thiocarboxanilide non-nucleoside RT inhibitor (NNRTI) that was 
being developed as both a vaginal and rectal microbicide (Bunge et al., 
2012; Anton et al., 2011). UC781 has reduced activity against NNRTI 
resistant HIV-1 (Hossain & Parniak, 2006) but remains active at 
concentrations of 25 M, which is above the levels delivered by current 
UC781 formulations. Combinations of cellulose acetate 1,2-
benzenedicarboxylate (CAP) and UC781 have been shown to provide 
synergistic inhibition of HIV replication (Liu, Lu, Neurath, & Jiang, 2005). 
Preclinical evaluation of UC781 was unremarkable (Balzarini et al., 1998), 
and explant studies have demonstrated inhibition of HIV-1 replication and 
prevention of migration of infected cells from cervical explant tissue (Fletcher 
et al., 2005). Unfortunately, the clinical development of UC781 as a 
microbicide was suspended in 2010 despite supportive safety data from 
completed Phase 1 studies. 
1.4.4.3 Dapivirine 
TMC-120 is a diarylpyrimidine NNRTI with high activity against wild type and 
mutant HIV (Van et al., 2004). Prevention of vaginal transmission of HIV-1 
has been demonstrated in a humanized severe combined immunodeficient 
mouse model using TMC-120 gel (Di Fabio et al., 2001; Di Fabio et al., 
2003). The International Partnership for Microbicides (IPM) is currently 
developing TMC-120 as a microbicide. Initial Phase 1 studies used a gel 
formulation but IPM is now focusing on the development of a silicone 
elastomer slow release vaginal ring, which offers the possibility of once 
monthly application (Malcolm, Woolfson, Toner, Morrow, & McCullagh, 2005; 
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Woolfson, Malcolm, Morrow, Toner, & McCullagh, 2006). This approach 
would provide women with another non-coitally dependent method of HIV-1 
prevention. Two Phase 3 intravaginal ring studies (MTN-020 and IPM-027) 
are currently enrolling in Sub-Saharan Africa. 
 
The advantages of the RT inhibitor class of microbicides include: (i) there 
are several products available, (ii) the cost of production is likely to 
reasonable, (iii) there is extensive proof of concept animal model studies 
suggesting efficacy, and (iv) RT inhibitor microbicides could be used in a 
non-coitally dependent fashion.  
 
The primary disadvantage for ARV microbicides or indeed any form of ARV 
PrEP is the concern that their use might result in the emergence of ARV 
resistance (Hurt, Eron, Jr., & Cohen, 2011). This could happen in two 
situations. Women or men who are unaware of their HIV-1 status might use 
product for prolonged periods of time. The combination of repeated low dose 
exposure to an RT inhibitor in an individual with untreated HIV-1 infection 
might lead to the evolution of viral resistance. A second scenario would be 
an individual who seroconverts whilst receiving PrEP. This would be a 
particular problem if the individual were using a slow release formulation 
device such as an ARV intravaginal ring (Malcolm et al., 2005) or parenteral 
long acting ARV injection (Baert et al., 2009). In both cases it has been 
argued that the limited systemic absorption of RT inhibitors after mucosal 
application minimizes the risk of viral resistance. To date, only 3 cases of 
ARV resistance have occurred among 80 seroconverters on PrEP trials and 
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these all occurred in participants with unrecognised acute HIV infection at 
the time of enrollment into their respective trials (Parikh & Mellors, 2012). In 
contrast, a recent study from KwaZulu-Natal demonstrated that 95% of 
treatment naïve patients with HIV infection starting first line combination 
ARV therapy, who do not fully suppress their viral infection, will develop ARV 
resistance (Singh et al., 2011). The magnitude of PrEP-associated ARV 
resistance will only be quantifiable when PrEP programs are rolled out at a 
community level. As of yet, all the data available have been generated within 
clinical trials where participants are closely monitored with frequent HIV 
testing.  
 
Over the last two decades a broad range of products have been evaluated 
as vaginal microbicides. With the exception of N9 gel, the majority of 
microbicide candidates were found to be safe and acceptable in Phase 1/2 
studies and many were also shown to be effective when evaluated in animal 
models of HIV infection (McGowan, 2006; Minces & McGowan, 2010).  
Unfortunately when these products were studied in Phase 2B/3 
effectiveness trials they proved to be either safe but ineffective 
(Carraguard®, C31G (SAVVY), BufferGel®, and PRO-2000 (Skoler-Karpoff 
et al., 2008; Peterson et al., 2007; Feldblum et al., 2008; Abdool Karim et al., 
2011; McCormack et al., 2010) or they may have actually increased the risk 
of HIV infection (N9 and cellulose sulphate) (Van Damme et al., 2002; Van 
et al., 2008).  
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In 2010, Quarraisha and Salim Abdool Karim presented the results of the 
Center for the AIDS Programme of Research in South Africa (CAPRISA) 004 
study (http://clinicaltrials.gov/: NCT00441298) that evaluated the safety and 
efficacy of TFV 1% gel in preventing HIV infection in 889 women in Kwazulu-
Natal, South Africa (Abdool et al., 2010). Product was administered in a 
pericoital fashion. Women were requested to insert one dose of gel within 12 
hours before sex and a second dose with 12 hours after sex and no more 
than two doses of gel in a 24-hour period. The authors coined the term 
“BAT24” to describe this pattern of pericoital microbicide dosing. The 
CAPRISA 004 study demonstrated that the incidence of HIV infection in 
women randomised to receive TFV gel was reduced by 39% (95% CI, 6 to 
60; P=0.017) compared to women receiving a placebo gel. Product 
effectiveness was increased to 54% in women with high product adherence 
(defined as >80% use based on returned applicator counts). In addition, 
product effectiveness was also related to the concentration of TFV in the 
genital tract; women with TFV concentrations greater than 1,000 ng/mL had 
a significantly lower HIV incidence rate than the placebo recipients (2.4 vs. 
9.1 per 100 person years; incidence rate ratio (IRR) = 0.26, 95% CI 0.05-
0.80, P = 0.01) and there was no difference in incidence rates between 
women receiving placebo gel and women with  less than 1,000 ng/mL of 
TFV, IRR = 0.86, 95% CI 0.54-1.35, P = 0.51) (Karim, Kashuba, Werner, & 
Karim, 2011).  
 
CAPRISA 004 was clearly a landmark study within HIV prevention research 
and defined several unique microbicide attributes; (i) it demonstrated that 
44 
 
pericoital use of a topical ARV microbicide could reduce the rate of HIV 
acquisition in women at significant risk of infection, (ii) product effectiveness 
was linked to both adherence and product concentration within the genital 
tract, and (iii) subsequent mathematical modeling suggested that use of TFV 
gel by women in South Africa was a cost-effective strategy for HIV 
prevention (Williams, Abdool Karim, Karim, & Gouws, 2011).  
 
In contrast, a second PrEP effectiveness study evaluating both oral and 
topical TFV has generated divergent results. The Microbicide Trials Network 
(MTN)-003 or Vaginal and Oral Interventions to Control the Epidemic 
(VOICE) study (http://clinicaltrials.gov/: NCT00705679) enrolled 
approximately 5,000 women who were randomised to receive TFV gel, 
placebo gel, TDF, TDF/emtricitabine (FTC), or placebo tablet. A Data and 
Safety Monitoring Board (DSMB) review of the study took place in 
November, 2011 and included data for the period between September 2009, 
when the study began, and September 2011. Based on this review, the 
DSMB recommended that VOICE discontinue the TFV gel and placebo gel 
arms, because there was no difference in effect between them in preventing 
HIV infection (MTN, 2012). The HIV incidence rates in the two groups were 
nearly identical, with a 6.1 percent incidence rate in the placebo gel group 
and 6.0 percent in the TFV gel group. A number of hypotheses could explain 
the negative results in the VOICE study. These include poor product 
adherence, inadequate genital tract drug concentrations, and the possibility 
that daily, but not pericoital, use of TFV gel may induce mucosal changes 
that diminish product effectiveness and/or increase the risk of HIV 
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acquisition (Kashuba, Patterson, Dumond, & Cohen, 2011; van der Straten, 
Van Damme, Haberer, & Bangsberg, 2012; Hendrix, 2012). Marrazzo et al. 
presented unblinded data from the VOICE trial at the 2013 Conference on 
Retroviruses and Opportunistic Infections in Atlanta, Georgia, USA. 
Unfortunately, the most likely explanation for the failure to demonstrate 
product effectiveness in the VOICE study was the fact that the majority of 
women in all of the study arms did not use the study products (Marrazzo et 
al., 2013). 
 
A third effectiveness study of TFV gel is currently ongoing. The Follow-on 
African Consortium for Tenofovir Studies (FACTS) 001 study 
(http://clinicaltrials.gov/: NCT00705679) is evaluating the safety and 
effectiveness of TFV gel administered using the BAT24 regimen that was 
successful in the CAPRISA 004 study. The FACTS 001 study plans to enroll 
approximately 2,900 women in South Africa and hopes to be completed in 
2015.  
 
The recent, and ongoing, effectiveness studies of TFV gel have been 
presented in some detail because they have important implications for rectal 
microbicide development. It is obvious that a microbicide product, whether 
intended for vaginal or rectal use, will not work unless adequate quantities of 
the microbicide are used by individuals hoping to reduce their risk of HIV 
infection. It is also assumed that a successful microbicide will have to deliver 
the right amount of drug, in the right place, at the right time, and that 
therapeutic drug concentrations will persist beyond the period of viral 
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exposure (Hendrix, 2012). Unfortunately, it is not entirely clear what quantity 
of microbicide product or active pharmaceutical ingredient (API) is needed to 
achieve this goal. The quantity may differ by compartment (vaginal vs. 
rectal) and/or drug class. Recent Phase 1 microbicide trials (described in 
Chapter 2) are beginning to generate compartmental pharmacokinetic (PK) 
and pharmacodynamic (PD) data that may help define target drug 
concentrations prior to embarking on large and expensive microbicide 
effectiveness trials.  
1.5 Rationale for rectal microbicide development 
The rationale for the development of rectal microbicides is based upon 
several criteria; (i) despite almost three decades of health education and 
widespread availability of condoms significant proportions of MSM and other 
populations continue to practice URAI, (ii) the majority of individuals 
practicing RAI use some form of sexual lubricant and so a microbicide that 
had lubricant like properties would not require the type of behavioral 
modification associated with other forms of HIV prevention, (iii) several 
studies have documented interest in developing, evaluating, and the 
potential use of rectal microbicides by MSM, (iv) preclinical evaluation of 
candidate microbicides have shown protection in colorectal explant 
challenge studies, (v) rectal microbicides have also been shown to be 
efficacious in non-human primate (NHP) rectal challenge studies, and (v) 
rectal microbicides have been shown to be efficacious in Phase 1 clinical 
trials that have conducted ex vivo / in vitro colorectal explant challenge 
experiments. These criteria are discussed in more detail below. 
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1.5.1 Introduction 
As early as 1996, Carballo-Dieguéz and Dolezal had determined that Puerto 
Rican MSM living in New York were using condoms inconsistently for anal 
sex and suggested that a safe and effective microbicidal gel that could be 
used rectally would be an important component of a HIV prevention strategy 
for MSM (Carballo-Dieguez & Dolezal, 1996). The first rectal microbicide 
study, the HIV Network for Prevention Trials (HIVNET)-008 study, evaluated 
the safety of N9 gel, and started enrollment in August 1996 (Tabet et al., 
1999; Gross et al., 1999).  In 1998, Gross et al. reported the results of a 
large survey that interviewed 3,257 MSM from six cities in the United States 
(US); Boston, Chicago, Denver, New York, San Francisco, and Seattle. The 
majority of the participants used lubricants for anal sex and approximately 
two thirds stated that they were willing to participate in rectal microbicide 
clinical trials (Gross, Buchbinder, Celum, Heagerty, & Seage, III, 1998). 
About this time community advocates began to become more involved in 
raising awareness about microbicide research in general and rectal 
microbicide development in particular (Scarce, 1999; Forbes & Harrison, 
1999). In 2001, The American Foundation for AIDS Research (amfAR) 
convened a two day meeting in Baltimore, Maryland, USA to help develop a 
research and development agenda for rectal microbicides (amfAR, 2001). 
The remit of the conference was broad and the meeting included 
discussions on the prevalence and risks of anal intercourse, the anatomy, 
physiology, and immunology of the anorectal mucosa, the HIVNET-008 
study, microbicide formulation considerations, and consumer preference.  In 
the subsequent five years several studies took place that explored rectal 
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microbicide formulation preferences (gels, suppositories, and douches) from 
a theoretical (Carballo-Dieguez, Bauermeister, Ventuneac, Dolezal, & 
Mayer, 2010) and practical perspective (Carballo-Dieguez et al., 2007; 
Carballo-Dieguez et al., 2008). An additional study, the HIV Prevention Trials 
Network (HPTN)-056 protocol investigated the stability of rectal mucosal 
safety parameters that might be measured in future Phase 1 rectal 
microbicide studies (McGowan et al., 2007).  
1.5.2 Prevalence of anal sex in various populations 
Anal sex is a relatively common practice among MSM although prevalence 
rates are highly variable depending on the population studied. In a recent 
study from Rosenberger et al. that characterized sexual behavior in 24,787 
gay and bisexually identified US men, anal sex was reported by 37.2% of the 
respondents (Rosenberger et al., 2011). In contrast, in a smaller study from 
California 303/398 (76%) of MSM reported anal sex within the previous 12 
months (Xia et al., 2006). Unfortunately, a significant proportion of anal sex 
occurs without the use of condoms. The prevalence of URAI varies by the 
population studied but rates of greater than 30% are commonly reported 
from US and United Kingdom (UK) MSM (Xia et al., 2006; Lattimore, 
Thornton, Delpech, & Elford, 2011). Similar patterns of behaviour have been 
reported for MSM across the world (Beyrer et al., 2012).   This includes Sub-
Saharan Africa where recent studies have documented the presence of 
MSM in most African countries; these MSM have high rates of HIV infection 
and little or no access to basic HIV prevention services including the 
provision of condoms (Baral et al., 2009; Beyrer et al., 2010; Arnold, 
Struthers, McIntyre, & Lane, 2012). 
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There is increasing recognition that anal sex is also practiced by 
heterosexual couples. The National Survey of Sexual Health and Behavior 
(NSSHB) is a study of human sexual behavior conducted in the US by the 
Center for Sexual Health Promotion at Indiana University in Bloomington. 
The study enrolled 5,865 men and women aged 14-94 in the US. More than 
20% of men ages 25-49 years and women ages 20-39 years reported anal 
sex in the last year. More than 40% of both men and women reported a 
lifetime experience of insertive or receptive anal intercourse (Herbenick et 
al., 2010).  
 
Within the UK, the National Surveys of Sexual Attitudes and Lifestyles 
(Natsal) study has been documenting UK sexual behavior since 1990. In the 
most recent report (Natsal-3), interviews were completed with 15, 162 
participants. The Natsal-3 survey found that the heterosexual repertoire had 
increased since the Natsal-2 survey. Overall, 13.4% of men and 10.5% of 
women had experienced heterosexual anal intercourse in the previous year 
and 40% of participants born after 1966 had a lifetime experience of anal 
sex (Mercer et al., 2013). 
 
A number of US studies have described linkages between URAI in young 
women and STIs as well as illicit drug use (Risser, Padgett, Wolverton, & 
Risser, 2009; Gorbach et al., 2009). It is also apparent that women in the 
developing world are at risk of HIV infection through URAI as well as vaginal 
sex (Kalichman, Simbayi, Cain, & Jooste, 2009).  
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This brief survey of the epidemiology of anal sex suggests that this practice 
is common among men and women in both the developed and developing 
world. A significant proportion of anal sex is also unprotected. A safe and 
effective rectal microbicide would therefore be a valuable addition to the HIV 
prevention options available to individuals at risk of HIV infection through 
URAI. 
1.5.3 Sexual lubricant use 
Although sexual lubricants are not intended to prevent HIV infection their use 
does provide a rationale for the development of similar microbicides that do 
have the potential to prevent HIV infection. As discussed below, lubricant 
use is a common practice among men and women and products have been 
used with vaginal and anal intercourse. However, some lubricants have the 
potential to cause mucosal disruption and potentially increased vulnerability 
to HIV infection. Lessons learned from the assessment of lubricant safety 
and acceptability can help focus the development of safe, acceptable, and 
effective rectal microbicides. 
1.5.3.1 Sexual lubricant use by women 
Sexual lubricant use is a relatively common practice among women in the 
developed world. Products are used for a variety of reasons including 
managing vaginal dryness or dyspareunia or for enhancement of sexual 
pleasure (Sutton, Boyer, Goldfinger, Ezer, & Pukall, 2012; Herbenick et al., 
2011). Herbenick et al. conducted a survey of 2,056 US women of whom 
62% had ever used a sexual lubricant and 25.3% had used a lubricant within 
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the last month (Herbenick et al., 2010). Data on lubricant used by women in 
the developing world are more complex.  There are strong cultural norms 
about the desirability of vaginal dryness or lubrication. Braunstein and Van 
de Wijgert undertook a literature review and key informant interview process 
that suggested that women from countries such as India, Kenya, South 
Africa, Thailand and Zimbabwe are concerned about excess lubrication 
whereas women from Brazil and the US were more concerned about vaginal 
dryness (Braunstein & van de Wijgert, 2005). In a recent study where 
women were provided with a range of sexual lubricants and asked to 
complete an internet based survey it was apparent that the products were 
used for both vaginal and anal sex (Herbenick et al., 2011). In a more 
detailed study, Exner et al. conducted in-depth interviews with 28 women 
who had a history of RAI. Key findings included (i) condom use for anal sex 
was rare; 23 of the 28 women reported no condom use during the last 
episode of RAI and (ii) slightly less than half the women used a sexual 
lubricant; the reminder used saliva and/or vaginal fluid to facilitate RAI 
(Exner et al., 2008). These findings support the concept of developing dual 
compartment microbicides. 
1.5.3.2 Sexual lubricant use by MSM 
Carballo-Dieguéz et al. conducted a survey of rectal lubricant use among 
307 Latino MSM in New York during 1995/1996. The majority of study 
participants (94%) had experience of using lubricants with RAI and 74% 
used a lubricant during at least 80% of all episodes of RAI. The study also 
demonstrated high rates of URAI (43%) with a willingness to use rectal 
microbicides if available (92%) (Carballo-Dieguez et al., 2000). A second 
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larger study conducted among 879 MSM living in San Francisco in 
2002/2003 demonstrated high levels of URAI (36%), high levels of lubricant 
use (89%), including significant use of N9 containing products (26%) 
(Carballo-Dieguez et al., 2007). The study documented variability in 
microbicide acceptability based on the perceived level of protection afforded 
by microbicides. Whereas 65% of men would consider using a rectal 
microbicide if it was as effective as a condom, only 15% would consider 
using a microbicide if it was less effective than a condom. More recently, 
Clark et al. conducted a quantitative behavioral survey among 547 MSM 
from Lima, Peru (Clark et al., 2013). Approximately 50% of the men reported 
lubricant use with RAI; reasons for non-use included: no lubricant available 
(32%), used pre-lubricated condoms (24%), used saliva as a lubricant 
(13%), or could not afford to buy lubricant (8%). URAI was common among 
men using lubricants (63%). In a second recent study from Latin America, 
Kinsler et al. used Conjoint Analysis (CJA) to explore consumer preferences 
for potential rectal microbicides among 128 MSM in Peru, Ecuador, and 
Brazil (Kinsler et al., 2012). Parameters used in the CJA included: cost 
($0.30 vs. $5.00), effectiveness (40% vs. 80%), side effects (none vs. 
some), dosing (before sex vs. daily), formulation (gel vs. liquid), dosage (15 
vs. 35 mL), and availability (prescription vs. over the counter (OTC)).  The 
favored product profile was a microbicide that was; $0.30, 80% effective, no 
side effects, use before sex, gel formulation, 15 mL dosage, and provided 
through a prescription. Although CJA does not involve consumers trying 
products it does provide an important framework for an ideal product. In this 
analysis, effectiveness had the greatest impact on product acceptability; 
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participants chose 80% rather than 40% (the level of protection seen in the 
CAPRISA 004 study (Abdool et al., 2010)) and price was also significant - 
$0.30 representing the approximate cost of a condom in Peru, Ecuador, or 
Lima. 
1.5.3.3 Sexual lubricants and their potential for mucosal damage 
In 2007, sexual lubricant sales in the US totaled more than $110 million 
(Andelloux, 2011). Currently within the US, lubricants are regulated as 
medical devices and therefore do not require the extensive preclinical and 
clinical testing required for drugs. Although there are a very large number of 
lubricants marketed in the US they can be broken down into a number of 
categories (Table 1.1). 
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Table 1-1 Categories of sexual lubricants 
Category Examples Comments 
   
Petroleum-based Petroleum jelly (Vaseline®) 
Mineral oil 
Massage oil 
Compatible with 
polyurethane but not latex 
condoms 
   
Natural oil Vegetable oil 
Olive oil 
Coconut oil 
Crisco® 
Compatible with 
polyurethane but not latex 
condoms 
   
Water-based Astroglide® 
KY jelly® 
Wet® 
Liquid silk® 
Slippery stuff® 
Most commonly used 
lubricants 
   
Silicone-based Eros® 
Wet Platinum® 
Gun oil® 
 
Hypoallergenic and condom 
compatible. Provides 
lubrication for longer than 
water-based lubricants 
   
 
Several studies have been conducted to evaluate lubricant safety. Sudol et 
al. evaluated a number of OTC lubricants including KY-Plus (containing N9) 
in a mouse model wherein the mice received the test formulation followed by 
challenge with HSV-2 (Sudol & Phillips, 2004). In addition, mice also 
underwent rectal lavage, following product exposure, to determine whether 
formulations had the potential to cause rectal sloughing of epithelial cells. 
Use of KY-Plus was associated with significant cellular toxicity, 
enhancement of rectal HSV-2 infection, and rectal sloughing. Other, non-
surfactant products such as Astroglide also increased HSV-2 infection and 
55 
 
rectal sloughing. Astroglide is known to be a hypersomolar gel (8,064 
mOsm/kg; (Begay et al., 2011)) and in a subsequent study conducted in 
healthy volunteers, the use of hyperosmolar gels, including Astroglide, was 
associated with significant mucosal injury (Fuchs et al., 2007). Begay et al. 
evaluated a total of 41 lubricants for their osmolality, potential cytotoxicity 
(using an XTT assay), and antiviral activity against HIV (using TZM-bl cell 
lines and CXCR4 and CCR5 tropic HIV) (Begay et al., 2011). Product 
osmolality varied from 15 (FemGlide™) to 9,177 (ForPlay® Gel Plus) 
mOsm/Kg. None of the products inhibited HIV infection but four products (all 
Astroglide derivatives with high osmolality) significantly enhanced HIV 
replication. Dezzutti et al. recently published data on OTC lubricant safety 
using ectocervical and colorectal explant tissues (Dezzutti et al., 2012). All of 
the hyperosmolar gels were associated with cellular toxicity and epithelial 
damage and did not appear to have any antiviral activity (Table 1.2).The two 
iso-osmolar products (Good Clean Love and PRÉ) as well as the two 
silicone-based products (Female Condom 2 lubricant and Wet Platinum) 
were found to be safe in the testing algorithm. 
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Table 1-2 Physical characteristics of OTC lubricants 
Lubricant Osmolality
(mOsm/kg) 
pH CC50 ED50 Therapeutic 
Index 
      
Aqueous-based     
      
 Astroglide 6,113 4.0 0.9 0.8 1 
 Elbow Grease 3,865 5.7 5.7 0.4 14 
 Good Clean Love 269 4.8 >1,000 0.6 >1,000 
 Gynol II 1,406 4.7 0.4 0.1 4 
 ID Glide Ultra 3,150 5.2 4.8 0.8 6 
 KY Jelly 2,510 4.5 11.8 5 2 
 PRÉ 502 7.3 308 4.4 70 
 Replens 1,875 2.9 19.8 0.5 40 
 Slippery stuff 26 6.8 > 1,000 26 >40 
 Sliquid Organic 106 6.8 3.0 3.9 0.8 
      
Lipid-based      
      
 Boy Butter H2O 1,307 7.4 ND ND ND 
 Boy Butter original NA NA ND ND ND 
      
Silicone based      
      
 FC 2 lubricant NA NA ND ND ND 
 Wet Platinum NA NA ND ND ND 
      
Adapted from Dezzutti et al. (Dezzutti et al., 2012); ND: Not determined; NA: Not applicable 
 
An important, but as yet unanswered, question is whether the use of 
currently available lubricants could be harmful and/or increase the risk of 
HIV infection associated with URAI. It is known that the frequent use of an 
N9-based vaginal microbicide was associated with an increase in HIV 
acquisition in the COL1492 study (Van et al., 2002) but, with the exception of 
some spermicidal products, N9 is no longer used in sexual lubricants. 
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However, Gorbach et al. have suggested that consistent rectal use of 
lubricants (defined as use of a lubricant in the prior month) was associated 
with an increased risk of STIs including rectal gonorrhoea (GC)/chlamydia 
(CT) infection.  The cross-sectional study was conducted in a very 
heterogeneous population including HIV-positive and negative men and 
women. Lubricant use was based on participant recall. A definitive, if 
challenging, study to answer the question as to whether lubricants could 
increase STI acquisition including HIV would require enrollment of an at risk 
population into a large prospective study.  In the absence of definitive data, 
but based on the preclinical studies from Begay and Dezzutti (Begay et al., 
2011; Dezzutti et al., 2012), it seems appropriate to counsel individuals to 
use iso-osmolar water soluble lubricants whenever possible. 
1.5.4 The colorectal explant model 
There is increasing interest in using human tissue biopsies or explants to 
evaluate the safety and efficacy of candidate microbicides. A wide range of 
tissues have been used including cervicovaginal (Greenhead et al., 2000), 
colorectal (Fletcher et al., 2006; Abner et al., 2005), penile (Harman, 
Herrera, Armanasco, Nuttall, & Shattock, 2012), and foreskin tissue (Zhou et 
al., 2011). Colorectal and cervicovaginal explants can be harvested from 
surgical resection specimens or can be collected as multiple biopsies from 
healthy donors. With regards to the colorectal explant system, two 
experimental techniques have emerged. Abner et al. have described the use 
of a polarized tissue model in which the explant is physiologically orientated 
in a transwell system (Abner et al., 2005). In contrast, Fletcher et al. have 
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Supernatant is collected over a 14 day period and evidence of infection is 
demonstrated by quantifying HIV-1 p24 antigen levels in the explant 
supernatant. It also possible to quantify accumulation of HIV-1 RNA and 
DNA in the explant tissue as illustrated in Figure 1-4. 
 
Table 1-3 Microbicide candidates with colorectal explant efficacy 
Product Reference
  
Cellulose acetate 
PRO2000 
SPL7013 
Vena Gel 
UC781 
(Abner et al., 2005) 
  
PRO2000 
Dextrin sulfate 
(Fletcher et al., 2006) 
  
Tenofovir (Dezzutti et al., 2012) 
  
C34 
T20 
T1249 
L’644 
(Harman et al., 2012) 
  
Tenofovir 
Emtricitabine 
UC781 
TMC120 
(Herrera, Cranage, McGowan, Anton, & 
Shattock, 2011) 
  
Saquinavir (Stefanidou, Herrera, Armanasco, & 
Shattock, 2012) 
  
 
These assays have characterized many potential rectal microbicide 
candidates including non-specific entry inhibitors (Fletcher et al., 2006), non-
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nucleoside and nucleotide/nucleoside reverse transcriptase inhibitors, fusion 
inhibitors, and protease inhibitors (Fletcher et al., 2006; Herrera, Cranage, 
McGowan, Anton, & Shattock, 2009; Herrera et al., 2011; Harman et al., 
2012) (Table 1-3).  
 
Microbicide candidates have been typically evaluated as single entity 
agents. However, combinations of APIs are now being tested and much like 
systemic therapy, it appears that combinations of up to three APIs (TFV or 
FTC with UC781 and dapivirine) are much more potent against HIV-1 
infection in colorectal tissue than single agents, even against drug resistant 
HIV-1 (Herrera et al., 2011). These data will help inform microbicide 
developers as to which candidates/combinations are optimal to pursue for 
further development. 
1.5.5 Non-human primate rectal challenge studies 
NHP infection models use two different challenge schemes that involve 
either a multiple low-dose or single high-dose challenge with simian 
immunodeficiency virus (SIV) or a chimeric SIV/HIV virus (SHIV) (Veazey, 
Shattock, Klasse, & Moore, 2012). Typically the virus used to evaluate 
microbicides is an SIV modified to express the HIV-1 envelope (SHIV) or the 
HIV-1 reverse transcriptase (RT-SHIV) (Pal et al., 2012).  
 
Using the NHP model, gel formulations of an entry inhibitor, cyanovirin-N 
(Tsai et al., 2003), and the reverse transcriptase inhibitors, TFV and MIV-
150 (Cranage et al., 2008; Singer et al., 2011) prevented rectal challenge of 
SHIV or RT-SHIV.  
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In the study by Tsai et al., macaques (Macaca fasicularis) were randomized 
to receive 1% cyanovirin (n = 5), 2% cyanovirin (n = 5), placebo (n = 5), or 
no gel (n = 4). Twenty minutes after a 2 mL rectal gel application the animals 
were challenged with 1,000 TCID50 of SHIV89.6P (Tsai et al., 2003). All the 
animals receiving cyanovirin gel were protected from SHIV infection whereas 
the placebo gel or no gel animals all became infected with SHIV. 
 
In the study by Cranage et al., a total of 20 Indian rhesus macaques were 
used to evaluate the protective efficacy of topical TFV (Cranage et al., 
2008). Nine animals received rectal TFV 1% gel up to 2 hours prior to virus 
challenge, four macaques received placebo gel, and four macaques 
remained untreated. In addition, three macaques were given TFV gel 2 
hours after virus challenge. Following intrarectal instillation of 20 median 
rectal infectious doses (MID50) of a non-cloned, virulent stock of 
SIVmac251/32H, all animals were analysed for virus infection, by virus 
isolation from PBMC, quantitative proviral DNA load in PBMC, plasma viral 
RNA (vRNA) load by sensitive RT-PCR, and presence of SIV-specific serum 
antibodies by ELISA. Eight of nine macaques given TFV per rectum up to 2 
hours prior to virus challenge were protected from infection (n = 6) or had 
modified virus outcomes (n = 2), while all untreated macaques and three of 
four macaques given placebo gel were infected, as were two of three 
animals receiving TFV gel after challenge. Moreover, analysis of lymphoid 
tissues post mortem failed to reveal sequestration of SIV in the protected 
animals. There was a strong positive association between the concentration 
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of TFV in the plasma 15 minutes after rectal application of gel and the 
degree of protection in the six animals challenged with virus at this time 
point. Moreover, colorectal explants from non-SIV challenged TFV-treated 
macaques were resistant to infection ex vivo, whereas no inhibition was 
seen in explants from the small intestine. Tissue-specific inhibition of 
infection was associated with the intracellular detection of TFV. Intriguingly, 
in the absence of seroconversion, Gag-specific gamma secreting T cells 
were detected in the blood of four of seven protected animals tested, with 
frequencies ranging from 144 spot forming cells (SFC)/106 PBMC to 261 
SFC/106 PBMC (Cranage et al., 2008).  
 
Singer et al. have evaluated the non-nucleoside reverse transcriptase 
inhibitor (NNRTI) MIV-150, in a carageenan formulation, in a rhesus 
macaque rectal challenge model (Singer et al., 2011). A total of four 
macaques received the MIV-150 gel either 30 minutes or four hours before 
rectal challenge with either 103 or 104 TCID50 of a SHIV-RT 
(SIVmac239/HIV-1HXB2). A control group was treated with a placebo methyl 
cellulose placebo gel. All the MIV-1 treated macaques exposed to 103 
TCID50 of the SHIV-RT were protected from infection whereas only two of the 
four macaques exposed to the higher dose of SHIV-RT (104 TCID50) were 
protected from infection.  
  
The most recent NHP rectal challenge study evaluated maraviroc (MVC) that 
had been formulated in a rectal specific hydrogel based formulation (Dobard 
et al., 2013). The MVC gel formulation was designed to have a neutral pH 
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and to be close to iso-osmolar. Chinese Rhesus macaques were assigned to 
a matching rectal placebo gel (n = 5) or MVC gel (n = 6). Twice-weekly rectal 
SHIVSF162p3 challenges (500 TCID50) were performed for 5 weeks. Gel (4 
mL) was applied rectally 30 minutes before each challenge. MVC was 
measured in plasma 30 minutes after gel application using LC/MS. Infection 
was monitored by PCR of SHIV in plasma. Infected macaques continued to 
receive gel for an additional six weeks to monitor the potential impact of drug 
exposure on systemic viremia. All the placebo-treated macaques were 
infected after a median of four challenges. In contrast, four of six macaques 
receiving MVC gel remained protected after ten challenges, demonstrating 
high efficacy (84%, p=0.020; Fisher’s exact test).  Low levels of MVC 
(median = 4 ng/ml; range: 0-19) were detected in plasma 30 minutes after 
rectal dosing, suggesting MVC was rapidly released from the gel and 
absorbed. Plasma viremia in breakthrough infections was similar to controls.  
 
To begin to address where rectal microbicides might distribute after dosing 
in a more formal way, a multi-compartment pharmacokinetic study in 
macaques after vaginal or rectal dosing with TFV gel was done (Nuttall et 
al., 2012). Macaques dosed with TFV gel vaginally showed rectal drug levels 
only 1 log10 lower than the vaginal drug levels. Both mucosal compartments 
were 4-5 log10 higher than plasma drug levels. Similar results were found 
when the macaques were dosed with TFV gel rectally. These data suggest 
that vaginal or rectal dosing of a soluble microbicide could protect against 
HIV-1 regardless of the route of exposure.  
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The NHP rectal microbicide challenge model provides compelling evidence 
to suggest that a rectal microbicide could provide significant protection from 
HIV acquisition in human efficacy studies. However, the model also 
illustrates that product efficacy may be impacted by the size of the NHP viral 
inoculum and the temporal association between when products are 
administered and when the animals are challenges with virus.  
1.6 Rectal microbicide formulation considerations 
Formulation of APIs for rectal use will likely be in a liquid or semi-solid 
dosage form to cover areas that are at most risk for HIV-1 exposure (Wang, 
Schnaare, Dezzutti, Anton, & Rohan, 2011). Preclinical testing of formulated 
APIs adds additional complexity because pH, osmolality, and viscosity of the 
product will impact the results.  For instance, the polymers used in the 
formulation may enhance toxicity or efficacy due to smothering of individual 
cells or non-specifically binding HIV-1. Therefore, it is critical to include the 
vehicle control, the same formulation but without the API, in all assays to 
accommodate the impact the formulation may have on the testing results. As 
with unformulated APIs, testing algorithms have been developed (Rohan et 
al., 2010). Typically, the testing done with the formulations is to ensure the 
APIs activity has not been impaired and the formulation is safe. Mucosal 
tissues are used for testing the formulations, but are polarized, keeping the 
apical surface at the liquid/air interface (Rohan et al., 2010; Abner et al., 
2005; Cummins, Jr. et al., 2007). The formulation with or without HIV-1 can 
be applied to the apical surface recapitulating the use by a person. Using 
this testing algorithm, it was recently reported the TFV 1% gel was 
hyperosmolar and consequently demonstrated epithelial fracture and 
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sloughing in polarized mucosal tissue (Rohan et al., 2010). The gel was 
reformulated to reduce the glycerin content and thus reduce the osmolality 
(Dezzutti et al., 2012). The reduced glycerin TFV 1% gel showed improved 
epithelial retention in polarized rectal and ectocervical tissue explants. These 
data support the clinical trial results (discussed below) that showed that 
gastrointestinal AEs were significantly more common when the original TFV 
1% gel was used rectally compared to the reduced glycerin gel formulation 
(Anton et al., 2011; McGowan et al., 2012). The preclinical testing of 
formulations is thus important to ensure those products that move into 
clinical trials are safe as well as effective. 
1.7 Preclinical evaluation of rectal microbicides 
Preclinical testing of API, has been standardized but there are subtle 
variations in the specific assays used based on the preferences of the 
laboratory doing the testing (Buckheit, Jr. & Buckheit, 2012; Lackman-Smith 
et al., 2008; Lard-Whiteford, 2004). Initial tests using primary immune cells, 
such as peripheral blood mononuclear cells, and indicator cell lines are 
performed to determine mechanisms of action and potency of the API 
against standard laboratory and primary clinical isolates of HIV-1. Some 
testing is now being conducted with the newly identified primary isolates 
known as transmitter/founder viruses from persons who acquired HIV-1 
through penile-vaginal or penile-rectal coitus (Keele et al., 2008; Dezzutti et 
al., 2012). The incorporation of biological fluids such as semen, 
cervicovaginal fluid, or their simulants is also used early in the testing to 
ensure the API remains potent during coitus (Neurath, Strick, & Li, 2006; 
Patel et al., 2007).  
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1.8 Clinical evaluation of rectal microbicides 
To date, the majority of rectal microbicide studies have evaluated either 
placebo formulations or been restricted to the Phase 1 rectal safety 
evaluation of antiretroviral candidates such as TFV or UC781 gels. A Phase 
2 extended rectal safety study of TFV gel has just started screening and 
enrollment (MTN-017; http://clinicaltrials.gov/: NCT01687218). The general 
characteristics of Phase 1-3 microbicide development are outlined below. 
1.8.1 Phase 1  
Drug development including microbicide development involves a number of 
different stages. In the preclinical phase, new molecules are evaluated for 
safety and efficacy in cell lines and animal models. Compounds with an 
adequate safety profile are then advanced into Phase 1 safety studies where 
small groups of participants (10-30) are exposed to the product in very 
controlled circumstances for relatively short periods of time (1-2 weeks). The 
participants in Phase 1 RM studies are usually at very low risk of HIV 
acquisition and are asked to be sexually abstinent during the study.  
1.8.2 Phase 2 
On completion of Phase 1 studies, candidate microbicides are then 
evaluated in Phase 2 studies. Characteristically, Phase 2 microbicide studies 
are conducted in larger groups of sexually active participants (100-200) for 
three to six months and are designed to identify safety or acceptability 
issues associated with frequent use of the product. On completion of Phase 
2 development a candidate microbicide then advances into an effectiveness 
(Phase 2B/3) study. This is the final phase of testing and seeks to determine 
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whether the product can actually reduce HIV acquisition rates in at risk 
populations.  
1.8.3 Phase 2B/3 
Phase 2B/3 evaluation of microbicides is the most arduous phase of 
assessment. Of necessity, the microbicide intervention has to be evaluated 
in populations who are already receiving a comprehensive HIV prevention 
package. The components of this package continue to evolve but would be 
expected to include diagnosis and treatment of STIs, frequent safer sex 
counseling, condom provision, and possibly male circumcision (UNAIDS, 
2007). The net effect of these interventions is that the participants enrolled in 
Phase 2B/3 studies often develop a lower risk of infection than their peers 
not participating in the study, potentially reducing the overall HIV incidence 
in the study population and therefore the power to find a statistically 
significant result. As a consequence, Phase 2B/3 studies are usually large 
(2000-3000 participants), long (2-3 years), and expensive.  
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2 Previous rectal microbicide studies 
2.1 Introduction 
As of October, 2013, the majority of rectal microbicide research has involved 
evaluation of placebo formulations or the conduct of Phase 1 rectal safety 
studies. Increasingly, the design of Phase 1 rectal microbicide integrates 
characterisation of safety, acceptability, and PK/PD endpoints. 
2.2 HIVNET-008  
The HIVNET-008 study was designed to assess the safety of N9 when 
applied one to four times daily to the rectum and penis. Twenty five HIV-
negative and ten HIV-positive, seroconcordant, monogamous gay male 
couples were enrolled in Seattle, WA, USA. Each partner was exclusively 
insertive or receptive while using N9 gel and served as his own control 
during placebo gel use compared to during N9 gel use. The study was 
conducted over 7 weeks. During the first week participants used the placebo 
gel. Thereafter, couples used the N9 gel and the frequency of use was 
escalated from once daily to two applicators twice daily in the final week of 
the study. Despite the frequency of administration, AEs were generally mild 
and transient. No rectal ulcers were detected; superficial rectal erosions 
were noted in two HIV-negative participants. Abnormal or slightly abnormal 
histologic abnormalities of rectal biopsies were detected in 31 (89%) of 
receptive participants after N9 gel use compared to 24 (69%) of participants 
after 1 week of placebo gel use. Excluding participants who felt no need for 
an HIV prevention method, 58% said they would use N9 if approved for 
rectal use; 69% of receptive users reported rectal fullness and related side 
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effects after insertion of the gel, and 68% reported applicator-related 
discomfort; 59% of insertive participants found the gel too sticky (Gross et 
al., 1999). 
2.3 HPTN-056 
The purpose of this study was to evaluate the biological stability of mucosal 
parameters that might be used as endpoints in Phase 1 rectal safety studies 
(McGowan et al., 2007). Sixteen male participants were enrolled into four 
groups defined by HIV status, viral load, and sexual activity. Each participant 
underwent three flexible sigmoidoscopies at two-week intervals with 
collection of blood, intestinal biopsies, and rectal secretions. Intestinal 
histology, phenotypic characterization of mucosal mononuclear cells, 
cytokine mRNA profiles (RANTES, Interferon- (IFN-), and Interleukin-10 
(IL-10)), and immunoglobulin secretion were assessed. Intraclass correlation 
(ICC) was calculated to assess endpoint stability. Qualitative histology 
demonstrated minimal inflammation in > 95% of biopsies and remained 
stable throughout the study period. ICC for the tissue cytokine mRNA 
measurements and several T cell phenotypic markers was > 0.7, indicating 
stability over time. Mucosal CD4 lymphopenia was seen in the HIV positive 
participants and was more pronounced in those with higher viral loads. 
Modest differences were observed for cytokine expression (IFN-and T cell 
phenotype (CD3, CD4, CD8, CD19, CD4/CCR5, and CD4/CD38) between 
the tissue samples collected at 10 and 30 cm.  
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2.4 Placebo formulation studies 
In 1999, Gross et al. published acceptability data from the HIVNET-008 
study evaluating N9 as a rectal microbicide (Gross et al., 1999). Data were 
available for the 35 couples enrolled in the study. The majority of participants 
(54%) said that they would not use the product if it was approved for rectal 
use. Problems associated with the N9 gel included the gel being too sticky 
and drying out too quickly. In light of these findings, a number of microbicide 
placebo studies have been undertaken to assess the acceptability of 
potential rectal microbicide formulations including gels, enemas, and 
suppositories. In contrast to the majority of Phase 1 rectal microbicide 
studies involving formulated ARV products, where participants are usually 
sexually abstinent for the duration of the study, the placebo studies 
described below were designed to evaluate products in sexually active 
participants and can provide critical information about desirable 
characteristics for a candidate rectal microbicide. 
2.4.1 Rectal microbicide volume escalation study 
It is not known what volume of a microbicide gel will be needed to provide 
protection from HIV infection associated with URAI. The majority of vaginal 
microbicide studies have used approximately 4 mL of study product. 
However, since the vaginal compartment is a relatively enclosed anatomical 
space and the rectum a potentially much larger space it has been assumed 
that a greater volume of gel would be needed in the rectal vs. vaginal 
compartments. A study, undertaken by Carballo-Dieguéz et al., was 
conducted among HIV-uninfected MSM in Boston, Massachusetts, USA and 
was designed to explore the acceptability of escalating volumes of placebo 
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gel in MSM practicing anal sex (Carballo-Dieguez et al., 2007). The placebo 
gel used in the study was FemGlide® (Trumbull, Connecticut, USA), an 
isosmolar vaginal lubricant. The gel was administered using a syringe; each 
of the 18 participants received sequentially 5, 20, 35, and 50 mL of study 
product. The participant then used the study product at the highest volume 
that he had rated as acceptable during RAI. Up to 35 mL of FemGlide was 
found to be acceptable to study participants. Beyond this volume there were 
increasing reports of leaking and messiness which were associated with 
poor product acceptability.  
2.4.2 Gel and suppository rectal microbicide preference study 
In a second study from the same group, again conducted in Boston 
Massachusetts, USA, 77 MSM were enrolled in a cross over study where 
they were asked to use either a placebo gel or a suppository (Carballo-
Dieguez et al., 2008). FemGlide was administered at a volume of 35 mL 
using an accordion type applicator and the suppository was manufactured 
using two polyethylene glycol bases (PEG 1450 and PEG 300) (JE 
Apothecary, Inc., Brookline, Massachusetts, USA). Participants were asked 
to insert the products up to 2 hours before anal intercourse on three 
separate occasions. Rectal gel was preferred over the suppository for both 
the recipient (75% vs. 25%, P <0.001) and the partner (71% vs. 29%, 
P<0.01). Although these data suggest a clear preference for gel over 
suppository, the authors did comment that the suppository used in this study 
was quite large (8 g and 2.5 inches) and they felt that a smaller suppository 
might have been more acceptable.    
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2.4.3 Rectal microbicide formulation preference study 
In a recent study, Pines et al. evaluated a gel, suppository, and enema in 
117 HIV-uninfected males (79%) and females (21%) (Pines et al., 2012). 
The study was conducted in Los Angeles, California, USA and participants 
received an isosmolar gel (4 mL of Pre-Seed®; Spokane, Washington, 
USA), an isotonic enema (125 mL of Normosol-R; Hospira Inc., Lake Forest, 
Illinois, USA), and a suppository commonly used for the treatment of 
haemorrhoids (Tucks™; McNEIL-PPC Inc., Skillman, New Jersey, USA). 
The study products were administered in a randomized sequence and 
participants were asked to use each product 3-5 times over a two week 
period before moving on to the next product. During follow-up, 75, 76, and 
66% of participants reported using the enema, gel, and suppository 
respectively. There was no difference in the frequency of anorectal 
symptoms or adverse events (AEs) by product and, based on computer-
assisted self-interviews (CASI), the gel was the most acceptable product 
overall.     
2.5 Product distribution studies 
A key component of microbicide development is to determine whether the 
candidate microbicide is “in the right place at the right time”. Increasingly 
sophisticated imaging technology is being used to track semen and 
microbicide surrogates to understand more about their distribution and 
persistence following rectal administration. Craig Hendrix and his colleagues 
at Johns Hopkins University (JHU), Baltimore, Maryland, USA have 
developed this area of prevention research with a number of innovative 
studies (Figure 2-1).  
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simulation on product distribution were evaluated. Both the microbicide and 
semen surrogates were labeled with gadolinium-diethylene triamine 
pentaacetic acid (DTPA) (as a magnetic resonance imaging (MRI) contrast 
agent) and 99mTechnetium-sulphur colloid (for single photon emission 
computed tomography (SPECT) imaging).  
 
The microbicide surrogate was administered using a syringe and the semen 
surrogate was administered via a commercially available artificial phallus or 
coital dynamic simulator (CDS) that was modified to allow delivery of the 
semen surrogate through a triple lumen catheter. The semen surrogate was 
delivered after a five minute period of insertion and removal of the device to 
simulate RAI. MRI studies conducted at one and four hours following product 
administration demonstrated presence of signal throughout the rectum with 
the highest signal being seen dependent/posterior aspect of the rectum 
(participants remained supine throughout the procedure). In contrast, 
SPECT imaging demonstrated more proximal product migration. At four 
hours post product exposure 4/16 studies demonstrated signal in the 
descending colon, two of which reached the splenic flexure. 
 
In a second study, the JHU team evaluated the distribution of cell-free and 
cell-associated HIV surrogates in the colon after simulated RAI in six men 
(Louissaint et al., 2012). In this study autologous leukocytes, collected from 
study participants were radiolabelled with 111Indium-oxine as the cell 
associated surrogate and sulphur colloid particles were labeled with 
99mTechnetium-sulphur as the cell-free surrogate. Both products were mixed 
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with 3 mL of autologous semen and delivered to the rectum via a CDS after 
5 minutes of simulated RAI. SPECT/CT images were acquired at 1, 4, 8, and 
24 hours post dosing. In this study cell-associated and cell-free surrogates 
generally co-localized, were largely confined to the rectosigmoid colon, and 
signal persisted for up to 24 hours in the absence of defecation. 
Furthermore, cell-free and cell-associated surrogates were found in tissue 
biopsies collected from the study participants. 
 
In the third published study, the group further evaluated microbicide and 
semen surrogate colonic distribution in eight participants using the 
methodological approach described above (Cao et al., 2012). Participants 
sequenced through three phases: (i) Phase I: Microbicide / Coital Simulation 
/ No Semen, (ii) Phase II: No Microbicide / Coital Simulation / Semen, and 
(iii) Phase III: Microbicide / Coital Simulation / Semen. Three novel PK 
parameters to describe product distribution were developed: (i) Maximum 
distance (Dmax): the distance of the proximal endpoint of the radiosignal 
(drug or pathogen), (ii) Distance at concentration maximum (DCmax): location 
within the colon with the highest drug or pathogen density/signal, and (iii) 
Mean residence distance (Dave): the mean distance within the colon 
throughout which the drug or pathogen is distributed at the time of the 
observation. In this study, gel distribution was limited to the rectosigmoid in 
84% (26/31) of the studies although 16% (5/31) studies had proximal spread 
to descending colon. Comparison of Dmax, DCmax, and Dave across different 
phases of the study did not generate any significant differences suggesting 
that microbicide and semen surrogates were generally co-localized. 
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In their most recent study, Leyva et al. conducted an evaluation of enemas 
as potential vehicles for microbicide delivery (Leyva et al., 2013). Three 
formulations were assessed, a hyperosmolar enema (Fleet Phosphate 
Enema [2,100mOsmol/kg], Fleet Laboratories, Lynchburg, VA, USA), a 
hypoosmolar enema (distilled water), and an isoosmolar enema (Normosol-
R enema [294mOsmol/Kg], Hospira, Inc., Lake Forest, IL, USA). The study 
was conducted in a crossover fashion so that the nine study participants 
were exposed to all three formulations in a randomised order. Enemas were 
radiolabeled with 99mTechnetium (Tc)-DTPA to assess enema distribution in 
the colon using SPECT/CT imaging. Plasma 99mTc-DTPA was measured to 
assess mucosal permeability. Sigmoidoscopic colon tissue biopsies were 
collected to assess mucosal injury as well as tissue penetration of the 99mTc-
DTPA. Acceptability was assessed after each product use and at the end of 
the study. SPECT/CT imaging showed that the isoosmolar enema had 
greater proximal colonic distribution (up to the splenic flexure) and greater 
luminal and colon tissue concentrations of 99mTc-DTPA when compared to 
the other enemas. Only the hyperosmolar enema caused sloughing of the 
colonic epithelium. In permeability testing, the hypoosmolar enema had 
higher plasma 99mTc-DTPA compared to the hyperosmolar and isoosmolar 
enemas, respectively. Acceptability was generally good with no clear 
preferences among the three enema types. The team concluded that 
enemas have potential as rectal microbicide vehicles. 
 
Collectively, these highly innovative studies suggest that the rectosigmoid is 
the area of highest viral exposure following RAI and that rectal microbicides 
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also appear to co-localize in this area. Obviously, these data need to be 
interpreted with some degree of caution; the participants are undergoing 
simulated RAI and receiving microbicide and semen surrogates. Actual 
semen and specific microbicide products may have different patterns of 
distribution.  However, this methodological approach is now being used to 
study distribution of actual rectal microbicides in the Combination HIV 
Antiretroviral Rectal Microbicide (CHARM) Program (Section 2.9). 
2.6 RMP-01 
In the Rectal Microbicide Program (RMP)-01 study, thirty six HIV-1 
seronegative, sexually-abstinent men and women were enrolled in Los 
Angeles, CA, USA and randomized into a double-blind, placebo-controlled 
trial comparing UC781 gel at two concentrations (0.10% and 0.25%) with a 
placebo gel (1:1:1). Safety and acceptability were the primary study 
endpoints. Changes in colorectal mucosal safety biomarkers and UC781 
plasma drug levels were secondary endpoints. Ex vivo explant infectibility 
with HIV-1 was an ancillary study endpoint. Samples were collected at 
enrollment, after a single rectal dose of study product, and after seven daily 
doses. The majority of AEs were mild. Product acceptability was high, 
including likelihood of future use. No changes in mucosal safety biomarkers 
were identified. Plasma levels of UC781 were not detected. Ex vivo infection 
of biopsies using two titers of HIV-1BaL showed marked suppression of HIV-1 
p24 in tissues exposed in vivo to 0.25% UC781. Ideally the product would 
have been advanced into Phase 2 development but the IND sponsor 
(CONRAD; http://www.conrad.org/) terminated the UC781 development 
program. 
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2.7 RMP-02/MTN-006 
Eighteen participants were enrolled from Pittsburgh, PA, USA and Los 
Angeles, CA, USA. All participants received a single 300mg dose of TDF 
and were then randomized 2:1 to receive a single then seven daily doses of 
TFV 1% gel or the HEC placebo gel. Safety endpoints included clinical AEs 
and mucosal safety biomarkers. Participants were assessed at enrollment, 
after single doses of oral TFV and study gel, and after seven daily doses of 
study gel. Blood and colonic biopsies were collected for PK analysis and ex 
vivo challenge with HIV-1. No serious AEs were reported. However, AEs, 
especially gastrointestinal AEs, were significantly increased with seven-day 
use of the TFV 1% gel. Only 25% of participants liked the TFV gel; however, 
likelihood of use, if the product was somewhat protective, was high (75%). 
No significant mucosal injury was detected. Tissue TFV diphosphate (TFV-
DP) Cmax 30-minutes after single rectal exposure was 112-times greater than 
single oral-exposure with tissue Cmax in 7-day exposure 5-times greater 
than single rectal-exposure. Seven-day exposure to rectal TFV was 
associated with significant suppression of explant infection. Increased AEs 
suggested that the vaginal formulation of TFV 1% gel used rectally was not 
entirely safe nor fully acceptable, suggesting a need for improved 
formulations. 
2.8 Project Gel 
The National Institutes of Health (NIH) has funded a project entitled 
“Microbicide safety and acceptability in young men” that attempts to evaluate 
rectal microbicide safety, adherence, and acceptability in young ethnic 
minority MSM in Boston, MA, USA; Pittsburgh, PA, USA; and San Juan, PR, 
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USA. The study design has two stages:  a clinical and behavioral evaluation 
(Stage 1A) with an acceptability and adherence trial (Stage 1B), followed by 
a Phase 1 randomized, double-blind, multi-site, placebo-controlled safety 
trial (Stage 2). The first 120 eligible participants who complete Stage 1A and 
report unprotected RAI in the previous 3 months will continue on to Stage 
1B. During Stage 1B, participants will be given condoms and a placebo gel 
to use during receptive anal intercourse. Over a three month period they will 
report the frequency of product use and be interviewed about the 
acceptability of the product. The first 24 participants who complete Stage 1B 
will be eligible to participate in Stage 2 where they will be randomized to 
receive an actual microbicide (reduced glycerin (RG)-TFV 1% gel) or 
matched placebo. It is hoped that data from this study will provide unique 
insights into the acceptability, safety, and adherence of rectal microbicides in 
young MSM.  
2.9 The CHARM Program 
The CHARM Program will develop and evaluate a combination ARV rectal 
specific product. TFV and maraviroc (MVC) are the two lead compounds and 
the ultimate goal is to develop a TFV/MVC combination product. Two Phase 
1 studies, CHARM-01 and CHARM-02 will start in 2013. CHARM-01 will 
assess the safety, acceptability, and PK/pharmacodynamic (PD) profile of 
three TFV gel formulations; the original TFV 1% gel used in vaginal 
microbicide studies, the RG-TFV 1% gel, and a rectal specific TFV gel. 
CHARM-02 will evaluate the safety, PK, and distribution of the same three 
gels. Similar techniques have been used to characterize the distribution of 
semen surrogates and microbicide products in the presence and absence of 
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simulated receptive anal intercourse (Louissaint et al., 2012; Cao et al., 
2012). Collectively, these studies will provide unique data on the influence of 
formulation characteristics, including osmolality, and product safety, PK/PD, 
and distribution.  
2.10 Current concepts in the design of rectal microbicide studies 
From a contemporary perspective, the first rectal microbicide study 
conducted by Tabet et al. (Tabet et al., 1999) was unusual as it enrolled both 
HIV-positive and HIV-negative participants. The study involved dose 
escalation and participants were sexually active. As rectal microbicide 
development has become more focused on ARV products a number of study 
design changes have occurred. All participants enrolled in Phase 1 ARV 
rectal microbicides are screened for HIV infection and only HIV-negative 
participants are enrolled in the study. This approach arises from concerns 
that an HIV-positive participant, especially one who is not receiving 
combination ARV therapy, exposed to a single agent ARV microbicide such 
as TFV gel, might develop HIV resistance to products used for treatment 
(Abbas, Hood, Wetzel, & Mellors, 2011). In addition, Phase 1 rectal 
microbicide studies involving the first exposure of the product in man are 
conducted in sexually abstinent populations. Emergent AEs can then be 
attributed to product use rather than coital associated trauma or infection. 
Initial product exposure is limited to 1-2 weeks of daily dosing to limit the 
potential for mucosal damage. In contrast, during the HIVNET-008 study of 
N9, participants received up to six weeks of product exposure. 
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2.10.1 Safety 
As with all clinical trials, emergent AEs in rectal microbicide studies are 
captured through participant interview/examination and events are 
documented and classified using the Medical Dictionary for Regulatory 
Activities (MedDRA) coding system. The severity of AEs is graded using the 
NIH/National Institute of Allergy and Infectious Diseases (NIAID)/Division of 
AIDS (DAIDS) “Table for Grading the Severity of Adult and Pediatric 
Adverse Events, Version 1.0, December 2004” (Clarification August 2009; 
http://rsc.tech-res.com/safetyandpharmacovigilance/gradingtables.aspx). In 
August 2009, NIH/DAIDS published an addendum to the 2004 DAIDS AE 
table: “Addendum 3: Rectal Grading Table for Use in Microbicide Studies” 
(available in Appendix 1, Section 9.1). This table provided a mechanism to 
capture the types of AEs (primarily anorectal and gastrointestinal) that might 
be anticipated to occur in rectal microbicide trials and was in fact developed 
by a number of clinical trials physicians working in this area of HIV 
prevention research. 
 
Colposcopic inspection of the cervicovaginal mucosa is a standard 
component of Phase 1/2 vaginal microbicide trials and is used to detect 
mucosal inflammation and/or epithelial disruption that might occur secondary 
to product application. Microbicide-specific atlases have been developed to 
assist with training of staff in performing colposcopy within microbicide trials 
(Bollen, Kilmarx, & Tappero, 2004). However, a number of recent studies 
have questioned the utility of colposcopy compared to simple naked eye 
examination of the cervicovaginal mucosa (Mauck, Weiner, Lai, & Schwartz, 
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2012; Chirenje et al., 2012). High resolution anoscopy (HRA) is an 
analogous technique used to provide magnified images of the anorectal 
mucosa. HRA is used primarily to diagnose and treat human papilloma virus 
(HPV) associated anal dysplasia that is commonly found in MSM with HIV 
infection (Jay, 2011). HRA is also being evaluated for its utility in identifying 
microbicide induced mucosal damage involving the anal canal and the distal 
rectum (Project Gel, Section 2.8). One practical limitation of HRA is that, 
depending on individual anorectal anatomy, it can only image the distal 6-9 
cm of the anorectum (Ross Cranston MD, personal communication). It is 
know from microbicide distribution studies that, following application, a 
candidate microbicide can spread in a retrograde fashion into the 
rectosigmoid colon, occasionally into the descending colon, and rarely as far 
as the splenic flexure (Hendrix et al., 2008; Cao et al., 2012). As a 
consequence, the majority of Phase 1 rectal microbicide studies have used 
flexible sigmoidoscopy to image the distal rectum as well as to collect 
mucosal samples for histology, safety biomarkers, and PK/PD samples. In 
theory, a flexible sigmoidoscope can reach the splenic flexure which is 
located approximately 45-60 cm from the anorectal margin. However, in the 
rectal microbicide studies conducted to date, the most proximal level for 
sample collection and observation has been 30 cm from the anorectal 
margin. Assessment of the endoscopic appearances of the colorectal 
mucosa is not a routine component of rectal microbicides studies. Overt 
lesions such as ulceration will be documented but capturing generalized 
changes such as “mild inflammation” are not particularly helpful. It is known 
from the inflammatory bowel disease (IBD) literature that there is very high 
84 
 
variability in the recognition of mild disease activity between observers 
(Travis et al., 2012; Dhanda, Creed, Greenwood, Sands, & Probert, 2012) 
and variable correlation between endoscopic evidence of inflammation and 
actual histopathological evidence of inflammation (Gomes, du Boulay, Smith, 
& Holdstock, 1986; Osada et al., 2008). 
 
In the absence of validated indices of microbicide induced mucosal injury, 
the rectal microbicide research community has taken an expansive view on 
including multiple potential biomarkers of mucosal injury within the design of 
Phase 1/2 studies. These biomarkers are summarized in Table 2-1 and 
discussed in more detail in Chapter 5. 
 
Table 2-1 Mucosal safety assays in rectal microbicide studies 
 Rectal Microbicide Studies 
Mucosal Assay RMP-01 RMP-02 / 
MTN-006 
MTN-007 MTN-017 
     
Histology X X X X 
     
Epithelial sloughing X X X  
     
Fecal calprotectin X  X X  
     
Luminex X X X  
     
qRT-PCR X X X X 
     
Microarray   X X 
     
Rectal microflora X X X  
     
 
In general, the biomarkers have been chosen because they have been used 
in previous animal or human vaginal microbicide studies (e.g. Luminex® 
assessment of chemokines/cytokines (Fichorova, Tucker, & Anderson, 
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2001)) or because they are closely linked to the initial events in HIV infection 
(e.g. the proportion and activation phenotype of gut-associated lymphoid 
tissue (GALT) CD4+/CCR5+ T cells (Cicala, Arthos, & Fauci, 2011)). 
2.10.2 Acceptability 
Rectal microbicides will only play an important role in HIV prevention if the 
target populations find them acceptable and use them correctly and 
consistently (Elias & Coggins, 2001; Severy & Newcomer, 2005; Mantell et 
al., 2005). Although there has been some discussion concerning whether 
acceptability studies should be postponed until efficacy of a product is 
demonstrated, others (Morrow & Ruiz, 2008; Mantell et al., 2005; Tolley & 
Severy, 2006) have convincingly defended the wisdom of integrating 
acceptability research in early clinical phases of microbicide development. 
Morrow and Ruiz state that Phase 1 trial participants “are an invaluable 
source of information regarding acceptability [for] they constitute the handful 
of individuals with actual product use experience and, thus, are in the best 
position to provide feedback on actual product characteristics and how these 
factors may influence individuals’ willingness to initiate and maintain product 
use over time” (Morrow & Ruiz, 2008).  They suggest that these trials assess 
a variety of factors, including product scent, color, and texture; clarity of 
instructions and ease of product preparation and application; qualities of 
product during and after use; frequency and timing of use; and related 
covariates, such as history of lubricant use, frequency of anal and vaginal 
sex, and relationship communication. Rosen et al. (Rosen et al., 2008) and 
Morrow and Ruiz (Morrow & Ruiz, 2008) propose the use of mixed methods 
(quantitative and qualitative) to assess the different factors.  This advice is 
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particularly sound in the case of small trials for which the utility of 
quantitative findings alone often has been limited (Bentley et al., 2000; 
Morrow et al., 2003; El-Sadr et al., 2006).  
 
Three recent papers have made important contributions to our knowledge of 
the acceptability of rectal microbicides. Importantly, the observations were 
based on interviews with participants who had actually used experimental 
rectal products rather than a theoretical discussion of product acceptability. 
A National Institute of Child Health and Human Development (NICHD) 
funded trial found that a sexually active cohort of middle aged MSM rated 
volumes up to 35 mL of gel acceptable for use during anal intercourse 
(Carballo-Dieguez et al., 2007). In a second study, MSM appeared to prefer 
microbicide gels rather than rectal suppositories (Carballo-Dieguez et al., 
2008). Acceptability data from a Phase 1 safety study of UC781 gel, an ARV 
microbicide gel, found the product to be highly acceptable and the majority 
of participants said that they would use such a product if it was commercially 
available (Ventuneac et al., 2009).   
2.10.3 Adherence 
A fundamental concept in clinical trials is that product effectiveness is 
determined by the combination of the product’s innate efficacy and the 
degree to which the product is used by study participants.  Non-adherence 
to product use can dramatically decrease the observed product 
effectiveness. As one example, in the iPrEx study of Truvada, the intention-
to-treat (ITT) analysis of efficacy in reducing HIV acquisition was only 42% 
(Grant et al., 2010) whereas the efficacy in a nested case-control study of 
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participants with detectable drug estimated the efficacy to be as high as 
92%. The iPrEx investigators have concluded that only 18% of participants 
were taking PrEP on a daily basis (Amico, 2012). The negative outcome of 
the FemPrEP study (evaluating Truvada PrEP in African women) was 
attributed to product non-adherence (Van et al., 2012). At the time of study 
discontinuation, 95% of women reported usually or always using the study 
drug. However, in the subset of participants randomized to receive Truvada 
who seroconverted, TFV was only detected in 7 of 27 (26%) women. These 
studies demonstrate two important features of PrEP studies; participants are 
not always able to give accurate estimates of product use and secondly PK 
levels can be an important marker of product use.  
 
As concerns have increased over non-adherence in PrEP studies, there is 
increasing interest in using behavioral techniques to improve product 
adherence (Amico et al., 2012; Amico, 2012) as well incorporating objective 
measures of adherence into clinical trial design. These objective measure 
include electronic monitoring of product use with medical event monitoring 
systems  (MEMS) (Moench, O'Hanlon, & Cone, 2012) or Wisebags™(van 
der Straten et al., 2013), techniques to determine whether microbicide 
applicators have been placed into the vagina (Moench et al., 2012), 
measurement of  systemic and compartmental drug levels (Hendrix et al., 
2013; Minnis et al., 2013) and demonstration of antiviral activity in body 
fluids (Keller et al., 2011). More recent techniques include tagging 
microbicide gels with secondary esters such as 2-butyl acetate that once 
metabolized in the body can be measured in breath (Morey et al., 2012).  
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To date, adherence monitoring in rectal microbicide studies has depended 
on self-reported behavior as well as PK monitoring. However, ongoing and 
planned rectal microbicide studies, in addition to conventional adherence 
monitoring (self-report assessed through interviews and computer assisted 
self-interview (CASI) and PK monitoring), are including newer techniques 
such as interactive voice response systems (IVRS) (Project Gel, Section 
2.8), Wisebags (CHARM Program, Section 2.9), and short message service 
(SMS) diaries (MTN-017). 
2.10.4 Pharmacokinetics 
Characterisation of the PK profile of novel APIs is a routine component of 
drug development and is also a common feature of HIV prevention trials. 
Intense PK monitoring routinely occurs in Phase 1/2 studies whereas less 
frequent sampling schedules are employed in later stage studies. In the 
context of HIV prevention studies, Phase 1/2 PK studies help address the 
question as to whether ARV exposure in the cervicovaginal or rectal 
compartment is sufficient to out distance and outlast the virus at the site of 
infection (Hendrix, 2012). In combination with PD assessments (discussed in 
Section 2.10.5), PK data can be used to generate PK/PD models that have 
the potentials to provide insights as to whether candidate PrEP or 
microbicide agents are likely to demonstrate efficacy in Phase 2B/3 
effectiveness trials. PK data can also be used as an important adherence 
biomarker in PrEP studies.  
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To date, the majority of PK data generated in HIV prevention trials have 
focused on TFV gel, oral TDF, and TDF/FTC.  TFV is a monophosphorylated 
adenine nucleoside analogue RTI that requires two phosphorylation steps, 
undertaken by nucleoside kinases, to form the active moiety, TFV 
diphosphate (TFV-DP). TFV has a plasma half-life of 17 h compared to TFV-
DP which has a half-life of 150-180 h in peripheral blood mononuclear cells 
(PBMCs) (Kearney, Flaherty, & Shah, 2004; Hawkins et al., 2005). TDF is an 
esterified prodrug with increased bioavailability compared to TFV. FTC is a 
cytidine nucleoside analogue RTI and requires three phosphorylation steps, 
undertaken by deoxycytidine kinase and cellular kinases, to form the active 
moiety, FTC triphosphate (FTC-TP). FTC has a half-life in plasma of 8-10 h 
and FTC-TP has a half-life in PBMC of 29-56 h (Blum, Chittick, Begley, & 
Zong, 2007; Wang et al., 2004).  
 
Several studies have evaluated the compartmental distribution of TFV, TFV-
DP, FTC, and FTC-TP.  Patterson et al. characterized the PK profile of a 
single oral dose of TDF/FTC to 12 healthy men and women (Patterson et al., 
2011). Blood plasma, genital secretions, and cervicovaginal and rectal tissue 
biopsies were collected over the subsequent 14 days. TFV and FTC were 
measured in blood and genital secretions. TFV-DP and FTC-TP were 
measured in the tissue samples. TFV and FTC were detected in plasma 
throughout the 14-day period. The concentration of FTC was 27-fold higher 
in genital secretions compared to plasma. However, TFV was only 2.5-fold 
higher in genital secretions compared to plasma. Rectal tissue TFV-DP was 
100-fold higher than cervicovaginal tissue levels and persisted throughout 
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the 14 days. FTC-TP levels in the vaginal biopsies were 10-15-fold higher 
than rectal tissue but only persisted for 2 days after oral dosing. The RMP-
02/MTN-006 study compared the safety, acceptability, and PK/PD profile of 
a single 300 mg oral dose of TDF to rectal TFV 1% gel (single and seven 
daily doses)(Anton et al., 2012). Plasma TFV levels were 23-fold greater 
after oral compared to rectal dosing but conversely, rectal TFV-DP levels 
were 10-fold higher after rectal compared to oral dosing. The study also 
enrolled female participants and demonstrated that rectal application of TFV 
1% gel resulted in measurable levels of TFV in cervicovaginal fluid; an 
observation also made by Nuttall et al. in a recent NHP study (Nuttall et al., 
2012). The MTN-001 study enrolled 144 African and US participants in a 
cross-design where all participants received 6 week sequences of oral TDF, 
vaginal TFV gel, and a combination of oral TDF and vaginal TFV gel 
(Hendrix et al., 2011; Minnis et al., 2012). Oral administration of TDF 
resulted in 60-fold higher plasma levels of TFV whereas vaginal dosing with 
TFV gel resulted in 130-fold higher levels of TFV-DP in vaginal tissue 
compared to oral dosing with TDF. Rectal fluid levels of TFV were also 
higher after vaginal than after oral dosing. 
 
Collectively, these studies demonstrate that oral PrEP with TDF/FTC results 
in higher systemic exposure than after topical dosing with TFV gel. However, 
topical dosing with TFV gel results in higher tissue levels of TFV-DP than 
after oral dosing. Oral TDF/FTC appears to preferentially deliver TFV-DP to 
the rectal vs. cervicovaginal tissues whereas FTC-TP is higher in the 
cervicovaginal tissues compared to rectal tissues after oral dosing. Finally, 
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topical TFV gel application in the rectal compartment can also result in TFV 
exposure in the cervicovaginal compartment.  
 
The majority of available PrEP PK data relate to TFV and TDF/FTC. 
However, the CCR5 antagonist, maraviroc (Selzentry®, ViiV Healthcare, 
North Carolina, USA (Dorr et al., 2005)), is also being considered as both an 
oral (HPTN-069, http://clinicaltrials.gov/: NCT01505114) and a topical agent 
for HIV prevention (as a vaginal ring (MTN-013) and a rectal microbicide 
(CHARM Program, Section 2.9). Brown et al. conducted a PK study in 12 
HIV-negative men who received 300 mg of maraviroc twice daily for 8 days 
(Brown et al., 2011). Rectal tissue maraviroc area under the curve (AUC) 
was 7.5 to 26-fold higher than blood plasma. In a second study in women, 
maraviroc AUC in cervicovaginal fluid following oral dosing was only 1.9 to 
2.5-fold higher than blood plasma (Dumond et al., 2009). Maraviroc has the 
potential to be an important drug for HIV prevention since greater than 95% 
of new HIV infections are transmitted by CCR5 (R5) tropic viruses (Meng et 
al., 2002; Moore, Kitchen, Pugach, & Zack, 2004). One note of caution was 
raised by a recent NHP study conducted by the Center for Disease Control 
and Prevention (CDC), Atlanta, USA in which 10 macaques received oral 
maraviroc (44 mg/kg) and were challenged rectally with SHIV162p3 (Massud 
et al., 2013).   Despite similar PK profiles to human PK studies of maraviroc 
(including high concentrations of maraviroc in rectal secretions (median = 
2,329 ng/mL vs. median = 451 ng/mL in blood), 5/6 macaques receiving 
maraviroc and 3/4 control macaques were infected with SHIV162p3. One 
possible explanation for these NHP data is that there are eight amino acid 
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differences between the macaque and human CCR5 receptor. Although both 
receptors bind maraviroc, disassociation of the maraviroc from the macaque 
CCR5 receptor was 10-fold faster than from the human CCR5 receptor 
(Napier et al., 2005). Additional studies, including explant challenge, will be 
required to further assess the utility of maraviroc as a PrEP agent. 
 
These preliminary PK observations may have profound implications for the 
success or failure of PrEP regimens. As one example, Hendrix has argued 
that since the median ARV levels in the FEM-PrEP study (with a relative risk 
reduction in HIV infection of 0.0 (Van Damme et al., 2012) were similar to 
the iPrEx study (with a relative risk reduction in HIV infection of 0.42), it is 
possible that the divergent study outcomes resulted from higher rectal PK 
exposure in the iPrEx study where the route of HIV acquisition was rectal 
(Hendrix, 2012). A second example, again provided by Hendrix, is that the 
failure to demonstrate efficacy of the vaginal TFV gel arm in the VOICE 
study and the modest results from the CAPRISA 004 study cannot be purely 
explained by non-adherence. Based on PK data from the MTN-001 study, 
even with poor adherence, Hendrix estimates that the vaginal tissue 
concentrations in the VOICE and CAPRISA 004 studies would be 10-fold 
higher than those seen in the Partner’s PrEP study that reported a relative 
risk reduction of 0.75. Hendrix further asserts that there may be a dose-
variable effect that diminishes the effectiveness of topical microbicides i.e. 
more is not always better. Marrazzo et al. have recently presented the 
preliminary results of the VOICE study (Marrazzo et al., 2013). Neither oral 
nor topical TFV use was associated with protection from HIV infection and 
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PK data suggest that these results were a reflection of poor product 
adherence. In some of the VOICE clinical sites product adherence was 
below 20%.  These results clearly emphasize the important of conducting PK 
assessments throughout all phases of oral PrEP and microbicide 
development. 
2.10.5 Pharmacodynamics 
In the context of HIV infection, a common PD relationship is the fall in 
plasma viral load that usually occurs when ARV combination therapy is 
started by a treatment naïve individual who is chronically infected with HIV 
infection. The magnitude of the PD response can be modulated by the ARV 
dose used to treat the individual. In the context of HIV prevention the PD 
concept is less obvious because the goal is to prevent an event (HIV 
acquisition) happening rather than treating a chronic condition. However, 
PK/PD relationships can be demonstrated in PrEP studies. As one example, 
Karim et al. showed that, within women enrolled in the CAPRISA 004 study, 
those participants randomised to receive TFV gel who had levels of TFV > 
1000 ng/mL in genital tract fluid had a significantly greater protection from 
HIV infection than those women receiving placebo gel (2.4 vs. 9.1 per 100 
person-years; P = 0.01) (Karim et al., 2011). 
 
Cervicovaginal and colorectal explant models have been developed to 
provide in vitro PD data for candidate microbicides (Greenhead et al., 2000; 
Abner et al., 2005; Fletcher et al., 2006; Fletcher, Wallace, Mesquita, & 
Shattock, 2006) and can be used to explore the impact of API dosage on 
viral replication (Figure 2.2). As discussed in Section 1.5.4, explant 
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included; (i) a SOFT p24 endpoint (the last time point when the increase in 
virus concentration between two consecutive time points is greater than the 
square root of the sum of sequential changes in virus concentration for the 
entire assay), (ii) Day 12 or Day 15 p24, (iii) the slope of the virus growth 
curve, and (iv) p24 AUC defined by the trapezoidal rule. Among the 
conclusions of the study, the authors suggested that the most important 
factors in obtaining reproducible results across sites were; (i) use of a 
common viral stock, (ii) adherence to standardized explant challenge 
protocols, and (iii) use of the SOFT endpoint or another standardised 
endpoint in explant studies.  
 
The in vitro explant model has now been adapted to explore microbicide 
efficacy within clinic trials. The ex vivo / in vitro explant challenge model has 
been used in Phase 1 rectal microbicide (Anton et al., 2011; Anton et al., 
2012) and intravaginal studies (MTN-013). It will also be used in a subset of 
the HPTN-069 (Next PrEP) study (http://clinicaltrials.gov/: NCT01505114) in 
which at risk MSM and women will be randomised to receive oral ARV 
combination therapy.  
 
The advantage of the ex vivo / in vitro explant challenge model is that the 
target tissue (colorectal or cervicovaginal) is exposed to pharmacologically 
relevant concentrations of the candidate agent delivered from the 
formulation that will be used in future clinical trials. 
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tissue UC781 concentrations. Logistic regression analyses showed that the 
EC50,90,95 values were inversely related to p24 levels and provided clinically 
relevant insights into the tissue drug concentrations that might be necessary 
to prevent tissue infection. 
 
Ongoing studies are currently looking at less invasive PD models that do not 
require tissue sampling. One example is the collection of cervicovaginal or 
rectal fluid at varying times following product exposure. The fluid is 
incubated with a reporter cell line such as TZM-bl and challenged with virus 
to see whether the fluid has antiviral efficacy (Keller et al., 2011). Similar 
studies are planned for the MTN-017 Phase 2 rectal safety study of TFV gel 
and will also include tissue explant challenge so that the two models can be 
compared.  
2.11 Rectal microbicide advocacy 
Drug development does not occur in a vacuum and from the outset 
advocacy groups have played a critical role in the development of rectal 
microbicides. The International Rectal Microbicide Advocates group (IRMA; 
http://www.rectalmicrobicides.org/) has helped focus attention on rectal 
microbicide development including conducting community/internet based 
studies on lubricant usage (Javanbakht, Murphy, Gorbach, LeBlanc, & 
Pickett, 2010; Dezzutti et al., 2012). IRMA has also led efforts to define the 
need for rectal microbicides for men and women at risk of HIV infection 
associated with URAI in Africa. IRMA convened a meeting in Addis Ababa, 
Ethiopia in November 2011 that has helped catalyze community interest in 
rectal microbicides within Sub-Saharan Africa. Proceedings from this 
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meeting are available at the IRMA website. Unfortunately, MSM activity is 
stigmatized, illegal, and even punished by death in many countries across 
the world (Altman et al., 2012) and conducting rectal microbicides trials or 
indeed rolling out rectal microbicides as prevention in these communities   
would currently be difficult if not impossible (Semugoma, Nemande, & Baral, 
2012; Kyomya, Todyrs, & Amon, 2012). From a human rights perspective, 
as well as a drug development perspective, there is much to be done.   
2.12 Summary 
The field of rectal microbicide development has advanced significantly since 
the HIVNET-008 study of N9. Although rectal microbicide development has 
been delayed compared to vaginal microbicide development, this delay has 
in many ways provided critical guidance for how the rectal microbicide 
development pathway should proceed. The vaginal microbicide research 
community spent almost two decades focused on non-ARV microbicide 
candidates before the first success was seen with the CAPRISA 004 study 
of vaginal TFV gel. During this period, much was learnt about product 
acceptability, the potential for microbicide candidates to actually increase the 
risk of HIV acquisition, the need for careful safety surveillance throughout 
microbicide development, the problems associated with non-adherence to 
study products as well as the need to enhance and objectively monitor 
adherence behaviour in microbicide trials, and the utility of animal models of 
HIV infection to generate preliminary evidence of product efficacy. Learning 
from this extensive experience, the rectal microbicide research community 
has focused on the development of potent ARV candidates from the outset. 
Systemic and mucosal safety assessment are a critical component of Phase 
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1 study design, objective measures of product adherence are being 
evaluated, and PK/PD measurements are being used to provide unique 
insights into potential product efficacy.  
 
As of October 2013, it is clear that new HIV infections among MSM have not 
fallen and indeed may be rising in incidence; there is a clear need to develop 
new prevention options for individuals at risk of HIV infection through URAI. 
The iPrEx study was a significant milestone in HIV prevention research for 
MSM but the overall level of effectiveness was modest and non-adherence 
was a common problem. Groups such as IRMA are advocating vigorously 
for rectal microbicides, NHP models provide proof of concept that a rectal 
ARV microbicide might be efficacious, and the PK/PD data emerging from 
human Phase 1 studies provide preliminary but supportive data to 
encourage later stage development of rectal microbicides.  
 
The MTN-007 study, that forms the experimental core of this thesis, was a 
Phase 1 safety and acceptability assessment of a new formulation of TFV 
gel. The experimental approach, results, and conclusions from this study are 
provided in Chapters 3-7 of this thesis. 
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Chapter 3 
 
MTN-007 Overview 
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3 MTN-007 overview 
Rectal microbicides are being developed to prevent or at least significantly 
reduce the risk of HIV acquisition associated with URAI (McGowan, 2011). 
Attention is currently focused on the development of TFV 1% gel as a 
potential rectal microbicide. The vaginal formulation of TFV used in the 
CAPRISA 004 study (Karim et al., 2011) was evaluated in the RMP-02/MTN-
006 study (Anton et al., 2012) and rectal use of the gel was associated with 
mild to moderate gastrointestinal symptoms including bloating, pain, 
urgency, and diarrhea. The vaginal formulation of TFV is hyperosmolar 
(3111 mOsmol/kg) and it is possible that these symptoms were linked to 
product osmolality (Rohan et al., 2010). Consequently, the TFV gel used in 
the MTN-007 study was formulated with a lower glycerin concentration (5% 
w/w mg rather than the 20% w/w in the vaginal formulation) that resulted in a 
product osmolality of 836 mOsmol/kg (Dezzutti et al., 2012). It was 
anticipated this formulation would be better tolerated by study participants. 
 
In the two Phase 1 rectal safety studies of ARV rectal microbicides 
conducted to date (RMP-01 and RMP-02/MTN-006), product use was not 
associated with any significant change in mucosal safety parameters (Anton 
et al., 2011; Anton et al., 2011). Whilst this is reassuring, the possibility 
exists that the range of mucosal safety parameters used in these studies 
was too narrow and might have missed unanticipated or subtle but important 
mucosal changes. To address this situation, the MTN-007 study was 
designed to include a broad range of mucosal safety parameters including 
the use of microarray assessment of mucosal gene expression. In addition, 
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an N9 arm was included to help determine the utility of individual mucosal 
safety assays in detecting mucosal injury. Rectal use of N9 in humans has 
been associated with transient mild gastrointestinal discomfort as well as 
minor histological abnormality (Tabet et al., 1999) and has been associated 
with induction of proinflammatory responses in cervical epithelial cells 
(Fichorova et al., 2001). It was hoped that these additional assessments 
would help provide a more comprehensive assessment of mucosal safety. 
3.1 The Microbicide Trials Network 
The MTN-007 study was conducted by the NIH sponsored Microbicide 
Trials Network (MTN). The MTN is an NIH/NIAID/DAIDS sponsored clinical 
trials network that was established in 2006 to identify safe and effective 
microbicides for HIV prevention. From the outset, the MTN has targeted key 
populations at risk of HIV including women in Sub-Saharan Africa, 
adolescents, pregnant and lactating women, and MSM. Over the last six 
years, the MTN has developed an expansive program in vaginal and rectal 
microbicide development, with unique and substantial contributions to the 
field in the understanding of the safety, effectiveness, pharmacokinetics, 
pharmacodynamics, and the behavioral context associated with the use of 
topical microbicides (Table 3-1). The MTN Core is based in Pittsburgh, 
Pennsylvania (PA), USA and provides oversight for the development and 
execution of all MTN clinical trials.  
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Table 3-1 Completed, ongoing, or planned MTN clinical trials 
Study Product(s) Route Sites N Phase Status 
       
HPTN 035 PRO-2000 BufferGel® Vaginal 
USA, MA, 
ZI, SA 3,101 2B Completed 
       
HPTN 059 TFV 1% gel Vaginal USA, IN 200 2 Completed 
       
MTN-001 TFV tablet TFV 1% gel 
Oral 
Vaginal 
USA, SA, 
UG 168 2 Completed 
       
MTN-002 TFV 1% gel in pregnancy Vaginal USA 21 1 Completed 
       
MTN-003 
VOICE 
study 
TFV 1% gel  
TDF tablet 
TDF/FTC 
tablet 
Oral 
Vaginal SA, UG, ZI 5,029 2B Completed 
       
MTN-003B 
VOICE-B 
VOICE bone 
density 
substudy 
 UG, ZI 518  Completed 
       
MTN-003C 
VOICE-C 
VOICE 
community 
substudy 
 SA 164  Completed 
       
MTN-003D 
VOICE-D 
VOICE 
efficacy 
dilution study 
 SA, UG, ZI 80  Ongoing 
       
MTN-P01 Wisebag pilot study  SA 50 N/A Completed 
       
MTN-004 VivaGel® Vaginal USA 61 1 Completed 
       
MTN-005 Placebo ring Vaginal Ring USA, IN 195  Completed 
       
RMP-02/ 
MTN-006 
TDF tablet 
TFV 1% gel 
Oral 
Rectal USA 22 1 Completed 
       
MTN-007 RG-TFV 1% gel Rectal USA 65 1 Completed 
       
MTN-008 
TFV 1% gel 
in pregnancy 
and lactation 
Vaginal USA 
90 
Pregnant: 
15 
Lactating: 
1 Completed 
       
MTN-009 
HIV 
resistance in 
the 
community 
N/A SA 1,074  Completed 
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MTN-011 TFV 1% gel Vaginal USA 40 couples 1 Ongoing 
       
MTN-012   
IPM 010 DPV gel Penile USA 48 1 Completed 
       
MTN-013  
IPM 026 
DPV ring 
MVC ring 
DPV + MVC 
ring 
Vaginal USA 48 1 Completed 
       
MTN-014 TFV 1% gel Vaginal Rectal USA, SA 28 1 Ongoing 
       
MTN-015 
HIV 
seroconverter 
protocol 
N/A  Not available* N/A Ongoing 
       
MTN-016 Pregnancy registry N/A 
USA, SA, 
UG,  ZI 
Women: 
274 
Infants: 
213 
N/A Ongoing 
       
MTN-017 
RG-TFV 1% 
gel 
TDF/FTC 
tablet 
Oral 
Rectal 
USA, SA, 
PE, TH 186 2 Ongoing 
       
MTN-020 
ASPIRE 
study 
DPV ring Vaginal SA, UG,  ZI, ZA, MA 3,476 3 Ongoing 
       
MTN-023 DPV ring in adolescents Vaginal USA 100 1 
In 
development 
       
MTN-024 
DPV ring in 
post-
menopausal 
women 
Vaginal USA 90 1 Ongoing 
 
 
Data as of February, 2014. *MTN Core blinded to number of seroconverters on MTN-015. 
Sites: United States of America (USA), India (IN), South Africa (SA), Uganda (UG), 
Zimbabwe (ZI), Zambia (ZA), Malawi (MA), Peru (PE), and Thailand (TH). N/A: Not 
applicable; TFV: Tenofovir; RG-TFV: Reduced glycerin tenofovir; TDF: Tenofovir disoproxil 
fumarate; TDF/FTC: Tenofovir disoproxil fumarate/emtricitabine (Truvada®); DPV: 
Dapivirine; MVC: Maraviroc 
 
MTN protocol development is a stepwise process that begins with 
submission of a protocol concept to the MTN Executive Committee (EC). 
Protocol concepts can be submitted by MTN Core staff, site investigators, or 
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external investigators. Concepts may arise as part of the developmental 
pathway for candidate microbicides being evaluated by the MTN, in 
response to needs within the broader microbicide/PrEP field, or in response 
to specific requests by other product sponsors. Once a protocol concept has 
been approved, a protocol team is assembled and a full protocol is 
developed. Protocol development is coordinated by MTN Core Staff and 
usually involves a one day face-to-face meeting at which all key stake 
holders (MTN Core staff, clinical investigators, community representatives, 
product sponsors, statisticians, and DAIDS Medical Officers) have the 
opportunity to comment on and contribute to the study protocol. Once the 
protocol is completed it has to be submitted to the DAIDS Prevention 
Science Review Committee (PSRC) for review and approval. The DAIDS 
PSRC is a multidisciplinary committee that includes NIH staff with expertise 
in clinical trial design, pharmacovigilance, pharmacy affairs, clinical 
operations, statistics, and ethics. PSRC review usually results in protocol 
revisions. Once any PSRC required protocol changes are completed and 
approved by the PSRC or the DAIDS Medical Officer assigned to the 
protocol, the protocol moves to final regulatory approval and generation of 
Version 1.0 of the protocol that can be submitted to Institutional Review 
Boards (IRBs) or Ethics Committees for local approval.  
3.2 The design of MTN-007 
The MTN-007 study was a Phase 1 randomised, double-blinded, multi-site, 
placebo controlled rectal safety study in which approximately 60 participants 
were randomised to one of four arms as illustrated in Figure 3-1.  
 Figure 3-
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 Must agree to use study provided condoms for the duration of the study 
for vaginal and insertive anal intercourse 
 Must be in general good health 
 Must agree not to participate in other drug trials 
 
In addition to the criteria listed above, female participants met the 
following criteria: 
 
 Postmenopausal or using (or willing to use) an acceptable form of 
contraception (e.g., barrier method, intra-uterine device (IUD), hormonal 
contraception, surgical sterilization, or vasectomization of male partner).  
If the female participant has female partners only, the method of 
contraception will be noted as a barrier method in the study 
documentation. 
3.2.2 MTN-007 exclusion criteria  
 Abnormalities of the colorectal mucosa, or significant colorectal 
symptom(s), which in the opinion of the clinician represents a 
contraindication to biopsy (including but not limited to presence of any 
unresolved injury, infectious or inflammatory condition of the local 
mucosa, and presence of symptomatic external hemorrhoids) 
 At screening: participant-reported symptoms, and/or clinical or laboratory 
diagnosis of active rectal or reproductive tract infection requiring 
treatment per current CDC guidelines or symptomatic urinary tract 
infection.  Infections requiring treatment include symptomatic bacterial 
vaginosis, symptomatic vaginal candidiasis, other vaginitis, 
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trichomoniasis, Chlamydia trachomatis (CT), Neisseria gonorrhoea (GC), 
syphilis, active herpes simplex virus (HSV) lesions, chancroid, pelvic 
inflammatory disease, genital sores or ulcers, cervicitis, or symptomatic 
genital warts requiring treatment.  Note that an HSV-1 or HSV-2 
seropositive diagnosis with no active lesions is allowed, since treatment 
is not required   
 Anorectal STI within six months prior to the Screening Visit 
 At screening: 
a. Positive for hepatitis B surface antigen 
b. Hemoglobin < 10.0 g/dL 
c. Platelet count < 100,000/mm3 
d. White blood cell count < 2,000 cells/mm3 or > 15,000 cells/mm3 
e. For females: calculated creatinine clearance < 60 mL/min by 
the Cockcroft-Gault formula where creatinine clearance in 
mL/min (140- age in years) x (weight in kg) x (0.85 for 
female)/72 x (serum creatinine in mg/dL) 
f. For males: calculated creatinine clearance < 60 mL/min by the 
Cockcroft-Gault formula where creatinine clearance in mL/min 
= (140 - age in years) x (weight in kg) x (1 for male)/72 x 
(serum creatinine in mg/dL) 
g. Serum creatinine > 1.3×  the site laboratory upper limit of 
normal (ULN) 
h. Alanine transaminase (ALT) and/or aspartate aminotransferase 
(AST) > 2.5×  the site laboratory ULN  
i. +1 glucose or +1 protein on urinalysis (UA) 
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j. History of bleeding problems  
 
 History of significant gastrointestinal bleeding in the opinion of the 
investigator 
 Allergy to methylparaben, propylparaben, sorbic acid, and components of 
N9 
 Known HIV-infected partners 
 By participant report at enrollment, history of excessive daily alcohol use 
(as defined by the CDC as heavy drinking consisting of an average 
consumption of more than 2 drinks per day for men, and more than 1 
drink per day for women), frequent binge drinking or illicit drug use that 
includes any injection drugs, methamphetamines (crystal meth), heroin, 
or cocaine including crack cocaine, within the past 12 months 
 Per participant report at screening, anticipated use and/or unwillingness 
to abstain from the following medications during the period of study 
participation: 
a. Heparin, including Lovenox® 
b. Warfarin 
c. Plavix® (clopidogrel bisulfate) 
d. Rectally administered medications (including over-the-counter 
products) 
e. Aspirin  
f. Non-steroidal anti-inflammatory drugs (NSAIDS) 
g. Any other drugs that are associated with increased likelihood 
of bleeding following mucosal biopsy 
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 By participant report at screening, use of systemic immunomodulatory 
medications, rectally administered medications, rectally administered 
products (including condoms) containing N9, or any investigational 
products within the 4 weeks prior to the Enrollment/Baseline Evaluation 
Visit and throughout study participation 
 History of recurrent urticaria  
 Any other condition or prior therapy that, in the opinion of the 
investigator, would preclude informed consent, make study participation 
unsafe, make the individual unsuitable for the study or unable to comply 
with the study requirements. Such conditions may include, but are not 
limited to, current or recent history of severe, progressive, or uncontrolled 
substance abuse, or renal, hepatic, hematological, gastrointestinal, 
endocrine, pulmonary, neurological, or cerebral disease 
 
In addition to the criteria listed above, female participants were 
excluded if they met any of the following criteria: 
 
 Pregnant at the Enrollment/Baseline Visit 
 Breastfeeding at screening or intend to breastfeed during study 
participation per participant report. 
3.2.3 Primary objectives and endpoints 
The primary objective of the MTN-007 study was to evaluate the safety of 
TFV 1% gel when applied rectally. Safety endpoints included Grade 2 or 
higher AEs as defined by the Division of AIDS Table for Grading the Severity 
of Adult and Pediatric Adverse Events, Version 1.0, December 2004 
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(Clarification dated August 2009) and/or Addenda 1 and 3  (Female Genital 
and Rectal Grading Tables for Use in Microbicide Studies) to this table.  
3.2.4 Secondary objectives and endpoints 
The secondary objectives and endpoints explored in the MTN-007 study 
were as follows: 
 To evaluate the acceptability of TFV 1% gel when applied rectally.  
The acceptability endpoint was defined as the proportion of participants who 
at their Final Clinic Visit report via the acceptability questionnaire that they 
would be very likely to use the candidate microbicide during receptive anal 
intercourse. 
 To evaluate the safety of HEC placebo gel when applied rectally 
The safety endpoint for the HEC placebo gel was defined as Grade 2 or 
higher adverse events, as defined by the Division of AIDS Table for Grading 
the Severity of Adult and Pediatric Adverse Events, Version 1.0, December 
2004 (Clarification dated August 2009) and/or Addenda  1 and 3 (Female 
Genital and Rectal Grading Tables for Use in Microbicide Studies). 
 To determine whether use of TFV 1% gel is associated with rectal 
mucosal damage  
 To determine whether use of 2% N9 gel (Gynol-II®) is associated with 
rectal mucosal damage  
 
The mucosal damage endpoints for both TFV and N9 gels were defined as 
changes in the following parameters (and are further discussed in Chapter 
5): 
 Epithelial sloughing 
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 Intestinal histopathology 
 Intestinal mucosal mononuclear cell phenotype 
 Intestinal mucosal cytokine messenger RNA (mRNA) 
 Intestinal mucosal gene expression arrays 
 Cytokine profile in rectal secretions 
 Fecal calprotectin 
 Microflora 
3.2.5 Exploratory objectives and endpoints 
The exploratory objectives and endpoints evaluated in the MTN-007 study 
were as follows: 
 To determine whether regional heterogeneity exists between mucosal 
endpoints in samples collected at 9 cm and 15 cm for all parameters 
examined 
 To determine whether there is a correlation between histological 
abnormality and changes in mucosal biomarkers  
Both exploratory objectives were evaluated by the analysis of changes in the 
following mucosal parameters: 
 Epithelial sloughing 
 Intestinal histopathology 
 Intestinal mucosal mononuclear cell phenotype 
 Intestinal mucosal cytokine messenger RNA (mRNA) 
 Intestinal mucosal gene expression arrays 
 Cytokine profile in rectal secretions 
 Fecal calprotectin 
113 
 
 Microflora 
3.3 Study products 
Each participant was assigned a carton of applicators, based on the 
randomisation number.  At the Treatment 1 Visit the participant’s first dose of 
study product was administered by the clinic staff. During the period of daily 
administration study participants were instructed to insert one dose of gel 
into the rectum once daily throughout the 7-day period.  Rectal 
administration of study product occurred in the evening or before the longest 
period of rest.  All study products were provided in identical opaque HTI 
polypropylene pre-filled applicators (HTI Plastics, Lincoln, NE, USA) 
containing 4 mL of study product. 
3.3.1 Reduced glycerin formulation of tenofovir 1% gel 
TFV 1% gel (weight/weight) is a gel formulation of TFV (PMPA, 9-[(R)-2-
(phosphonomethoxy)propyl]adenine monohydrate), formulated in purified 
water with edetate disodium, citric acid, glycerin, methylparaben, 
propylparaben, and hydroxyethyl cellulose, with a pH adjusted to 4-5.  TFV 
1% gel is a transparent, viscous gel that was filled into applicators to form 
pre-filled, single-use applicators.  Each pre-filled applicator contains a dose 
of approximately 4.0 mL of TFV 1% gel (equal to 4.4 g).  TFV 1% gel was 
supplied by CONRAD (Arlington, VA, USA).  Under direction from CONRAD, 
Patheon Inc., (Cincinnati, OH USA) a contract manufacturing facility, 
manufactured the TFV 1% gel and analysed/released the gels under cGMP.  
Patheon Inc. filled the applicators with TFV 1% gel to create pre-filled 
applicators and packaged each applicator and plunger in a wrapper.   
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3.3.2 2% Nonoxynol-9 gel  
N9 gel was provided as Gynol II® (Johnson & Johnson, Fort Washington, PA, 
USA).  Gynol II® contains 2% N9 and inactive ingredients including lactic 
acid, methylparaben, povidone, propylene glycol, purified water, sodium 
carboxymethyl cellulose, sorbic acid and sorbitol sodium.  N9 is a non-ionic 
surfactant.  It is the active ingredient in many commonly used over-the-
counter contraceptive preparations (gels, creams, foams, films, sponges and 
suppositories) in the United States and worldwide.  DPT Laboratories Ltd 
(San Antonio, TX, USA) filled the applicators with 2% N9 to create pre-filled 
applicators and Patheon, Inc., packaged each applicator and plunger in a 
wrapper. Each applicator contained approximately 4.0 mL of 2% N9 gel for 
delivery.   
3.3.3 Hydroxyethyl cellulose (HEC) placebo gel 
HEC gel, sometimes called the “Universal Placebo Gel” contains 
hydroxyethyl cellulose as the gel thickener, purified water, sodium chloride, 
sorbic acid and sodium hydroxide (Tien et al., 2005). The gel is isotonic and 
formulated at a pH of 4.4 to avoid disrupting the normal vaginal pH and has 
minimal buffering capacity to avoid the inactivation of sexually transmitted 
pathogens.  HEC, the gelling agent, is used to approximate the viscosity of 
other microbicide gel candidates.  Each pre-filled applicator contained 
approximately 4 mL of placebo gel for delivery.   
 
HEC gel was supplied by CONRAD (Arlington, VA, USA).  Under direction 
from CONRAD, Patheon Inc., (Cincinnati, OH USA) a contract 
manufacturing facility, manufactured the HEC gel, and analysed/released 
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the gels under cGMP.  Patheon Inc., filled the applicators with HEC gel to 
create pre-filled applicators and packaged each applicator and plunger in a 
wrapper. 
3.4 Study procedures 
The MTN-007 study included a total of five study visits and two follow-up 
phone calls. After obtaining informed consent all participants were screened 
with a thorough medical history, a targeted physical examination, a digital 
rectal examination, and collection of swabs for CT and GC nucleic acid 
amplification testing (NAAT).  Urine was collected for CT/GC NAAT and for 
pregnancy testing in the female participants (pregnancy testing was 
repeated at all subsequent clinical visits). Blood was collected for safety labs 
(complete blood count, urea nitrogen, creatinine, ALT, and AST) and 
serology (syphilis, HIV-1, hepatitis B, and HSV-1/2). Participants who met 
the inclusion and exclusion criteria during the Screening Visit proceeded to 
an Enrollment Visit. At the Enrollment Visit participants were randomized, a 
behavioral questionnaire was administered and a rectal examination and a 
focused physical examination were performed. Swabs were collected for 
assessment of rectal microflora and quantification of cytokines/chemokines 
in rectal secretions. Participants then received a 120 mL Normosol-R pH 7.4 
enema and effluent was collected for evidence of epithelial sloughing and a 
sample of feces collected for measurement of fecal calprotectin.    A flexible 
sigmoidoscope was then inserted into the rectum and 7 biopsies were 
collected at 15 cm from the anal verge. A disposable anoscope was inserted 
into the anal canal and high resolution anoscopy (HRA) of the anorectum 
was performed at 16X magnification with collection of 7 rectal biopsies at 9 
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cm from the anal verge. Biopsies were used for histology, qRT-PCR, 
microarray analysis, and flow cytometry. At the Treatment 1 Visit (performed 
within 7-28 days of the Enrollment visit), all participants randomized to 
receive gel product had a single applicator of study gel inserted into the 
rectum. Within 30 minutes, swabs were collected for microflora and 
cytokines. An isotonic enema was administered and the same rectal 
samples, including biopsies, were collected as occurred during the 
Enrollment Visit. At the Treatment 2 Visit (performed at least 7 days after 
Treatment Visit 1) participants randomized to receive gel product were 
provided with 7 applicators of study product to take home and asked to 
insert the contents of one applicator daily for 7 days. The Final Clinic Visit 
occurred no more than 21 days after Treatment Visit 2 and was identical to 
the Enrollment Visit except that anogenital testing (CT/GC) was only 
performed if clinically indicated. 
3.5 Statistics and data management 
The statistical analysis plan for the MTN-007 study was developed in 
collaboration with the MTN Statistics and Data Management Center (SDMC) 
located within the Statistical Center for HIV/AIDS Research & Prevention 
(SCHARP) at the Fred Hutchinson Cancer Research Center, Seattle, WA, 
USA. The methodological approach was based on previous Phase 1 studies 
conducted by the MTN and was reviewed and approved by the US Food and 
Drug Administration (FDA) as the MTN-007 study was conducted under an 
FDA Investigational New Drug (IND) application (CONRAD IND#: 73,382). 
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3.5.1 Accrual, randomization, blinding, and sample size 
The study planned to recruit a total of 60 RAI abstinent, HIV uninfected men 
and women from the three study sites (Pittsburgh, PA, USA; Boston, MA, 
USA; and Birmingham, AL, USA).  Within each study site, twenty 
participants were to be enrolled and randomised to each of four study arms 
at a 1:1:1:1 ratio.  Based on the prior studies with similar eligibility 
requirements, each site was expected to enroll 4 participants per month.  
Therefore accrual was anticipated to take approximately 5 months.  The 
target for retention was 95% of enrolled participants over the study period. 
To preserve the study power in the case of discontinuation/non-adherence, 
additional participants would be allowed to enroll, at discretion of the 
protocol team, to replace participants who are discontinued or non-adherent 
to study product or scheduled study visits.  Therefore the total sample size 
might exceed 60 at the end of the study.   
 
The SDMC provided each study site with a series of numbered, sealed 
envelopes containing the randomization assignment for each participant.  
The envelopes were to be assigned sequentially by site staff.  Each 
participant was assigned a product code number. Using a blinded list of 
product codes and assigned products, the pharmacist at each site supplied 
the study product.  Multiple codes were utilised to conceal and protect the 
randomisation assignments in this study.  
 
Throughout the period of study implementation and data analysis, neither 
study staff nor participants were informed of the participants’ random 
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assignments.  Study staff and participants were unblinded after all study 
visits and data analyses were completed. In emergency situations, if a 
participant experienced a serious AE (SAE) that, in the opinion of the 
investigator required unblinding to protect participant safety, the investigator 
was able to request unblinding. 
 
For the proposed study sample size, the statistical properties of this study in 
assessing the safety of study products are summarized in Table 3-2.  With 
15 participants in each study arm, the probability of observing zero safety 
events, at least one safety event, and two or more safety events are listed in 
Table 3-2 assuming various true event rates. For instance, if the true rate of 
a safety endpoint is 5%, the probability of observing that endpoint in at least 
one participant out of 15 participants is 0.54.  A higher true event rate will 
result in a larger probability to observe at least one event. 
 
Table 3-2 Power considerations for MTN-007 
Event Rate Pr(0 event/n=15) Pr(≥ 1 event/n=15) Pr(≥ 2 events/n=15) 
    
1% 0.86 0.14 0.01 
5% 0.46 0.54 0.17 
10% 0.21 0.79 0.45 
15% 0.09 0.91 0.68 
25% ≤ 0.01 ≥  0.99 0.92 
 
The statistical properties of this study may also be characterized by the 
width of the confidence intervals (CI) around observed event rate.  Table 3-3 
presents the exact 95% confidence intervals (Clopper-Pearson method) of 
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the estimated rate when zero, one, or two endpoints are observed among 15 
participants: 
 
       Table 3-3 Confidence intervals for safety endpoints 
Number of Endpoints Lower Bound of CI Upper Bound of CI 
   
0 0.0% 16.1% 
1 0.1% 23.8% 
2 1.2% 30.4% 
   
 
3.6 Data analysis plan 
Descriptive statistics and graphics were used to summarize the 
characteristics of endpoints among the three treatment-randomized groups.  
For categorical variables, the numbers and the proportions were tabulated; 
for continuous variables, the mean, median, standard deviation, and 
quartiles were reported.  To assess the difference of certain endpoints after 
a treatment phase across treatment arms, Chi-square tests were used for 
categorical variables with exact P-values if the expected cell count in some 
stratum was small; t-test or linear regression were used for continuous 
variables; nonparametric methods such as Wilcoxon rank-sum test were 
used if sample size was small and data were non-normal.  Generalized 
linear models were used to regress continuous or categorical response 
variables on treatment arm, with or without adjusting for important baseline 
predictors.  The longitudinal data combining endpoints measured at two 
treatment phases were analyzed using generalized estimation equations 
(GEE) with robust variance estimates. Baseline characteristics were 
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tabulated for three arms to check any imbalance of randomisation.  Due to 
small sample size, formal comparison was not performed. 
3.6.1 Primary and secondary safety analysis  
For the primary safety analysis, per-protocol or modified intention to treat 
analysis based on the participants who have completed the baseline visit 
and at least one of two treatment visits were used.  The rationale was that (i) 
the primary objective of this study was to evaluate the safety of study 
products.  Adverse effects could only be induced by actual exposure to the 
study products.  (ii) Due to the small sample size being planned, any missing 
data generated from discontinuation/non-adherence could be a serious 
threat to the study power. Therefore replacing participants who are 
discontinued /non-adherent was allowed.  The number and the frequency of 
≥ Grade 2 adverse events was tabulated by study arm and treatment visit.  
Additional safety analyses also tabulated the number and type of AEs 
observed overall, and by severity, site, and study arm. AEs that lead to 
discontinuation of product use and/or study participation were tabulated 
separately.  At each treatment visit, the rate of safety events was compared 
to the baseline within the same treatment arms using McNemar’s test, and 
the event rate was also compared across treatment arms by Chi-square test.  
Logistic regression was used to assess the difference of event rates across 
arms adjusting for baseline predictors. 
3.6.2 Secondary analysis on acceptability 
Consistent with the secondary study objective to evaluate the acceptability of 
TFV 1% gel when applied rectally, the secondary endpoint was to examine 
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the proportion of participants who at their Final Clinic Visit report in the 
Product Acceptability Questionnaire stated that they would be very likely to 
use the candidate microbicide during RAI.  The proportion of participants 
who report high intentionality, operationalized as having a rating in the upper 
one third of the 10-point Likert scale, to use the product in the future every 
time they have RAI was calculated and proportions by study arm were 
compared using a Chi-square test with exact P-values.   
 
Additionally, to address the secondary study objective, non-parametric tests 
(Kruskal-Wallis non-parametric test), were used if data were non-normal and 
sample sizes were unequal across the three conditions, to evaluate whether 
acceptability assessed at the Final Clinic Visit in the Product Acceptability 
Questionnaire was different by study condition.  Because of insufficient 
statistical power to detect small or medium differences and the need to be 
aware of any trends, the distributions of each acceptability variable by 
treatment condition were also assessed.  Furthermore, effect sizes were 
estimated to determine whether how much variance in the measure of 
acceptability is accounted by the treatment arms.   
3.6.3 Secondary analysis on mucosal safety  
The association of six sets of mucosal parameters with study products was 
examined. Epithelial sloughing, histopathology scores, mucosal 
mononuclear cell phenotype, mucosal cytokine profile, weck cel cytokine 
levels, and fecal calprotectin were treated as continuous measures.  All six 
parameters were measured at baseline, after the Treatment 1 Visit and at 
the Final Clinic Visit.  
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Statistical analyses were first performed to evaluate the potential changes in 
immunological biomarkers after exposure to the N9.  It is known that the N9 
exposure induces transient rectal mucosal inflammation. Therefore the 
mucosal parameters, namely various histology measures, cytokines, cell 
phenotypes or calprotectins, were compared in biopsies sampled before and 
after the N9 single-dose or seven-dose administration.  The control arm 
without gel use was included in this analysis to adjust for the within-subject 
fluctuation of these mucosal parameters across 3 sampling time-points. In 
particular, two sample t-tests (Wilcoxon rank-sum test if skewed data) was 
used to compare the differences of each individual parameter before and 
after gel use to those of the control arm.  Longitudinal data modeling (GEE 
method) combining all three sampling time-points in both the N9 arm and the 
placebo arm was used to evaluate the differences of biomarkers induced by 
the N9 application. Despite the randomisation, the imbalance of baseline 
predictors could occur due to small sample size, additional regression 
analysis were performed adjusting for other baseline demographic factors.  
Those markers that were significantly associated with N9 application were 
considered as candidate mucosal parameters.  
 
For the TFV and HEC placebo gel arms, the mucosal parameters were 
evaluated before and after the gel application, using similar statistical 
methods as above. If there were mucosal parameters that were changed 
upon microbicide gel use, these parameters would be candidate markers for 
mucosal damage; however if there are no difference detected, we would 
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determine whether there is no mucosal damage or the parameter is not a 
good marker of mucosal damage by an inspection of results of this 
parameter from the N9 arm.  
3.6.4 Exploratory analyses on regional heterogeneity  
To determine whether regional heterogeneity exists between mucosal 
endpoints, the mucosal parameters were first compared between samples 
from 9 cm and 15 cm at each time point, using McNemar’s test if the 
parameter was categorical, paired t-test (Wilcoxon signed-rank test if 
skewed data) if the parameter was continuous. Mixed-effect ANOVA models 
were used to evaluate the heterogeneity of two sites across time with subject 
level modeled as a random effect.  Additional analyses were performed to 
evaluate the correlation between mucosal biomarkers and histological 
abnormality across arms and three time points. At each time point, various 
cytokines, cell phenotypes or calprotectins were compared between groups 
with different levels of histological abnormality, defined by sloughing or 
histopathology.  Longitudinal data modeling (GEE method) combining three 
time points were employed to evaluate the collected association of 
biomarkers with mucosal damage over the study period.  
3.6.5 Behavioral and product adherence questionnaire 
Data collected using the Baseline Behavioral Questionnaire was primarily 
descriptive on demographic variables, such as ethnic background, age, 
education, income; sexual behavior in the prior three months; behavioral 
practices, such as lubricant and enema use; frequency of HIV testing; and 
substance use in the prior three months.  Associations between pre-existing 
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practices (i.e., lubricant use) and willingness to use a microbicidal gel was 
also explored. 
 
Product adherence data was tallied by the Phone Reporting System was 
analyzed using repeated measures logistic regression to compare gel-use 
rates (the proportion of outpatient doses used of the seven, once-daily doses 
prescribed) between treatment arms. GEE was used to adjust for the within-
subject correlations for repeated measures. 
3.7 Trial oversight 
The development and execution of the MTN-007 study was conducted in 
observance with the MTN Manual of Operational Procedures (MOP; 
available at http://www.mtnstopshiv.org/node/187) and guidelines from the 
International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH). Oversight of the 
study was provided by multiple parties as illustrated in Figure 3-2 and 
discussed below. 
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Figure 3-2 Oversight of the MTN-007 study 
SMC: Study Monitoring Committee, IRB: Institutional Review Board (Ethics Committee), 
MTN EC: Microbicide Trials Network Executive Committee, DAIDS PSRC: DAIDS 
Prevention Science Review Committee, FDA: US Food and Drug Administration, FHI 360: 
Family Health International 360, CONRAD (www.conrad.org), PSRT: Protocol Safety 
Review Team 
 
Day-to-day management of the study (illustrated in green) was conducted by 
the site investigators and their clinical research teams, Medical Officers from 
DAIDS and CONRAD, the PSRT, and FHI 360. More distant oversight was 
provided by the groups in blue.  Specific responsibilities of the different 
parties are discussed below. 
3.7.1 MTN-007 protocol team 
The MTN-007 protocol team included the Protocol Chair (Ian McGowan MB 
ChB, DPhil, FRCP), the site PIs (Boston, MA, USA: Kenneth Mayer MD; 
Pittsburgh, PA, USA: Ross Cranston MD, FRCP; Birmingham, AL, USA: 
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Craig Hoesley MD), MTN Core staff (Pharmacy, Core Laboratory, and safety 
physicians) and representatives from FHI 360, DAIDS, the National Institute 
of Mental Health (NIMH), CONRAD, and SCHARP. The protocol team met 
by teleconference on a monthly basis during the conduct of the study and 
communicated through email listservs between teleconferences.  
3.7.2 Protocol Safety Review Team 
A Protocol Safety Review Team (PSRT) was established for the MTN-007 
study and included one MTN CORE protocol safety physician (PSP), the 
DAIDS and CONRAD Medical Officers, the Protocol Chair, and a Clinical 
Affairs Safety Associate from SCHARP. The PSRT conducted routine 
reviews (typically by monthly conference call) of the safety-data reports 
produced by SCHARP. The CORE safety physician received all queries from 
the site staff, formulated PSRT responses to the queries and circulated 
these to the rest of the PSRT, issued consensus PSRT responses to the 
queries, and maintained documentation of the query process.  
 
The CORE safety physician reviewed all safety-data reports and distributed 
a summary of each report for consideration by PSRT members prior to each 
PSRT conference call. Based on their review of the safety-data reports, the 
CORE PSP worked closely with the SCHARP Clinical Affairs Safety 
Associate to query the study sites for accurate, complete, and consistent AE 
reporting. The CORE safety physician chaired PSRT calls and led 
discussions regarding potential safety concerns. In the event that PSRT 
discussions raised questions about reported safety data, the CORE safety 
physician coordinated with the SCHARP Clinical Affairs Safety Associate to 
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query the sites for additional information. Site investigators were responsible 
for providing additional information to the PSRT when requested. When 
applicable, the CORE safety physician communicated consensus PSRT 
opinions or guidance to site investigators related to safety-data reporting, 
toxicity management, and/or study-product use management. 
3.7.3 CONRAD 
CONRAD is a not for profit research organization that focuses on the 
development of safe, acceptable, affordable products and methods that 
provide contraception and/or prevent the sexual transmission of HIV/AIDS 
and other infections (http://www.conrad.org/). Originally based at the Eastern 
Virginia Medical School, Norfolk, VA, USA, CONRAD now has its 
headquarters in Arlington, VA, USA. In December 2006, Gilead Sciences, 
Inc. granted rights to the International Partnership for Microbicides (IPM; 
http://www.ipmglobal.org) and CONRAD to develop, manufacture and, if 
proven efficacious, arrange for distribution in resource-limited countries of 
TFV gel as a microbicide to prevent infection with HIV. The MTN-007 study 
evaluated a reduced glycerin formulation of TFV 1% gel developed by 
CONRAD and the study was conducted under a CONRAD IND application 
(#73,382). As a consequence, CONRAD had the regulatory responsibility to 
keep the US FDA informed about the conduct (including emergent AEs) that 
occurred in the study and therefore played an active role in the MTN-007 
protocol team. 
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3.7.4 FHI 360 
The MTN partners with FHI 360, a not for profit research organization 
located in Durham, NC, USA that provides operational support for MTN 
studies conducted in the USA and in international settings 
(http://www.fhi360.org/). FHI 360’s responsibilities include site training, 
monitoring of study progress, and community engagement at clinical trial 
sites. FHI 360 designates a Clinical Research Manager (CRM) for each MTN 
protocol. The CRM works with the Protocol Chair to ensure that the study is 
conducted to a high standard and is completed within the anticipate timeline. 
3.7.5 DAIDS Medical Officer 
The MTN-007 study was sponsored by DAIDS and so a DAIDS Medical 
Officer (MO) formed part of the protocol team. The DAIDS MO helped with 
development of the protocol, the DAIDS PSRC review and approval process, 
and assessment of emergent safety events during the study as part of the 
PSRT team. 
3.7.6 US Food and Drug administration 
The MTN-007 study was conducted under an FDA IND and so the protocol 
was reviewed by the FDA as part of the ongoing oversight of the TFV 1% gel 
IND. At the end of the study the Protocol Chair and MTN Core staff will be 
required to generate an ICH compliant Clinical Study Report (CSR) that 
formally describes the conduct and results from the MTN-007 study.  
3.7.7 DAIDS Prevention Science Review Committee 
The DAIDS PSRC is an NIH multidisciplinary committee that reviews all 
clinical protocols submitted by DAIDS sponsored investigators for their 
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scientific and ethical merits. The DAIDS PSRC can request changes to the 
protocol if they feel that they are required and the review process routinely 
generates questions and comments that have to be addressed by the 
protocol team before the protocol can be finalized. 
3.7.8 MTN Executive Committee 
All MTN studies are reviewed at the monthly MTN EC meetings. This allows 
the conduct of the study to be monitored by a group of extremely 
experienced clinical investigators who can provide advice and support to 
address any emerging study issues.  
3.7.9 Local Institutional Review Boards 
Local IRBs are required to review and approve MTN protocols before trials 
can be activated for screening and enrollment. FHI 360 works with the sites 
to facilitate IRB submission, review, and approval of MTN protocols. 
3.7.10 Study Monitoring Committee 
The MTN uses a DSMB to provide independent oversight of Phase 2B/3 
effectiveness studies. For smaller Phase 1/2 studies such as MTN-007 
DSMBs are not routinely used. However, the MTN Core does use a Study 
Monitoring Committee (SMC) to provide oversight of Phase 1/2 studies. The 
SMC is comprised of the SMC Chair and staff from the MTN CORE, FHI 
360, Network Laboratory, SCHARP, and DAIDS. In addition, external 
experts can be asked to join the committee to provide additional expertise 
related to the study if requested by the SMC and Protocol Chair.  
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The SMC provides peer review of the conduct of most MTN studies, with an 
emphasis on key performance indicators such as participant accrual and 
retention, protocol and intervention adherence, data quality, and laboratory 
quality. For each protocol, requirements for the SMC review are contained 
within the protocol. For studies not subject to DSMB review, the SMC also 
reviews participant safety data. Studies are typically reviewed at an interval 
determined in accordance with the SMC (unless the SMC Chair waives 
review). The review schedule for each study is established by the SMC 
Chair, in consultation with other SMC members, based on a number of 
factors, including the study design, duration of participant accrual and follow-
up periods, and prior review findings. SMC reviews that take place via 
conference call may be conducted in two sessions:  
 
 In a closed session, SMC members and authorized observers discuss 
the SMC report and other materials submitted for review. 
 In an open session, the Protocol Chair(s) join the SMC to clarify 
issues and answer questions. Other Protocol Team representatives 
also may be invited to join the open session, if requested by the SMC 
Chair or Protocol Team.  
 
Some SMC reviews include a closed safety data review. Typically, this type 
of review is conducted for randomized and/or multi-cohort studies that are 
not subject to DSMB review. Closed safety data reviews are scheduled by 
the SDMC to take place immediately preceding full SMC reviews and are 
restricted to voting SMC members and the Protocol Statistician. The SDMC 
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distributes the closed safety data report to voting SMC members just prior to 
the SMC review. No written summary of the safety review is prepared; 
however, the SMC Chair communicates review findings to Protocol Team 
representatives during the open session of the full SMC review, and this 
discussion is summarized in the written summary of the full SMC review. For 
non-randomized and single cohort studies that are not subject to DSMB 
review, safety data is included in the main (open) SMC report and is 
reviewed as part of the full SMC review (with SMC members and authorized 
observers present).  
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Chapter 4 
 
Overall Safety and Acceptability Results 
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4 Overall safety and acceptability results 
4.1 Study conduct 
The MTN-007 study began screening in October 2010 and completed follow-
up visits in July 2011. Specific dates of site activation, first screening, first 
enrollment, final enrollment, and final follow-up for each site are shown in 
Table 4-1.  
 
Table 4-1 Key dates for the MTN-007 study 
Clinical Research 
Site 
Site 
Activation 
Date 
First 
Screening 
Visit 
First 
Enrollment 
Date 
Final 
Enrollment 
Date 
Final 
Follow-up 
Date 
      
Pittsburgh, PA  October 8, 
2010 
October 13, 
2010 
October 28, 
2010 
April 20, 
2011 
May 17, 
2011 
      
Birmingham, AL  October 14, 
2010 
October 20, 
2010 
November 
8, 2010 
June 20, 
2011 
July 20, 
2011 
      
Boston, MA  October 22, 
2010 
November 
8, 2010 
November 
30, 2010 
May 23, 
2011 
July 7, 
2011 
      
 
Table 4-2 Screening and enrollment by site 
Site 
Total 
Number 
Screened
Screen 
Failures 
Total 
Number 
Enrolled 
Total Number 
Replacements 
Enrolled 
Total 
Number 
Completed 
      
Pittsburgh, PA  26 5 21 1 21 
      
Birmingham, AL  33 10 23 3 23 
      
Boston, MA  43 22 21 1 21 
      
Total 102 37 65 5 65 
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4.1.1 Screening and enrollment  
Screening and enrollment data by site and arm are shown in the Tables 4-2 
and 4-3. Sixty-five participants were enrolled including five replacement 
participants. Three replacement participants were needed at the 
Birmingham, AL site. Two gel arm participants were replaced since they 
used less than five doses of gel, and another no-treatment arm participant 
was replaced since her Final Clinic Visit anoscopy/sigmoidoscopy was not 
completed. One replacement participant was needed at the Boston, MA site 
since he used less than five doses of gel. Likewise, one replacement 
participant was needed at the Pittsburgh, PA site since he used less than 
five doses of gel. The accrual process was completed in approximately eight 
months from the start of the study. All 65 participants were accrued and 
completed study follow-up as expected. 
 
Table 4-3 Screening and enrollment by arm 
Arm 
Total 
Number 
Screened
Screen 
Failures 
Total 
Number 
Enrolled 
Total Number 
Replacements 
Enrolled 
Total 
Number 
Completed 
      
Tenofovir 1% gel  NA NA 16 1 16 
      
2% Nonoxynol-9 gel  NA NA 17 2 17 
      
Placebo gel  NA NA 16 1 16 
      
No treatment  NA NA 16 1 16 
      
Total 102 37 65 5 65
      
4.2 Baseline demographics 
Tables 4-4 and 4-5 show the distribution of age, gender, Hispanic origin and 
race of the enrolled participants by site and arm, respectively. The average 
age of participants was 35.7 years, with a median age of 34.0 years. Thirty-
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one percent of participants were females, with six (38%), four (24%), four 
(25%), and six (38%) in the TFV gel, N9 gel, HEC placebo gel, and no gel 
arms, respectively. Nine percent of participants reported that they were of 
Hispanic origin, 68% reported they were White, 17% reported they were 
Black or African American. Asian race accounted for 5%, Native Hawaiian or 
Other Pacific Islander accounted for 2% and other race accounted for the 
remaining 9%.  
 
Table 4-4 Baseline demographics by site 
 All sites Pittsburgh Birmingham Boston 
    
Age      
 N 65 21 23 21 
 Mean (STD) 35.7 (11.0) 38.9 (11.8) 32.8 (9.1) 35.6 (11.7) 
 Median 34.0 35.0 32.0 38.0 
 Min, Max 18.0, 61.0 29.0, 47.0 23.0, 41.0 25.0, 45.0 
 25th, 75th percentile 27.0, 45.0 29.0, 47.0 23.0, 41.0 25.0, 45.0 
    
Gender      
 Male 45 (69%) 18 (86%) 9 (39%) 18 (86%)  
 Female 20 (31%) 3 (14%) 14 (61%) 3 (14%) 
    
Latino or of Hispanic origin    
 Yes 6 (9%) 1 (5%) 1 (4%) 4 (19%) 
 No 59 (91%) 20 (95%) 22 (96%) 17 (81%) 
    
Race    
 American Indian or 
Alaska Native 
0 (0%) 0 (0%) 0 (0%) 0 (0%) 
 Asian 3 (5%) 0 (0%) 1 (4%) 2 (10%)  
 Black or African 
American 
11 (17%) 4 (19%) 5 (22%) 2 (10%) 
 Native Hawaiian or  
 other Pacific Islander 
1 (2%) 0 (0%) 1 (4%) 0 (0%)  
 White 44 (68%) 16 (76%) 15 (65%) 13 (62%) 
 Other 6 (9%) 1 (5%) 1 (4%) 4 (19%)  
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Table 4-5 Baseline demographics by arm 
 All arms TFV gel N9 gel HEC gel No Rx 
  
Age      
 N 65 16 17 16 16 
 Mean (STD) 35.7 (11.0) 35.3 (8.7) 37.0 (9.9) 36.8 (12.6) 33.5 (13.0)
 Median 34.0 35.0 32.0 34.0 32.0 
 Min, Max 18.0, 61.0 22.0, 48.0 25.0, 57.0 20.0, 57.0 18.0, 61.0
 25th, 75th 
percentile 
27.0, 45.0 28.5, 42.5 29.0, 45.0 27.0, 46.0 22.5, 43.0
     
Gender      
 Male 45 (69%) 10 (63%) 13 (76%) 12 (75%) 10 (63%) 
 Female 20 (31%) 6 (38%) 4 (24%) 4 (25%) 6 (38%) 
     
Latino or of Hispanic 
origin 
    
 Yes 6 (9%) 1 (6%) 2 (12%) 2 (13%) 1 (6%) 
 No 59 (91%) 15 (94%) 15 (88%) 14 (88%) 15 (94%) 
  
Race     
 American 
Indian or 
Alaska Native 
0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
 Asian 3 (5%) 1 (6%) 1 (6%) 0 (0%) 1 (6%) 
 Black or 
African 
American 
11 (17%) 3 (19%) 2 (12%) 5 (31%) 1 (6%) 
 Native 
Hawaiian or 
other Pacific 
Islander 
1 (2%) 0 (0%) 0 (0%) 0 (0%) 1 (6%) 
 White 44 (68%) 10 (63%) 13 (76%) 9 (56%) 12 (75%) 
 Other 6 (9%) 2 (13%) 1 (6%) 2 (13%) 1 (6%) 
     
4.2.1 Study retention  
Tables 4-6 and 4-7 show the retention of participants for each study visits by 
site and arm, respectively. The proportion retained at a scheduled visit was 
obtained by dividing the number of participants who completed the visit by 
the number of participants expected for that visit. The MTN-007 study 
targeted ≥ 95% retention by site and by arm and this metric was achieved in 
the study. 
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Table 4-6 Study retention by site 
Site Treatment 1 Treatment 2 Final Clinic Visit 
    
Pittsburgh, PA  100% 100% 100% 
    
Birmingham, AL  96% 96% 91% 
    
Boston, MA  100% 95% 95% 
    
All sites 98% 97% 95%
    
 
Table 4-7 Study retention by arm 
Arm Treatment 1 Treatment 2 Final Clinic Visit 
    
Tenofovir 1% gel  100% 94% 94% 
    
2% Nonoxynol-9 gel  100% 94% 94% 
    
Placebo gel  100% 100% 100% 
    
No Gel 94% 100% 94% 
    
All arms 98% 97% 95%
    
4.2.2 Study termination  
The last study participant was terminated on July 20, 2011 at the 
Birmingham, AL site. Sixty-one (94%) of participants terminated at their 
scheduled exit visit. One participant enrolled in the TFV gel arm from the 
Birmingham, AL site and another participant enrolled in the N9 gel arm from 
the Boston, MA site refused further participation. One participant enrolled in 
the No Gel arm from the Birmingham, AL site was terminated since the study 
staff could not contact her. One participant enrolled in the HEC placebo gel 
arm from the Boston, MA site was terminated because he was incarcerated.  
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4.2.3 Visit adherence: completion of procedures  
Tables 4-8 and 4-9 summarize visit adherence by completion of required 
and expected procedures, by arm and site, for participant-visits for the 
following: (i) rectal exams collected including perianal visual examination 
and digital rectal examination; (ii) anoscopy and sigmoidoscopy results; (iii) 
pregnancy tests; (iv) laboratory tests; (v) specimen storage; and (vi) 
Computer Assisted Self-Interview (CASI) of the Acceptability Questionnaire.  
Completion of a procedure was defined for post-enrollment follow-up visit as 
follows:  
4.2.3.1 Follow-up visits where rectal exams were required and expected 
Rectal exams were required at Treatment 1, Final Clinic and Early 
Termination visits for all participants. For the TFV gel, N9 gel, HEC placebo 
gel and no gel arms, staff completed the perianal visual examination at 94%, 
97%, 100% and 100% as well as the digital rectal examination at 94%, 97%, 
97% and 100% of the participant-visits, respectively. For the Pittsburgh, PA, 
Birmingham, AL and Boston, MA sites, staff completed the perianal visual 
examination at 100%, 98% and 95% as well as the digital rectal examination 
at 100%, 95% and 95% of the participant-visits, respectively.  
4.2.3.2 Follow-up visits where anoscopy and sigmoidoscopy were required 
and expected  
Anoscopy and sigmoidoscopy were required at Treatment 1 and Final Clinic 
visits for all participants. For the TFV gel, N9 gel, HEC placebo gel and no 
gel arms, staff completed the anoscopy and sigmoidoscopy at 97%, 97%, 
100% and 100% of the participant-visits, respectively. For the Pittsburgh, 
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PA, Birmingham, AL and Boston, MA sites, staff completed the anoscopy 
and sigmoidoscopy at 100%, 100% and 95% of the participant-visits, 
respectively.  
4.2.3.3 Follow-up visits where pregnancy tests were required and expected 
Pregnancy tests were required for females of childbearing potential at 
Treatment 1, Treatment 2, Final Clinic and Early Termination Visits and 
during Interim visits (as recorded on the Interim Visit CRF) where the 
participant visited the clinic for one of the following reasons:  
 In-person visit to report new symptoms;  
 Participant needed study product; or  
 Participant was returning unused study product.  
For the Pittsburgh, PA, Birmingham, AL and Boston, MA sites, as well as for 
each arm, staff completed the pregnancy tests at 100% of the participant-
visits.  
4.2.3.4 Follow-up visits where laboratory tests were required and expected 
Laboratory tests were required at Final Clinic and Early Termination Visits 
only and were based on the following:  
 Full blood count: WBC, hemoglobin, hematocrit, MCV, platelets  
 Differential: Neutrophils (both percentage and absolute count), 
lymphocytes, monocytes, eosinophils, and basophils  
 Liver function tests: aspartate aminotransferase (AST) and alanine 
transaminase (ALT) 
 Renal function tests: Creatinine, blood urea nitrogen (BUN)  
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 Dipstick urinalysis tests: Leukocyte esterase (LE), nitrites, protein, 
glucose  
 HIV EIA test: If positive, the final HIV status must be confirmed on the 
HIV Test Results Case Report Form (CRF).  
 
For the TFV gel, N9 gel, HEC placebo gel and no gel arms, staff completed 
laboratory tests at 100%, 94%, 100% and 93% of the participant-visits, 
respectively. For the Pittsburgh, PA, Birmingham, AL and Boston, MA sites, 
staff completed laboratory tests at 100%, 100% and 90% of the participant-
visits, respectively.  
4.2.3.5 Follow-up visits where specimen storage was required and expected  
Specimen storage was required at Treatment 1 and Final Clinic Visits only 
and was based on the following:  
 Rectal swabs for microflora  
 Rectal sponge specimens  
 Rectal lavage fluid  
 Anoscopic biopsies for:  
o Histology 
o Cytokine gene expression 
o Phenotyping of mucosal mononuclear cells 
o Gene expression (microarray) 
 Sigmoidoscopy biopsies for: 
o Histology 
o Cytokine gene expression 
o Phenotyping of mucosal mononuclear cells 
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o Gene expression (microarray) 
 Fecal sample (calprotectin)  
Specimen storage (n = 12) was considered completed when the stored or 
collected box was marked for each specimen specified above. Specimen 
storage was considered partially completed when less than 12 of the stored 
or collected boxes specified above were marked, and not completed if all 12 
of the stored or collected boxes specified above were not marked.  
 
For the TFV gel, N9 gel, HEC placebo gel and No Gel arms, staff completed 
specimen storage at 81%, 67%, 97% and 77% of the participant-visits, 
respectively. For the Pittsburgh, PA, Birmingham, AL and Boston, MA sites, 
staff completed specimen storage at 76%, 98% and 66% of the participant-
visits, respectively.  
4.2.3.6 Follow-up visits where completion of CASI product acceptability 
questionnaire is required and expected  
The CASI Product Acceptability Questionnaire was required at Final Clinic 
and Early Termination Visits only for participants in any of the gel groups. 
Ninety-eight percent of participants in the gel groups completed the 
Questionnaire at their Final Clinic Visit. One participant (2%) who did not 
complete the Questionnaire was in the TFV gel arm at the Birmingham, AL 
site. 
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Table 4-8 Completion of study procedures by site 
 All sites Pittsburgh Birmingham Boston 
    
Perianal visual 
examination  
98% 100% 98% 95%  
    
Digital rectal 
examination  
97% 100% 95% 95%  
     
Anoscopy  98% 100% 100% 95% 
    
Sigmoidoscopy 98% 100% 100% 95% 
  
Pregnancy tests 100% 100% 100% 100%  
    
Laboratory tests 97% 100% 100% 90%  
    
Specimen 
storage 
80% 76% 98% 66%  
    
Completion of 
CASI 
98% 100% 94% 100%  
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Table 4-9 Completion of study procedures by arm 
 All arms TFV gel N9 gel HEC gel No Rx 
   
Perianal visual 
examination  
98% 94% 97% 100% 100% 
   
Digital rectal 
examination  
97% 94% 97% 97% 100% 
   
Anoscopy  98% 97% 97% 100% 100% 
      
Sigmoidoscopy 98% 97% 97% 100% 100% 
   
Pregnancy 
tests 
100% 100% 100% 100% 100% 
      
Laboratory 
tests 
97% 100% 94% 100% 93% 
      
Specimen 
storage 
80% 81% 67% 97% 77% 
      
Completion of 
CASI 
98% 94% 100% 100% 0% 
      
 
4.2.4 Product adherence  
Adherence to the study product is shown by site and arm in Tables 4-10 and 
4-11, respectively. Of the 46 out of 65 participants who were randomized to 
the gel arms and dispensed study product, 98% completed at least 80% of 
the expected product use from the Treatment 2 visit to the Final Clinic Visit.  
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Table 4-10 Product adherence by site 
 All sites Pittsburgh Birmingham Boston 
    
Participants enrolled  65 21 23 21
    
Participants 
randomized to gel 
groups  
48 16 17 15  
     
Participants dispensed 
gel product 
46 16 15 15 
    
Participants not 
dispensed product 
2 0 2 0 
  
Percentage of study 
product use 
    
 0.0% 0 (0%) 0 (0%) 0 (0%) 0 (0%)  
 0.1-49.9% 1 (2%) 1 (6%) 0 (0%) 0 (0%)  
 50.0-79.9% 0 (0%) 0 (0%) 0 (0%) 0 (0%)  
 ≥ 80.0% 45 (98%) 15 (94%) 15 (100%) 15 (100%)  
     
Number of used 
applicators returned 
    
 0 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
 1 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
 2 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
 3 1 (2%) 1 (6%) 0 (0%) 0 (0%) 
 4 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
 5 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
 6 4 (9%) 3 (19%) 1 (7%) 0 (0%) 
 7 37 (80%) 12 (75%) 13 (87%) 12 (80%) 
 8 4 (9%) 0 (0%) 1 (7%) 3 (20%)  
    
 
Thirty-seven participants (80%) used seven applicators (the expected dose), 
four participants (9%) used eight applicators, four participants (9%) used six 
applicators and one participant (2%) used three applicators. The participant 
who used three applicators was enrolled in the N9 gel arm and from the 
Pittsburgh, PA site.  
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Table 4-11 Product adherence by arm 
 All arms TFV gel N9 gel HEC gel No Rx 
   
Participants 
enrolled  
65 16 17 16 NA 
   
Participants 
randomized to gel 
groups  
48 16 16 16 NA 
      
Participants 
dispensed gel 
product 
46 15 16 15 NA 
      
Participants not 
dispensed gel 
product 
2 1 0 1 NA 
      
Percentage of 
study product use 
     
 0.0% 0 (0%) 0 (0%) 0 (0%) 0 (0%) NA 
 0.1-49.9% 1 (2%) 0 (0%) 1 (6%) 0 (0%) NA 
 50.0-79.9% 0 (0%) 0 (0%) 0 (0%) 0 (0%) NA 
 ≥ 80.0% 45 (98%) 15 (100%) 15 (94%) 15 (100%) NA 
      
Number of used 
applicators 
returned 
     
 0 0 (0%) 0 (0%) 0 (0%) 0 (0%) NA 
 1 0 (0%) 0 (0%) 0 (0%) 0 (0%) NA 
 2 0 (0%) 0 (0%) 0 (0%) 0 (0%) NA 
 3 1 (2%) 0 (0%) 1 (6%) 0 (0%) NA 
 4 0 (0%) 0 (0%) 0 (0%) 0 (0%) NA 
 5 0 (0%) 0 (0%) 0 (0%) 0 (0%) NA 
 6 4 (9%) 1 (7%) 2 (13%) 1 (7%) NA 
 7 37 (80%) 12 (80%) 12 (75%) 13 (87%) NA 
 8 4 (9%) 2 (13%) 1 (6%) 1 (7%) NA 
      
4.2.5 Product discontinuation  
The number and percentages of participants with product holds, reasons for 
holds, and whether or not the product holds were resumed are presented in 
Tables 4-12 and 4-13 by site and arm, respectively. Three participants were 
placed on product hold. One participant, enrolled in the HEC placebo gel 
arm and from the Birmingham, AL site, reported a Grade 4 adverse 
experience consisting of a major depression episode judged not related to 
study product. This participant was permanently discontinued from product 
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use. The other two participants resumed product use. They were from the 
Boston, MA site, with one participant enrolled in the TFV gel arm and the 
other one enrolled in the N9 gel arm. 
 
Table 4-12 Product hold/discontinuation by site 
 All sites Pittsburgh Birmingham Boston 
    
Participants enrolled  65 21 23 21  
    
Participants with at 
least one product hold  
3 0 1 2  
     
Reasons for product 
hold 
    
 Pregnancy 0 (0%) 0 (0%) 0 (0%) 0 (0%)  
 HIV infection 0 (0%) 0 (0%) 0 (0%) 0 (0%)  
 Adverse event 2 (67%) 0 (0%) 1 (100%) 1 (50%)  
 Other 1(33%) 0 (0%) 0 (0%) 1 (50%)  
     
Product resumed     
 Yes 2 (67%) 0 (0%) 0 (0%) 2 (100%) 
 No 1 (33%) 0 (0%) 1 (100%) 0 (0%) 
    
 
Table 4-13 Product hold/discontinuation by arm 
 All arms TFV gel N9 gel HEC gel No Rx 
     
Participants enrolled  65 16 17 16 NA 
     
Participants with at 
least one product 
hold 
3 1 1 1 NA 
     
Reasons for product 
hold 
    
 Pregnancy 0 (0%) 0 (0%) 0 (0%) 0 (0%) NA 
 HIV infection 0 (0%) 0 (0%) 0 (0%) 0 (0%) NA 
 Adverse event 2 (67%) 0 (0%) 1 (100%) 1 (100%) NA 
 Other 1 (33%) 1(100%) 0 (0%) 0 (0%) NA 
     
Product resumed   
 Yes 2 (67%) 1 (100%) 1 (100%) 0 (0%) NA 
 No 1 (33%) 0 (0%) 0 (0%) 1 (100%) NA 
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4.2.6 Protocol deviations and enrollment violations  
There was one protocol deviation identified in this study. This deviation 
occurred at the Boston, MA site and involved enrollment of an ineligible 
participant due to site staff misreading a screening urine protein result. The 
result, originally thought to be “trace”, was discovered to be +1 (see 
exclusion criterion 4i above) after the participant had been enrolled. Site staff 
immediately brought the participant in for retesting, at which time the urine 
protein result was negative. Since this participant was randomized to the “no 
treatment” arm, the PSRT decided that the participant should remain in 
follow-up for the duration of the study.  
4.2.7 Study Monitoring Committee review history  
There was one Study Monitoring Committee (SMC) review for the MTN 007 
study that occurred on May 23, 2011. The Committee commented that they 
would like to see an improvement in the response time for data clarifications 
from the Boston site. There were no other recommendations to change the 
conduct of the study. 
4.3 General product safety 
4.3.1 Adverse events  
Table 4-14 shows the incidence of adverse events by severity and by arm.  
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Table 4-14 Incidence and severity of adverse events by arm 
 All arms TFV gel N9 gel HEC gel No Rx 
     
N  65 16 17 16 16 
     
Participants with one 
or more adverse 
events 
    
     
 Grade 1 30 (46%) 7 (44%) 10 (59%) 7 (44%) 6 (38%) 
 Grade 2 18 (28%) 3 (19%) 7 (41%) 4 (25.0%) 4 (25%) 
 Grade 3 2 (3%) 0 (0%) 0 (0%) 0 (0%) 2 (13%) 
 Grade 4 1 (2%) 0 (0%) 0 (0%) 1 (6%) 0 (0%) 
 Grade 5 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
     
 Total 51 (79%) 10 (63%) 17 (100%) 12 (75%) 12 (75%) 
     
 
Table 4-15 shows the incidence of adverse experiences and relationship to 
study product by arm.  
 
Table 4-15 Incidence of adverse events and relationship to study product 
 All arms TFV gel N9 gel HEC gel No Rx 
     
N  65 16 17 16 16 
     
Participants with one 
or more adverse  
    
     
 Not related 22 (34%) 3 (19%) 4 (24%) 3 (19%) 12 (75%) 
 Related 29 (45%) 7 (44%) 13 (77%) 9 (56%) 0 (0%) 
 Total 51 (79%) 10 (63%) 17 (100%) 12 (75%) 12 (75%) 
     
 
Table 4-16 shows the total number and percentages of adverse events by 
severity and relationship to study product overall.  
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Table 4-16 Adverse event severity and relationship to study product 
 Total Related Not Related 
   
Severity Grade     
  
 Grade 1 121 (80%) 41 (34%) 80 (66%) 
 Grade 2 27 (18%) 6 (22%) 21 (78%) 
 Grade 3 2 (1%) 0 (0%) 2 (100%) 
 Grade 4 1 (1%) 0 (0%) 1 (100%) 
 Grade 5 0 (0%) 0 (0%) 0 (0%) 
   
 Total 151 (100%) 47 (31%) 104 (69%) 
   
 
Figure 4-1 Adverse events and relationship to product use 
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Figure 4-1 shows the number of adverse experiences and their reported 
relationship to study product for the TFV gel, N9 gel, HEC placebo gel and 
No Gel arms, respectively. 
  
There was only one SAE in the MTN-007 study. The participant, enrolled in 
the HEC placebo gel arm and from the Birmingham, AL site, reported a 
Grade 4 adverse experience consisting of a major depression episode 
judged not related to study product.  
4.3.2 Primary endpoints  
Consistent with the primary study objective to assess the safety of TFV 1% 
gel when applied rectally, the following primary endpoint was assessed:  
 
Grade 2 or higher AEs as defined by the Division of AIDS Table for Grading 
the Severity of Adult and Pediatric Adverse Events, Version 1.0, December 
2004 (Clarification dated August 2009) and/or Addenda 1 and 3 (Female 
Genital and Rectal Grading Tables for Use in Microbicide Studies) to this 
table. 
 
Table 4-17 shows the primary endpoint analyses of participants with at least 
one Grade 2 or higher AE from the full cohort. The full cohort included all 
participants that were randomized into the study, and any replacement 
participants. The analysis was completed for three separate time frames as 
follows: post-randomization up to the Treatment 2 visit, the Treatment 2 visit 
through the end of the study, and post-randomization through the end of the 
study. The table displays the total number of Grade 2 AEs out of the total 
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number of participants who were eligible for assessment within the time 
frame. Note that there were three participants who missed product 
dispensation at the Treatment 2 visit and so, therefore, were removed from 
the number of eligible participants analyzed for the Treatment 2 visit through 
the end of the study time frame.  
 
Table 4-17 Primary endpoint analysis (All) 
 Post-Randomization 
Up to Treatment 
 Visit 2  
(N=65) 
Treatment Visit 2 
through end of the 
Study  
(N=62) 
Post-Randomization 
through End of the 
Study  
(N=65) 
 n/N (%) P-value* n/N (%) P-value* n/N (%) P-value* 
Arm  HEC No Rx HEC No Rx HEC No Rx
 
TFV 1/16 (6.3) 0.60 1.0 
2/15 
(13.3) 1.0 0.65 
3/16 
(18.8) 0.69 0.43 
N9 2/17 (11.8) 0.66 1.0 
5/16 
(31.3) 0.69 1.0 
7/17 
(41.2) 0.72 1.0 
HEC 3/16 (18.8)  1.0 
3/16 
(18.8)  0.69 
5/16 
(31.3)  1.0 
No Rx 2/16 (12.5)   
4/15 
(26.7)   
6/16 
(37.5)   
*P-values based on Fisher’s Exact Test 
Comparisons between randomization arms of TFV gel versus HEC placebo 
gel and No Rx, N9 gel versus HEC placebo gel and No Gel, and HEC 
placebo gel versus No Rx showed no statistically significant results based on 
the nominal p-values found using Fisher’s Exact Test.  
 
Table 4-18 shows the primary endpoint analyses of participants with at least 
one Grade 2 or higher AE from the ITT cohort. The ITT cohort includes only 
participants that were randomized into the study, excluding any replacement 
participants. The analysis was completed for three separate time frames as 
follows: post-randomization up to the Treatment 2 visit, the Treatment 2 visit 
through the end of the study, and post-randomization through the end of the 
study. The table displays the total number of Grade 2 AEs out of the total 
number of participants who were eligible for assessment within the time 
frame.  
 
Table 4-18 Primary endpoint analysis (Intention to Treat Cohort) 
 Post-Randomization 
Up to Treatment 
 Visit 2  
(N=60) 
Treatment Visit 2 
through end of the 
Study  
(N=57) 
Post-Randomization 
through End of the 
Study 
 (N=60) 
 n/N (%) P-value* n/N (%) P-value* n/N (%) P-value* 
Arm  HEC No Rx HEC No Rx HEC No Rx
 
TFV 1/15 (6.7) 0.60 1.0 
2/14 
(14.3) 1.0 0.65 
3/15 
(20.0) 1.0 0.43 
N9 1/15 (6.7) 0.60 1.0 
5/14 
(35.7) 0.21 1.0 
6/15 
(40.0) 0.7 1.0 
HEC 3/15 (20.0)   1.0 
2/15 
(13.3)   0.39 
4/15 
(26.7)   0.7 
No Rx 2/15 (13.3)     
4/14 
(28.6)     
6/15 
(40.0)     
*P-values based on Fisher’s Exact Test 
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Note that there were three participants who missed product dispensation at 
the Treatment 2 visit and so, therefore, were removed from the number of 
eligible participants analyzed for the Treatment 2 visit through the end of the 
study time frame. Comparisons between randomization arms of tenofovir gel 
versus HEC placebo gel and no gel, N9 gel versus HEC placebo gel and no 
gel, and HEC placebo gel versus no gel showed no statistically significant 
results based on the nominal p-values found using Fisher’s Exact Test. 
 
Table 4-19 below shows primary endpoint analyses of participants with at 
least one Grade 2 or higher AE adjusting for the number of returned 
applicators. This analysis was conducted on the Treatment 2 through the 
end of the study time frame only for both the full and ITT cohorts.  
 
Table 4-19 Primary endpoint analysis based on returned applicators 
  Treatment Visit 2 through End of the Study 
Randomization 
Arm HEC Placebo Gel 
  Full Cohort ITT Cohort 
  OR (95% CI) P-value OR (95% CI) P-value 
Tenofovir gel 0.35 (0.03, 4.0) 0.40 0.61 (0.05, 8.3) 0.71 
N9 gel 1.9 (0.36, 10.1) 0.45 3.4 (0.53, 22.3) 0.20 
 
 
The HEC placebo arm was used as the reference group and was compared 
to TFV gel and N9 gel groups. Although not statistically significant, odds 
ratios showed that there was a trend toward protection with respect to Grade 
2 AEs of TFV gel compared to HEC placebo gel in the full and ITT cohorts. 
Conversely, but also not statistically significant, odds ratios showed that 
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there was a trend toward harm from N9 with respect to Grade 2 AEs 
compared to HEC placebo gel.  
 
Table 4-20 Rectal examination findings at the enrollment visit by arm 
 All arms TFV gel N9 gel HEC gel No Rx 
     
N  65 16 17 16 16 
     
Findings from the 
enrollment perianal 
examination  
    
     
Normal 57 (88%) 15 (94%) 15 (88%) 13 (81%) 14 (88%) 
     
Abnormal 8 (12%) 1 (6%) 2 (12%) 3 (19%) 2 (13%) 
 Warts 2 (3%) 0 (0%) 0 (0%) 0 (0%) 2 (13%) 
 Fissure 1 (2%) 0 (0%) 0 (0%) 1 (6%) 0 (0%) 
 Ulceration 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
 Pigmentation 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
 Haemorrhoids 1 (2%) 0 (0%) 1 (6%) 0 (0%) 0 (0%) 
 Skin tags 4 (6%) 1 (6%) 1 (6%) 1 (6%) 1 (6%) 
 Leukoplakia 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
 Fistula 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
 Petechiae  0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
 Purpura 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
 Ecchymosis 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
 Other abnormal 
findings 
1 (2%) 0 (0%) 0 (0%) 1 (6%) 0 (0%) 
     
Findings from the 
enrollment digital 
rectal exam 
    
     
Normal 62 (95%) 13 (81%) 17 (100%) 16 (100%) 16 (100%) 
     
Abnormal 3 (5%) 3 (19%) 0 (0%) 0 (0%) 0 (0%) 
 Palpable warts 1 (33%) 1 (33%) 0 (0%) 0 (0%) 0 (0%) 
 Sphincter defect 1 (33%) 1 (33%) 0 (0%) 0 (0%) 0 (0%) 
 Anal canal mass 1 (33%) 1 (33%) 0 (0%) 0 (0%) 0 (0%) 
     
 
4.3.3 Rectal examination 
Table 4-20 shows the number and percentages of rectal exam findings 
reported by arm at the enrollment visit. Table 4-21 shows the number and 
percentages of new rectal exam findings reported after enrollment by arm.  
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Table 4-21 New rectal examination findings after enrollment 
 All arms TFV gel N9 gel HEC gel No Rx 
  
N  64 16 17 16 15 
     
New perianal 
findings after the 
enrollment 
examination 
    
     
New findings 2 (3%) 0 (0%) 0 (0%) 2 (13%) 0 (0%) 
     
 Warts 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
 Fissure 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
 Ulceration 1 (2%) 0 (0%) 0 (0%) 1 (6%) 0 (0%) 
 Pigmentation 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
 Haemorrhoids 1 (2%) 0 (0%) 0 (0%) 1 (6%) 0 (0%) 
 Skin tags 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
 Leukoplakia 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
 Fistula 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
 Petechiae  0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
 Purpura 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
 Ecchymosis 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
 Other abnormal 
findings 
0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
     
New digital 
examination findings 
after the enrollment 
examination 
    
     
Normal 62 (95%) 13 (81%) 17 (100%) 16 (100%) 16 (100%) 
     
Abnormal 3 (5%) 0 (0%) 2 (12%) 1 (6%) 0 (0%) 
 Increased 
mucosal 
granularity 
1 (2%) 0 (0%) 1 (6%) 0 (0%) 0 (0%) 
 Haemorrhoids 1 (2%) 0 (0%) 1 (6%) 0 (0%) 0 (0%) 
 Circumferential 
discomfort 
1 (2%) 0 (0%) 0 (0%) 1 (6%) 0 (0%) 
     
 
Two participants enrolled in the HEC placebo gel arm from the Pittsburgh, 
PA site had new rectal exam findings from the perianal examination with one 
having ulceration and the other one having hemorrhoids. Three participants 
had new rectal exam findings from the digital rectal examination.  
The first participant was enrolled in the N9 gel arm from the Boston, MA site 
and was reported to have increased granularity to fingertip at right lateral 
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and left lateral area of the anorectal canal. The second participant was 
enrolled in the N9 gel arm from the Pittsburgh, PA site and had hemorrhoids 
felt in the anal canal. The third participant was enrolled in the HEC placebo 
gel arm from the Pittsburgh, PA site and had circumferential discomfort.  
 
Gastrointestinal adverse events occurring in more than 10% of participants 
(approximately equal or greater than 2 participants per arm) are summarized 
in Table 4-22.   
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Table 4-22 Incidence of gastrointestinal adverse events by arm 
 TFV gel N9 gel HEC gel No Rx All Arms 
  
N  16 17 16 16 65 
      
Abdominal pain lower  
 Grade 1 2 (12.5%) 0 (0%) 1 (6.3%) 0 (0%) 3 (4.6%) 
 Grade 2 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
 Grade 3 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
 Grade 4 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
      
Defecation urgency      
 Grade 1 0 (0%) 5 (29.4%) 1 (6.3%) 0 (0%) 6 (9.2%) 
 Grade 2 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
 Grade 3 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
 Grade 4 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
  
Diarrhoea      
 Grade 1 1 (6.3%) 3 (17.6%) 1 (6.3%) 2 (12.5%) 7 (10.8%) 
 Grade 2 0 (0%) 1 (5.9%) 0 (0%) 0 (0%) 1 (1.5%) 
 Grade 3 0 (0%) 0 (0%) 0 (0%) 1 (6.3%) 1 (1.5%) 
 Grade 4 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
      
Flatulence      
 Grade 1 6 (37.5%) 2 (11.8%) 1 (6.3%) 3 (18.8%) 12 (18.5%) 
 Grade 2 0 (0%) 0 (0%) 1 (6.3%) 0 (0%) 1 (1.5%) 
 Grade 3 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
 Grade 4 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
      
Painful defecation      
 Grade 1 0 (0%) 2 (11.8%) 0 (0%) 0 (0%) 2 (3.1%) 
 Grade 2 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
 Grade 3 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
 Grade 4 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
      
Proctalgia      
 Grade 1 1 (6.3%) 2 (11.8%) 0 (0%) 0 (0%) 3 (4.6%) 
 Grade 2 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
 Grade 3 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
 Grade 4 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
      
Post procedural diarrhoea     
 Grade 1 2 (12.5%) 0 (0%) 0 (0%) 0 (0%) 2 (3.1%)  
 Grade 2 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
 Grade 3 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
 Grade 4 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
      
 
The majority of events were either Grade 1 or 2 with only one Grade 3 event 
(diarrhoea) seen in a No Rx participant. Most events were more common in 
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the N9 gel arm with the exception of flatulence which was more common in 
the TFV gel recipients.  
4.4 Product acceptability 
There were 47 participants who completed the CASI, and 46 with valid 
responses to the secondary endpoint question as follows: If a rectal 
microbicide were available that provided some protection against HIV, and it 
looked like the gel you have used in this study, how likely would you be to 
use it (a microbicidal gel) every time you have RAI? In the TFV gel group 
13/15 (86.7%), N9 gel group 10/16 (62.5%), and HEC placebo gel group 
14/15 (93.3%) reported high intentionality, operationalized as having a rating 
in the upper one third of a 10-point Likert scale (values of 7-10), to use the 
product in the future every time they have RAI. The overall comparison 
across groups using Fisher’s Exact Test showed a p-value of 0.11. Pairwise 
comparisons between the TFV gel group versus the HEC placebo gel group, 
and the N9 gel group versus the HEC placebo gel group showed nominal p-
values of 1.0 and 0.08, respectively. 
4.5 Discussion 
In the HIVNET-008 trial of N9, Tabet et al. enrolled a seroconcordant 
population of MSM who underwent a complex dose escalation evaluation of 
an N9 gel. Couples were also allowed to be sexually active (Tabet et al., 
1999). Subsequent Phase 1 studies of antiretroviral rectal microbicides 
(RMP-01 and RMP-02/MTN-006) have adopted a more conservative study 
design in which participants are sexually abstinent, have a baseline 
evaluation, receive a single dose of study product followed by a recovery 
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period, and then seven daily doses. Comprehensive evaluation of safety and 
acceptability occurs after the single and repeated dosing periods. The MTN-
007 followed this study design but, in contrast to the RMP-01 and RMP-
02/MTN-006 studies, did not include PK or PD assessments as it was felt 
these data had already been collected in the RMP-02/MTN-006 study of TFV 
gel.  
 
Similar to the RMP-01 and RMP-02/MTN-006 studies, the MTN-007 study 
recruited a population with a mean age of 35.7 years of whom 69% were 
men and 31% were women. All participants had a history of receptive anal 
intercourse. The fact that almost one third of the participants recruited in to 
the MTN-007 study were women highlights the need to develop rectal 
microbicides for both men and women. The majority of participants in the 
MTN-007 study were white (68%). Racial disparity in study recruitment is a 
common feature of US clinical trials (Colon-Otero et al., 2008) but 
particularly unfortunate in the context of domestic HIV prevention trials as 
the current US HIV epidemic is focused on the African American community. 
Project Gel (described in Section 2.8) is one attempt to conduct a rectal 
microbicide safety and acceptability study in young ethnic minority MSM. 
 
Study retention was excellent (>94%) as is usual for Phase 1 studies.  Data 
quality, judged by the number of quality control (QC) notes sent to the site, 
was good and equivalent across all three sites (range 4.6 to 7.1 per 100 
records). All QCs were resolved prior to the database lock. The original 
target of 60 participants (15 per study arm) was expanded to 65 to ensure 
160 
 
that there were 60 participants who had evaluable mucosal safety samples. 
The primary reason for participants being dropped from the study was 
because they had used less than 5 doses of the study product (4/5). One 
participant failed to have the final mucosal sampling studies and was 
therefore replaced. 
 
Product adherence was measured using a phone reporting system (PRS). 
Participants were asked to use the PRS after each episode of gel use 
Adherence was calculated using PRS data (Leu et al., 2013). Based on 
these data, 98% of study participants reported using at least 80% of the 
expected product doses. Recent failures in HIV prevention trials have 
documented a significant gap between reported accounts of adherence and 
actual levels of product adherence based on objective measures such 
plasma PK. In the FEM-PrEP study of Truvada, 95% of the participants 
reported that they had usually or always taken the assigned drug. However, 
among women who seroconverted in the study, PK assessment suggested 
that only 26% of the women had taken the drug in the last 48 hours (Van 
Damme et al., 2012). Similar results have been seen in other PrEP studies 
such as VOICE study (van der Straten et al., 2012). One limitation of the 
MTN-007 study is that product adherence was based on self-report, albeit 
using a sophisticated PRS and PK data are not available to substantiate, or 
refute, reported adherence. The HIV prevention field is rapidly moving to 
develop novel objective markers of behavior, including adherence. Studies 
are beginning to incorporate “real time” PK monitoring into study design. 
This provides the opportunity, at least in open label studies, to provide 
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participants with feedback on how adherent they have been but also raises 
ethical and operational issues about what you do with non-adherent 
participants. Another approach, that will be used in a future MTN Phase 1 
PK study of vaginal and rectal TFV gel (MTN-014), is for the participants to 
administer study product under supervision (directly observed therapy or 
DOT). With regards to topical PrEP, this is really only feasible for Phase 1 
studies, but DOT has been used in a recently completed study of oral PrEP 
in injection drug users in Thailand (Choopanya K et al., Lancet 2013).  
 
A primary goal of the MTN-007 study was to determine whether a reduced 
glycerin formulation (RG)-TFV gel had an improved safety and acceptability 
profile compared to the TFV gel formulation used in the RMP-02/MTN-006 
study. Based upon the primary safety endpoint (the number participants with 
a Grade 2 or higher AE), there was no significant difference seen across the 
four arms of the study. However, there did seem to be more frequent 
gastrointestinal AEs in the N9 arm (see Table 4-22). The one exception was 
flatulence which was more common in the TFV gel arm. Interestingly, there 
was a significant increase in diarrhea among women receiving TFV gel in 
the CAPRISA 004 study (Sokal et al., 2013). Since TFV is known to cross 
from vaginal to rectal compartments (Nuttall et al., 2012), it is possible that 
this gastrointestinal AE is TFV-related. Overall, the prevalence of 
gastrointestinal symptoms with the RG-TFV gel appeared lower than the 
levels seen in the RMP-02/MTN-006 study (Table 4-23). 
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Table 4-23 GI adverse events in MTN-007 and RMP-002/MTN-006 
Symptom (%) 
RG-TFV gel 
used in MTN-007 
TFV gel 
used in RMP-02/MTN-006 
   
Abdominal pain 16% 50% 
Rectal urgency 0% 42% 
Bloating 0% 42% 
Nausea 0% 33% 
Diarrhea 6% 58% 
Flatulence 38% 25% 
Proctalgia 6% 0% 
   
 
It is presumed that the improved safety profile seen with the RG-TFV gel 
relates to its lower osmolality compared to the TFV gel used in the RMP-
02/MTN-006 study (836 vs. 3,111 mOsmol/kg). The safety and acceptability 
data seen in the MTN-007 study have allowed the RG-TFV gel to advance to 
Phase 2 testing in the MTN-017 study. However, an even lower osmolar 
formulation of TFV gel (479 mOsmol/kg) will be evaluated in the CHARM-01 
study (Section 2.9). 
 
One concern raised about the design of Phase 1 vaginal microbicide trials is 
that they enroll too few participants who are then followed for an insufficient 
period of time to fully evaluate the safety and acceptability profile of novel 
candidate microbicides (Poynten et al., 2009). However, in the context of 
rectal microbicide development, the sample size on active product in the 
RMP-02/MTN-006 study (N = 12) was sufficient to recognise that the 
formulation was not optimal for rectal use. Whether this sample size is 
sufficient to evaluate changes in mucosal safety biomarkers, where multiple 
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comparisons are routinely undertaken, is discussed in Chapter 6 of this 
thesis. 
4.6 Summary 
The Phase 1 MTN-007 study enrolled 65 participants and demonstrated that 
a RG-TFV gel, in comparison to a placebo gel and a no treatment arm, was 
both safe and acceptable for rectal use. It is possible that conventional 
parameters such as reported adverse events or acceptability are insufficient 
to exclude product-associated perturbation of mucosal tissue that might, 
over an extended period of time, result in changes that could increase the 
risk of HIV infection in participants using these products. As a consequence, 
the MTN-007 study was designed to include a portfolio of exploratory 
mucosal biomarker studies (described in Chapters 5 and 6) that might 
provide preliminary evidence of product associated changes in mucosal 
biology. These changes could be further evaluated in Phase 2 studies where 
the study sample size and duration of product exposure might provide more 
robust data on the interactions between antiretroviral microbicides and the 
intestinal mucosa.  
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Chapter 5 
 
Mucosal Toxicity Assays Used in 
MTN-007 
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5 Mucosal safety assays used in MTN-007 
5.1 Introduction 
The rectal compartment is highly vulnerable to HIV transmission.  A single 
layer of columnar epithelium separates the intestinal lumen from the lamina 
propria.  The lamina propria is populated with a broad range of HIV target 
cells including macrophages, dendritic cells, and activated CD4+ T 
lymphocytes expressing the CCR5 and CXCR4 HIV-1 coreceptors (Poles et 
al., 2001; Grivel et al., 2007).  It is likely that the immune composition of the 
rectal mucosa is at least partially responsible for the 10-20 fold increased 
risk of HIV transmission associated with URAI compared to unprotected 
vaginal intercourse (UVI) (Baggaley et al., 2010; Boily et al., 2009).  Any 
product or process, including STIs, that induces local inflammation is likely to 
further increase this risk by recruiting and/or enhancing activation of immune 
target cells in the rectal mucosa. It has been shown that HSV infection, a 
significant cause of anorectal mucosal ulceration / inflammation, increases 
the risk of HIV infection in MSM. Lama et al. demonstrated that HSV-2 
seroprevalence in HIV seropositive Peruvian MSM was 80.5% compared to 
40.8% in HIV seronegative MSM (Lama et al., 2006). This effect may be 
mediated through the persistence and enrichment of HIV-receptor positive 
inflammatory cells in the anorectum following HSV infection (Zhu et al., 
2009) and/or the presence of HSV-associated 47hi CD4 positive T cells in 
the rectal mucosa (Martinelli et al., 2011). Another possible example of 
mucosal inflammation was seen in the STEP trial that evaluated an 
adenovirus vector HIV vaccine in high risk men and women (Buchbinder et 
al., 2008). An unanticipated outcome of the study was the finding that 
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uncircumcised, adenovirus antibody positive, MSM who received the HIV 
vaccine had an increased risk of HIV acquisition compared to the placebo 
recipients. Although the mechanism underlying this phenomenon was 
unclear, the study authors postulated that one possible explanation was that 
vaccine recipients with previous adenovirus exposure had an amnestic 
vaccine response that resulted in accumulation of HIV target cells in the 
foreskin and/or rectal mucosa (Duerr et al., 2012). Collectively, these 
observations suggest that an STI, vaccine, or microbicide that induces 
mucosal inflammation and/or recruitment of target cells to the rectal mucosa 
is likely to increase vulnerability to HIV infection. It is therefore critical that all 
candidate rectal microbicides are carefully evaluated for potential mucosal 
toxicity. 
 
Methods to assess microbicide induced toxicity in the rectal compartment 
are in a state of evolution.  Mucosal changes may be subtle and require new 
modes of detection above and beyond the collection of adverse event data 
and the histological assessment of rectal biopsies following exposure to 
microbicide candidates. Based on experience from the vaginal microbicide 
development pathway, possible new approaches have included (i) collection 
of rectal swabs for the quantification of locally released cytokines and 
chemokines, (ii) extraction of RNA from biopsies for the characterization of 
the expression of selected genes associated with mucosal inflammation, and 
(iii) the isolation of mucosal mononuclear cells (MMCs) from rectal biopsies 
for flow cytometric assessment of GALT T cells. Prior to integrating these 
types of assays into rectal microbicide trials, the HIV Prevention Trial 
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Network (HPTN) sponsored the HPTN-056 study “Characterization of 
baseline mucosal indices of injury and inflammation in men for use in rectal 
microbicide trials” to explore the biological variability of selected mucosal 
parameters that might be relevant for rectal microbicide development 
(McGowan et al., 2007).   The HPTN-056 study enrolled 16 men (8 HIV-
seronegative (4 with a history of RAI and 4 who did not practice RAI) and 8 
HIV-1 seropositive men (4 with a plasma HIV-1 RNA viral load of ≥ 10,000 
copies/mL and 4 with a plasma HIV-1 RNA viral load < 50 copies/mL)) who 
underwent flexible sigmoidoscopy on three occasions separated by 2 week 
intervals. Rectal biopsies were collected at 10 and 30 cm from the anal 
verge. Swabs were also collected to quantify mucosal immunoglobulins. The 
range of assays conducted in HPTN-056 study is summarized in Table 5-1. 
 
Table 5-1 HPTN-056 mucosal assays 
Assay Analytes 
  
Histology Qualitative and quantitative 
  
RT-PCR for mucosal cytokine mRNA RANTES, IFN-, IL-10 
  
Mucosal immunoglobulins IgG total and IgA total 
  
MMC flow cytometry CD3+, CD4+, CD8+, CD19+, CD16+, 
CD56+, CD4+/CCR5+, CD4+/CXCR4+, 
CD4+/CCR5+/CXCR4+, CD4+/CD38+, 
CD8+/CD38+, CD4+/HLA-DR+, CD8+/HLA-
DR+, HLA-DR+/DCSIGN- 
  
RT-PCR: reverse transcription polymerase chain reaction; RANTES: regulated and normal 
T cell expressed and secreted 
 
Mixed linear models were used to characterize the stability of these 
parameters. Parameters with an intraclass correlation (ICC) of > 0.7 (strong 
stability over time) included T cell phenotypic markers and cytokine mRNA. 
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In contrast, quantitative histology and mucosal immunoglobulins (IgG) had 
ICC scores < 0.35 and have not been included in future rectal microbicide 
trials. 
5.2 Histological assessment of rectal biopsies 
5.2.1 Introduction 
Histopathological assessment of intestinal tissue is a routine method of 
demonstrating mucosal abnormality associated with gastrointestinal 
diseases such as ulcerative colitis, Crohn’s disease, and gluten enteropathy 
(coeliac disease).  In general, mucosal change in these diseases can be 
quite dramatic whereas microbicide-induced changes may be quite subtle.   
5.2.2 Previous studies 
The HIVNET 008 rectal safety study of N9 employed a simple scoring 
system of normal, slightly abnormal (focal, mild acute inflammation), or 
abnormal (an intense inflammatory infiltrate, reactive changes (increased 
mitotic activity and enlarged nuclei)) (Tabet et al., 1999).  Using this 
histological system, 69% of the placebo recipients and 89% of the N9 
recipients had slightly abnormal or abnormal rectal biopsies. In contrast, 
there were no significant differences in rectal histology (using a qualitative 
scoring system discussed in Section 5.2.3) noted in the RMP-01 study of 
UC781 and the RMP-02/MTN-006 study of TFV gel (Anton et al., 2011; 
Anton et al., 2012). 
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5.2.3 Methods 
A qualitative scoring system developed by the inflammatory bowel disease 
community (Geboes et al., 2000) and adapted for use in the HPTN 056 
study (McGowan et al., 2007) was used to assess potential microbicide 
induced mucosal injury in MTN-007 (summarised in Table 5.2 and illustrated 
in Figure 5.1).  It was hoped that the scoring system developed for the HPTN 
056 study might provide better discrimination between abnormal and normal 
histology. Intestinal biopsies collected at 9 cm and 15 cm from the anal 
verge were placed in 10% formalin and stored at room temperature prior to 
being orientated and embedded in paraffin. 7 m sections of rectal tissue 
were then cut from the block and two ribbons placed on each slide, 
deparaffinised, and stained with haematoxylin and eosin (H & E).  
A pathologist with specialist training in gastrointestinal pathology then 
reviewed the H & E slides. Four slides (up to 32 tissue sections) from the 
rectal biopsies were graded at low power (40-100X magnification) with the 
inflammatory cells examined at higher power (200 or 400X magnification). A 
score was assigned based upon the highest degree of abnormality seen in 
the samples. 
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Table 5-2 MTN-007 histopathology scoring system 
 
 
Histology Grade 
Grade 0 
No abnormality 
Grade 1 
Mononuclear cell infiltrate 
Grade 2 
Neutrophilic infiltrate in the 
lamina propria 
Grade 3 
Neutrophilic infiltrate in the 
epithelium 
Grade 4 
Crypt destruction 
Grade 5 
Erosion or ulceration 
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5.3 Epithelial sloughing in rectal lavage fluid 
5.3.1 Introduction 
Rectal lavage and examination of effluent for shedding of epithelial cells has 
been used to characterize the rectal safety profile of sexual lubricants and 
microbicide candidates in murine (Sudol & Phillips, 2004), non-human 
primate (Patton, Sweeney, & Paul, 2009)  and human studies (Phillips, 
Taylor, Zacharopoulos, & Maguire, 2000; Phillips et al., 2004).   
5.3.2 Previous studies 
In two human studies, examination of rectal lavage fluid has demonstrated 
that exposure to N9 is associated with transient rectal epithelial disruption 
(Phillips et al., 2000; Phillips et al., 2004). Substantial reversal of these 
mucosal changes occurs after 2 hours and microscopically normal 
epithelium was seen after 24 hours. In both the RMP-01 and RMP-02/MTN-
006 studies, no increase in epithelial sloughing was noted after exposure to 
the active product or placebo (Anton et al., 2011; Anton et al., 2012).  
5.3.3 Methods 
With the participant resting in the left lateral position, approximately 120 mL 
of Normosol®-R isotonic solution (Hospira Inc., Lake Forest, IL, USA) is 
delivered into the rectum. The participants were asked to hold the fluid for 3-
5 minutes before expelling it into a collection hat. Approximately 30 mL of 
rectal lavage fluid was collected and sent to the laboratory for analysis. The 
lavage fluid was transferred to a 50 mL centrifuge tube and spun at 1,000 
rpm for 5 minutes. The supernatant was removed to a second 50 mL 
centrifuge tube, leaving a cell pellet in the first tube, and then spun for 1,000 
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5.4 Fecal calprotectin 
5.4.1 Introduction 
Calprotectin accounts for 60% of the cytoplasmic protein fraction of 
polymorphonuclear granulocytes and is also found in monocytes, 
macrophages, and eosinophils (Poullis, Foster, Mendall, & Fagerhol, 2003).  
Calprotectin plays an important role in innate immunity and has antibacterial, 
antifungal, and immunomodulatory effects in vivo.  Because intestinal 
granulocytes end their lifespan by migrating through the intestinal wall and 
since granulocyte-derived calprotectin can be found in feces, calprotectin is 
felt to be a useful indirect index of mucosal inflammation (Poullis et al., 2003; 
Abraham & Kane, 2012).  Fecal calprotectin levels are elevated in 
inflammatory bowel disease and correlate well with disease activity in 
Crohn’s disease and ulcerative colitis (Gaya et al., 2005; Roseth, Aadland, 
Jahnsen, & Raknerud, 1997; Komraus, Wos, Wiecek, Kajor, & Grzybowska-
Chlebowczyk, 2012; D'Haens et al., 2012).  In addition, fecal calprotectin 
levels have been found to be significantly elevated in first-degree relatives of 
patients with Crohn’s disease even though all the relatives were clinically 
asymptomatic (Tamboli, Richard, & Colombel, 2003). Elevated levels of fecal 
calprotectin are also seen in patients with enteric infections such as 
Campylobacter jejuni (Nielsen, Engberg, Ejlertsen, & Nielsen, 2013; Shastri 
et al., 2008). Fecal calprotectin levels associated with various 
gastrointestinal conditions are summarized in Figure 5-3. 
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immunosorbent assay (ELISA). The Genova Diagnostics laboratory states 
that fecal calprotectin levels of < 50 g/g of stool are considered to be 
normal whereas values between 50 and 100 g/g of stool suggests 
moderate inflammation of the mucosal tissue. 
5.5 Assessment of rectal microflora  
5.5.1 Introduction 
Characterization of colonic microbiota and their impact on health and 
disease has become an area of intense scientific research (Shanahan, 
2013).  The gut flora is composed of approximately 1014 bacterial cells, a 
figure that is estimated to be 10-fold higher than the total number of human 
cells in the body. Predominant bacterial phyla include Firmicutes, 
Bacteroidetes, and Proteobacteria although more interindividual diversity 
occurs at bacterial species and strain level (Hong, Croix, Greenberg, 
Gaskins, & Mackie, 2011; Shanahan, 2012). A critical step in the evolution of 
our understanding about colonic microbiota has been the development of 
culture-independent techniques for the characterization and quantification of 
gut bacteria. These techniques include extraction of bacterial DNA and 
amplification of 16S ribosomal RNA (Fraher, O'Toole, & Quigley, 2012).  It is 
now clear that there is an intimate relationship between the colonic 
microbiota, the mucosal immune system, and the metabolic environment of 
the gut. Acquired or inherited perturbations of any of these parameters can 
lead to gastrointestinal and systemic disease. Studies are currently ongoing 
to determine whether HIV infection is associated with significant changes in 
colonic microbiota (Saxena et al., 2012).  
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In the context of microbicide development, there has been significant 
concern that repetitive exposure to a microbicide might be associated with 
changes in vaginal or rectal flora that could increase the risk of HIV infection. 
It is known that women with bacterial vaginosis have an increased risk of 
acquisition (Atashili, Poole, Ndumbe, Adimora, & Smith, 2008) and 
transmission (Cohen et al., 2012) of HIV infection. Consequently, the 
majority of vaginal microbicide studies have evaluated vaginal microflora 
using conventional culture techniques (McGowan et al., 2011) and more 
recently with pyrosequencing of 16s RNA (Ravel et al., 2012). Studies 
evaluating cellulose sulphate, N9, and VivaGel® have demonstrated shifts in 
vaginal flora with reductions in Lactobacillus spp. and increases in anaerobic 
spp. but no significant increase in the prevalence of bacterial vaginosis 
(Ravel et al., 2012; McGowan et al., 2011). 
5.5.2 Previous studies 
Patton et al. have previously characterized the rectal microflora of the 
Macaca nemestrina (pig-tailed macaque) and healthy women using semi-
quantitative culture and biochemical techniques (Patton, Cosgrove-
Sweeney, Rabe, & Hillier, 2001; Patton, Sweeney, Rabe, & Hillier, 1996). 
They showed that rectal colonisation in both species was similar although 
the prevalence of H2O2 producing lactobacilli was higher in the macaques 
compared to the women (80% versus 48%) and women had a higher 
carriage rate of anaerobic gram-positive cocci compared to the macaques 
(98% versus 70%). Subsequently, the group evaluated the impact of a broad 
range of microbicide candidates (pH buffers, membrane disrupters, 
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entry/fusion inhibitors, and reverse transcriptase inhibitors) on rectal 
microflora (Patton et al., 2009). Only C31G (Patton, Sweeney, Balkus, & 
Hillier, 2006) and a combination of SPL7013 and BufferGel® (Patton et al., 
2009) resulted in transient changes in rectal microflora. The techniques 
developed by Patton and Hillier were subsequently used to characterize the 
impact of UC781 and TFV gels on human rectal microflora (Anton et al., 
2011; Anton et al., 2012). No significant changes in rectal microflora were 
noted at any time point in these studies.  
5.5.3 Methods 
Rectal specimens obtained per rectum with a sterile cotton swab were 
placed in an anaerobic transport tube (Port-a-Cul; Becton-Dickinson Corp., 
Cockeysville, MD, USA) and shipped by overnight mail to Magee-Womens 
Research Institute, Pittsburgh, PA, USA. The swab was removed, placed 
into 0.9 mL of buffered salt solution and vortexed to release fluid. Plates 
were incubated in an anaerobic chamber for 72-96 hours for detection of 
anaerobes; agar plates for aerobic bacteria were evaluated after 48 hours of 
incubation at 37 °C in 6% CO2. Given the enormous variety of normally-
present bacteria in the colon and the unknown variations related to diet and 
time, the bacterial groups selected for monitoring before and after product 
exposure was based on an FDA defined panel. Changes in bacterial 
frequencies and concentrations within exposed individuals as well as 
between study groups were examined between baseline visit and following 
the 7-day exposure (which included any changes occurring after the single 
dose exposure). Results were quantified by colonization growth on a scale 
from 0-4 as follows: 0 = no growth; 1 = 103cfu/mL; 2 = 105cfu/mL; 3 = 
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106cfu/mL; and 4 = 107cfu/mL.  Raw means and SDs were computed by time 
(before or/after gel use), using McNemar’s test for evaluating paired 
changes in colonization status. 
Table 5-3 Rectal microflora evaluated in the RMP-01 study 
Bacteria Baseline prevalence  
  
Lactobacillus (H2O2-producing) 30% 
Lactobacillus (H2O2-nonproducing) 17% 
Gardnerella vaginalis 8% 
Escherichia coli 89% 
Other gram-negative rods 22% 
Anaerobic gram-positive cocci 92% 
Anaerobic gram-positive rods (Clostridium) 81% 
Anaerobic gram-positive rods (other) 72% 
Anaerobic gram-negative rods 100% 
Black-pigmented anaerobic gram-negative 
rods 
83% 
  
*Based on samples from 36 participants (Anton et al., 2011) 
5.6 Rectal secretion of cytokines and chemokines 
5.6.1 Introduction 
In 2001, Fichorova et al. demonstrated that vaginal exposure to an N9 gel by 
healthy women was associated with increased release of pro-inflammatory 
cytokines and chemokines into vaginal fluid (Fichorova et al., 2001). As N9 
was later found to be harmful in the COL-1492 trial (Van Damme et al., 
2002) monitoring levels of both pro-inflammatory and anti-inflammatory 
molecules has become a routine component of vaginal microbicide trials. 
Levels of cytokines and chemokines can be highly variable in healthy 
women and are likely to be influenced by factors including the stage of the 
menstrual cycle, contraceptive use, vaginal flora, and recent sexual activity 
180 
 
(Kyongo et al., 2012). Levels are also likely to be influenced by collection 
methods and the period of sample storage before analysis (Dezzutti et al., 
2011; de, Bourcier, Rijkers, Prakken, & Seyfert-Margolis, 2009). A final 
consideration is that microbicide exposure may also be associated with 
decreases in these molecules (Keller et al., 2012). Since intestinal 
inflammation, irrespective of cause, is commonly associated with increased 
production of cytokines and chemokines (MacDonald & Monteleone, 2005), 
these molecules have also been measured in Phase 1 rectal microbicide 
studies. 
5.6.2 Previous studies 
In both the RMP-01 and RMP-02/MTN-006 trials, rectal fluid was collected 
with cellulose sponges and quantified for RANTES, MIP-1, TNF-, IFN-, 
IL-12p40, IL-6, and IL-1 using the BioRad Luminex® platform. Baseline 
values are presented in Figure 5-4. In the RMP-01 study, after single rectal 
dose exposure, there was a significant difference in RANTES between the 
placebo gel (71.79 ± 54.38 pg/mL) and the 0.1% UC781 gel (31.06 ± 17.2 
pg/mL) (Anton et al., 2011).  
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Figure 5-4 Baseline rectal fluid cytokine concentrations 
Baseline cytokine concentrations in rectal fluid from the RMP-01(blue) and RMP-02/MTN-
006 (red) Phase 1 rectal safety studies of UC781 and TFV gel. Cytokine concentrations 
were quantified using Luminex® and presented as mean ± SD values. 
 
In the RMP-02/MTN-006 study, after 7 days of dosing, there were significant 
cytokine reductions seen in the TFV gel compared to the HEC placebo gel: 
IL-1 (1.55 ± 1.64 vs. 5.43 ± 3.71 pg/mL), MIP-1 (4.69 ± 10.78 vs. 11.76 ± 
7.88 pg/mL), IL-6 (1.29 ± 1.48 vs. 4.13 ± 3.25 pg/mL), and TNF-(4.57 ± 
9.18 vs. 8.15 ± 9.49 pg/mL ) (Anton et al., 2012).  
5.6.3 Choice of cytokines and chemokines  
A key concern in microbicide development is whether repetitive application 
of a microbicide gel might induce mucosal inflammation and potentially 
increase the risk of HIV infection. The MTN-007 study evaluated a broad 
range of cytokines and chemokines that were chosen either because they 
were known to be increased in previous preclinical/clinical microbicide 
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studies or are thought to be involved in the pathogenesis of mucosal 
inflammation such as inflammatory bowel disease.  
5.6.3.1 IL-1 
IL-1is produced by activated macrophages and is an important mediator of 
the inflammatory response. It is involved in a variety of cellular activities, 
including cell proliferation, differentiation, and apoptosis. 
5.6.3.2 IFN- 
IFN-, or type II interferon, is a cytokine that is critical for innate and adaptive 
immunity against viral and intracellular bacterial infections and for tumor 
control. IFN- is an important activator of macrophages. Aberrant IFN- 
expression is associated with a number of inflammatory and autoimmune 
diseases. IFN- plays an important role in the immune system stems due to 
its immunostimulatory and immunomodulatory effects. IFN- is produced 
predominantly by natural killer (NK) T cells as part of the innate immune 
response, and CD4+ and CD8+ T lymphocytes during antigen specific 
responses.  
5.6.3.3 TNF- 
TNF-is a cytokine involved in systemic inflammation and is a member of a 
group of cytokines that stimulate the acute phase reaction. It is produced 
chiefly by activated macrophages although it can be produced by many 
other cell types such as CD4+ lymphocytes, NK cells and neurons. The 
primary role of TNF- is in the regulation of immune cells. TNF-, being an 
endogenous pyrogen, is able to induce fever, apoptotic cell death, sepsis, 
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cachexia, and inflammation. It can also inhibit tumorigenesis and viral 
replication. Dysregulation of TNF- production has been implicated in a 
variety of human conditions including Alzheimer's disease, cancer, major 
depression, and inflammatory bowel disease. 
5.6.3.4 IL-6 
IL-6 is an important mediator of fever and of the acute phase response. It is 
capable of crossing the blood brain barrier and initiating synthesis of PGE2 in 
the hypothalamus. IL-6 can be secreted by macrophages in response to 
specific microbial molecules, referred to as pathogen associated molecular 
patterns (PAMPs). PAMPs bind to highly important group of detection 
molecules of the innate immune system, called pattern recognition receptors 
(PRRs), including Toll-like receptors (TLRs). These are present on the cell 
surface and intracellular compartments and induce intracellular signaling 
cascades that give rise to inflammatory cytokine production. 
5.6.3.5 IL-8 
IL-8 has two primary functions. It induces chemotaxis in target cells, 
primarily neutrophils but also other granulocytes, causing them to migrate 
toward sites of infection. IL-8 also induces phagocytosis once they have 
arrived. IL-8 can be secreted by any cells with TLR that are involved in the 
innate immune response. Macrophages are often the first cells to engage 
with antigens and are therefore commonly the first cells to release IL-8 to 
recruit other cells.  
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5.6.3.6 IL-12 
IL-12 is involved in the differentiation of naive T cells into Th1 cells. It is 
known as a T cell-stimulating factor, which can stimulate the growth and 
function of T cells. It stimulates the production of IFN-and TNF- from T 
and NK cells, and reduces IL-4 mediated suppression of IFN-. IL-12 plays 
an important role in the activities of NK cells and T lymphocytes. IL-12 
mediates enhancement of the cytotoxic activity of NK cells and CD8+ 
cytotoxic T lymphocytes.  
5.6.3.7 IL-17 
IL-17 is a cytokine that acts as a potent mediator in delayed-type reactions 
by increasing chemokine production in various tissues to recruit monocytes 
and neutrophils to the site of inflammation, similar to IFN-. IL-17 is produced 
by T-helper cells and is induced by IL–23 which results in destructive tissue 
damage in delayed-type reactions. Interleukin 17 as a family functions as a 
proinflammatory cytokine that responds to the invasion of the immune 
system by extracellular pathogens and induces destruction of the pathogen’s 
cellular matrix. Interleukin 17 acts synergistically with TNF- and IL-1. IL-17 
has been linked to many immune/autoimmune related diseases including 
rheumatoid arthritis, asthma, lupus, allograft rejection, anti-tumour immunity 
and psoriasis.  
5.6.3.8 IL-23 
IL-23 is an important part of the inflammatory response against infection. It 
promotes upregulation of the matrix metalloprotease MMP9, increases 
angiogenesis, and reduces CD8+ T-cell infiltration. IL-23 can stimulate naive 
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CD4+ T cells to differentiate into a novel subset of cells called Th17 cells, 
which are distinct from the classical Th1 and Th2 cells. Th17 cells produce 
IL-17, a proinflammatory cytokine that enhances T cell priming and 
stimulates the production of other proinflammatory molecules such as IL-1, 
IL-6, and TNF- resulting in inflammation. 
5.6.3.9 MIP-1 / MIP-1 
Macrophage Inflammatory Proteins (MIP) belong to the family of chemotactic 
cytokines known as chemokines. In humans, there are two major forms, 
MIP-1 (CCL3) and MIP-1 (CCL4). They are produced by macrophages 
following stimulation with bacterial endotoxins and are important in 
generating immune responses towards infection and inflammation. They 
activate human granulocytes (neutrophils, eosinophils and basophils) which 
can lead to acute neutrophilic inflammation. They also induce the synthesis 
and release of other pro-inflammatory cytokines such as IL-1, IL-6, and 
TNF- from fibroblasts and macrophages.  
5.6.3.10 RANTES 
RANTES (Regulated on Activation, Normal T cell Expressed and Secreted) 
or CCL5 is an 8kDa protein classified as a chemotactic cytokine or 
chemokine. RANTES is chemotactic for T cells, eosinophils, and basophils, 
and plays an active role in recruiting leukocytes into inflammatory sites. With 
the help of particular cytokines such as IL-2 and IFN- that are released by T 
cells, RANTES also induces the proliferation and activation of NK cells. 
RANTES, along with the related chemokines MIP-1 and MIP-1, has been 
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identified as a natural HIV-suppressive factor secreted by activated CD8+ T 
cells and other immune cells.  
5.6.4 Methods 
A BioRad Luminex® platform was used to measure IFN-γ, IL-1β, IL-6, IL-8, 
IL-12 (p40), IL-17, MIP-1α, MIP-1β, RANTES, and TNF-α in rectal 
secretions. 
5.6.4.1 Elution of rectal fluid from Merocel sponges 
After collection of rectal fluid samples, the Merocel polyvinyl acetate 
sponges (Beaver-Visitec International Waltham, MA, USA) were placed 
immediately into pre-labeled 5mL Nalgene cryovials (Thermo Scientific, 
Rochester, NY, USA) containing 400µL of D-PBS and once received by the 
laboratory were stored at -80°C until processed. Batched samples were 
thawed at room temperature and then centrifuged at 12,000 rpm for 20 
minutes at 2-8°C using Corning® Costar® Spin-X® polypropylene centrifuge 
tubes with a 0.45μm cellulose acetate filter (Sigma-Aldrich, St. Louis, MO, 
USA). Aliquots (100L) of the filtered solution were then stored at -80C until 
performing the Luminex® assays.  
5.6.4.2 Quantification of cytokines/chemokines in rectal fluid 
Aliquots of filtered rectal fluid were processed following the Millipore 
MILLIPLEX human cytokine / chemokine kit assay protocol (EMD Millipore, 
Billerica, MA, USA). The cytokine / chemokine assays were performed in 
duplicate on a Luminex® 100 system (Luminex, Austin, TX, USA). A 
standard curve was constructed using the Millipore Human Cytokine 
Standard (10,000 pg/mL to 3.2 pg/mL) with the assay buffer used as the 0 
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pg/mL standard. The minimum detectable concentrations of the study 
analytes are summarized in Table 5-4. 
 
Table 5-4 Luminex assay sensitivity 
Cytokine / Chemokine Mean Minimum Detectable (pg/mL)* 
  
IFN- 0.1 
IL-1β 0.4 
IL-6 0.3 
IL-8 0.2 
IL-12 (p40) 10.5 
IL-17 0.2 
MIP-1α 3.5 
MIP-1β 4.5 
RANTES 1.0 
TNF-α 0.1 
  
*Data derived from the Millipore Human Cytokine / Chemokine Assay protocol 
5.7 Cytokine and chemokine gene expression in mucosal tissue 
5.7.1 Introduction 
The development of polymerase chain reaction (PCR) technology by Kary 
Mullis and his colleagues in 1986 revolutionised molecular biology as it 
provided a sensitive and specific technique to quantify gene expression in a 
broad range of biological systems (Mullis et al., 1986). In essence, PCR 
relies upon the ability of specific oligonucleotide primers to bind to denatured 
DNA and initiate DNA synthesis of the relevant gene of interest. A series of 
20-40 denaturing, annealing, and extension phases allows gene 
amplification. Theoretically, a single gene copy undergoing 20 rounds of 
PCR amplification will result in generation of approximately one million 
copies of the original target. PCR amplification has three main phases. The 
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early phase is when primers are binding to the template DNA, the mid phase 
is when amplification is underway with exponential accumulation of the 
product fragment, and a late phase, often referred to the plateau phase, 
when amplification is suboptimal either due to exhaustion of the reagents or 
inhibition of the PCR reaction. For semi-quantitative PCR, it is important that 
product accumulation is measured in the exponential phase of the PCR 
reaction (Giulietti et al., 2001).  
 
Since the initial description of PCR, numerous applications have been 
developed that attempt to provide absolute quantification of gene expression 
using “real-time” (RT) PCR techniques that do not require post-amplification 
processing to yield quantitative data. RT-PCR employs the use of specific 
primers together with either DNA-binding dyes (SYBR® or EvaGreen® 
technologies) that fluoresce when bound to double-stranded (ds) DNA or to 
specific oligonucleotide probes with a reporter dye bound to the 5’ end of the 
probe and a quencher dye at the 3’ end of the probe. When the probe is 
intact the quencher dye absorbs the fluorescence from the reporter dye. 
When the probe is hydrolyzed by 5’ exonuclease activity of the Taq 
polymerase during PCR amplification, the reporter dye is separated from the 
quencher dye resulting in fluorescence emission. RT-PCR is performed in 
sealed tubes thus limiting the likelihood of DNA contamination. In addition, 
with the incorporation of DNA standards, the system allows absolute 
quantification of gene expression in biological samples.  
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Although RT-PCR can accurately quantify gene expression, it is important 
for studies in which the input RNA is derived from tissue biopsies, especially 
when samples are being compared across arms of a study, that the levels of 
specific gene expression are standardized to a housekeeping gene. Ideally, 
expression of a housekeeping gene should not vary in the tissues under 
study and should not be influenced by experimental treatment such as 
exposure to candidate microbicides (Vandesompele et al., 2002). The 
stability of housekeeping genes may vary by tissue or experimental design 
and so in MTN-007 we explored the stability of three housekeeping genes 
(-Actin, -2 Microglobulin (2M), and Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH)) in the study samples. 
5.7.2 Previous studies 
Rectal mucosal cytokine gene expression has been quantified in two 
mucosal pathogenesis studies and two rectal microbicide studies. The 
cytokines / chemokines evaluated have varied by study and are summarized 
in Table 5-5. Baseline data for RANTES, IFN-, and IL-10 are presented in 
Figure 5-5.  
Table 5-5 Mucosal gene expression studies 
Study Cytokine / Chemokine Reference 
   
McGowan et al. JAIDS 2004 
RANTES, TNF-, IL-6, 
IL-1, IL-10, IL-2, IFN-, 
IL-12 
(McGowan et al., 2004) 
HPTN-056 RANTES, IL-10, IFN- (McGowan et al., 2007) 
RMP-01 IFN- (Anton et al., 2011) 
RMP-02/MTN-006 IFN- (Anton et al., 2012) 
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Figure 5-5 Cytokine mRNA levels from previous studies 
RNA was isolated from endoscopic rectal biopsies, reverse-transcribed, and amplified using 
specific cytokine primers and by measuring the increase in SYBR Green associated 
fluorescence. Cytokine copy number was standardised to 106 -Actin copies per sample.  
5.7.3 Methods 
Real-Time quantitative reverse transcription PCR (qRT-PCR) was used to 
quantify mucosal mRNA expression of the following proinflammatory 
cytokines, chemokines, and chemokine receptors: IL-1, IFN-, TNF-, IL-6, 
IL-8, IL-12, IL-17, IL-23, MIP-1, MIP-1, RANTES, and CCR5. 
5.7.3.1 RNA extraction 
Tissue was collected as pinch biopsy specimens harvested via anoscopy 
(ARB) or via flexible sigmoidoscopy (FSB).  Following collection, tissue 
biopsies were immediately placed in RNAlater™ (Applied 
Biosystems/Ambion, Austin, TX, USA) solution and kept at -4°C for at least 4 
hours prior to final storage at -80°C. In preparation for extraction of total 
RNA, the samples were thawed on ice. Biopsies were removed from the 
RNAlater™ and placed in guanidinium lysis buffer supplied with the 
RNAqueous®-4PCR Kit (Applied Biosystems/Ambion, Foster City, CA, 
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USA).  Samples were homogenized in the presence of 0.5 mm RNase-free 
zirconium beads with the aid of the Bullet Blender homogenizer (Next 
Advance Inc., Averil Park, NY). RNA was then purified on columns according 
to the RNAqueous®-4PCR Kit instructions (Applied Biosystems/Ambion, 
Foster City, CA, USA).    The extracted total RNA was eluted in a volume of 
100 µL and DNase-1 treated. DNase-1 was inactivated before RNA was 
used in cDNA preparation.  
5.7.3.2 Assessing RNA quantity and quality 
All DNAse-1- treated RNA samples were assessed for quantity and quality 
on the Agilent 2100 Bioanalyzer (Agilent Technologies, Inc. Santa Clara, CA, 
USA).  Quantitative measurements were determined and recorded in ng/µl. 
Quality measurement were assessed by the 18S/28S ribosomal RNA peak 
ratios (Figure 5-6). 
 
Based on these measurements, RNA Integrity Numbers (RIN) were 
calculated automatically by the Agilent 2100 Bioanalyzer software.  The 
absence of genomic DNA contamination was assessed by visualization of 
low baselines between the 18S and 28S ribosomal RNA peaks from the 
electropherogram image. RNA quality control limits were set within the 
laboratory as nucleic acid concentrations > 25 ng/µL, 18S/28S ratios of 2.0 + 
0.5, and RIN > 6.0.   
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Figure 5-6 Agilent electropherogram 
Lanes 1, 3, and 5-12 have sharp 18S/28S RNA bands indicating high quality RNA. 
Lanes 2 and 4 demonstrate degraded RNA 
  
5.7.3.3 Reverse transcription of total RNA into complementary DNA (cDNA) 
Equal quantities (1000 ng) of total RNA from biopsy samples were converted 
to cDNA using MultiScribe™ reverse transcriptase and TaqMan® Reverse 
Transcription reagents (Applied Biosystems, Roche Molecular Systems, Inc., 
Branchburg, NJ, USA).  Oligo(dT)20 (Invitrogen, Grand Island, NY, USA) was 
used to prime the reverse transcription (RT) reaction and reactions were run 
on the Applied Biosystems Veriti™ Dx Thermal Cycler (Life Technologies 
Corporation, Carlsbad, CA, USA). Identical quantities of RNA and reagents 
were used in the no reverse transcriptase (NRT) reaction which contained all 
components with the exception of reverse transcriptase.   
5.7.3.4 Quantitative real time PCR for reference gene expression 
Rectal cDNA was used as a template for the PCR amplification. The three 
reference genes used to normalize cytokine gene expression were GAPDH, 
18S 
28S 
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β-Actin and β2 Microglobulin (β2M). All PCR reactions were performed using 
the Bio-Rad CFX96 RT-PCR System (Bio-Rad, Hercules, CA, USA).  Probes 
and/or primers were designed to span the intron-exon boundaries to ensure 
amplification from cDNA rather than from genomic DNA. The master mix and 
primer/probe mixes for the reference genes (GAPDH, β-Actin, and β2M) 
were obtained from Solaris QPCR Gene Expression Assays (Thermo Fisher 
Scientific Inc., Waltham, MA, USA). One µL of the cDNA was added to 5 µL 
of Solaris qPCR Master Mix (2X), 0.5 µL of Primer/Probe Set (20X), and 3.5 
µL of nuclease free water for each reaction replicate. Solaris master mix 
assays utilized standard TaqMan cycling conditions of 95°C denaturation for 
15 minutes followed by 40 cycles of 95°C denaturation for 15 seconds and 
60°C annealing for 1 minute. Serial 1:10 dilutions of plasmid DNA were used 
to construct standard curves for quantitatively assessing reference gene 
expression.   
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Table 5-6 Gene sequences for PCR primers 
Gene Name Primers Sequence 5' to 3' Length 
    
GAPDH Forward GCCTCAAGATCATCAGCAATG  
 Reverse CTTCCACGATACCAAAGTTGTC  
 Probe GCCAAGGTCATCCATGA 89bp 
β-Actin Forward TGGAGAAAATCTGGCACCAC  
 Reverse GGTCTCAAACATGATCTGG  
 Probe ACCGCGAGAAGATGACC 106bp 
B2M Forward CTTTGTCACAGCCCAAGATAG  
 Reverse ATCCAAATGCGGCATCTTC  
 Probe CAGCATCATGGAGGTTTG 80bp 
CD45 Forward GGAAGTGCTGCAATGTGTCATT  
 Reverse CTTGACATGCATACTATTATCTGATCTCA  
 Probe ACAACTAAAAGTGCTCCTCCAAGCCAGGTCT 101bp 
IL-1β Forward ACAGATGAAGTGCTCCTTCCA  
 Reverse ATCCAGCTACGAATCTCCGAC  
 Probe CTCTGCCCTCTGGATGGCGG 73bp 
IL-6 Forward GGTACATCCTCGACGGCATCT  
 Reverse GTGAAAGCAGCAAAGAGGCACT  
 Probe AGCCCTGAGAAAGGAGACATGTAACAAGAGT
AACA 
81bp 
IL-12p40 Forward TGGAGTGCCAGGAGGACAGT  
 Reverse CAAACCTGACCCACCCAAGA  
 Probe ATGGTGGATGCCGTTCACAAGCTCAA 147bp 
IFN-γ Forward TCAGCTCTGCATCGTTTTGG  
 Reverse TTCAGATGTAGCGGATAATGGAAC  
 Probe TTGGCTGTTACTGCCAGGACCCATATGT 120bp 
TNF-α Forward CCAGGCAGTCAGATCATCTTCTC  
 Reverse AAGCTGAGGGGCAGCTCC  
 Probe AGCCTGTAGCCCATGTTGTAGCAAACCC 86bp 
IL-8 Forward CCACACTGCGCCAACA  
 Reverse ATCCAAGAATCAGTGAAGATGC  
 Probe CTGGGTGCAGAGGGTTGTGG 168bp 
MIP-1α Forward GAGACGAGCAGCCAGTGCTC  
 Reverse GCCGGCAGGTCTGTGC  
 Probe CGGTGTCATCTTCCTAACCAAGCGA 64bp 
MIP-1β Forward TCTCAGCACCAATGGGCTC  
 Reverse TTCTTACACCGCGAGGAAGC  
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 Probe CCCTCCCACCGCCTGCTGCT 63bp 
RANTES Forward CTACACCAGTGGCAACTGCT  
 Reverse AGAAGAAATGGGTTCGGGA  
 Probe TCACCCGAAAGAACCGCCAAGTGT 95bp 
    
 
5.7.3.5 Quantitative real time PCR for chemokine/cytokine gene expression 
CD45 gene expression by real-time PCR was used in addition to the 
expression of GAPDH, β-Actin and β2M as a reference gene (Pennington, et 
al., 2001) and was a means of assessing the presence of lymphoid cells in  
the biopsy specimen.   Real-time PCR assays were also used to measure 
the expression of cytokine/chemokine genes which included IL-1β, IL-6, IL-
12p40, IL-8, IL-17, IFN-γ, MIP-1α, MIP-1β, TNF-α, IL-23, CCR5 and 
RANTES (Table 5-6).  All PCR experimentation was performed using the 
Bio-Rad CFX96™ Real Time PCR Detection System (Bio-Rad, Hercules, 
CA, USA).  Probes and or primers were designed to span the intron-exon 
boundary to ensure the amplification of cDNA rather than genomic DNA.  
For each of the chemokine/cytokine gene targets and CD45, 1 µL of cDNA 
was added to the reaction mixture which consisted of 200 nM forward 
primer, 200 nM reverse primer, 200 nM probe, 200 nM dNTP, 0.5 units 
AmpliTaq Gold DNA Polymerase, in1X reaction buffer containing 3.5mM 
MgCl2  (Applied Biosystems, Carlsbad, CA, USA). Cycling conditions were: 
50°C for 2 minutes followed by a 95°C for 10 minutes. This was followed by 
40 cycles of denaturation at 95°C for 15 seconds and annealing at 60°C for 
1 minute. Serial dilutions of plasmid DNA were used to construct standard 
curves for quantitatively assessing copy numbers of target gene expression 
(Figures 5-7 to 5-12).   
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Figure 5-7 RT-PCR standard curves (I) 
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Figure 5-8 RT-PCR standard curves (II) 
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Figure 5-9 RT-PCR standard curves (III) 
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Figure 5-10 RT-PCR standard curves (IV) 
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RANTES 
 
Figure 5-11 RT-PCR standard curves (V) 
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Figure 5-12 RT-PCR standard curves (VI) 
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5.8 Flow cytometric analysis of mucosal T cells 
5.8.1 Introduction 
The gastrointestinal tract is a rich source of HIV-1 target cells. Isolated 
lymphoid follicles, which serve as inductive sites for immune responses, are 
found throughout the colon (Koboziev et al., 2010). The number of follicles 
generally increases toward the anus with the greatest numbers found in the 
rectum (Langman & Rowland, 1986; Langman & Rowland, 1992). Antigen 
presenting cells (macrophage and dendritic cells) along with effector and 
regulatory T cells are found within the follicles. These cells are generally 
activated and express HIV-1 co-receptors, CCR5 and CXCR4, as well as 
soluble immune mediators (Anton et al., 2000; Poles et al., 2001; Zhang et 
al., 1998; McGowan et al., 2004) thus creating the perfect environment for 
HIV-1 infection.  
 
A primary concern in rectal microbicide development is that repeated 
application of a candidate microbicide to the rectal mucosa might result in 
changes in the composition of the GALT that could increase the risk of HIV 
infection. Changes could include enhanced recruitment of HIV target cells to 
the mucosa, increased expression of HIV co-receptors (CCR5 or CXCR4) on 
resident cells and/or increased T cell activation. This possibility is not entirely 
theoretical. Two recent studies have demonstrated significant changes in T 
cell phenotype associated with the use of maraviroc in HIV-infected patients. 
These changes included an expansion of CCR5+/CD4+ T cells in peripheral 
blood (Cossarini et al., 2012), and an increase in both T cell activation and 
CCR5 expression in both peripheral blood and GALT (Hunt et al., 2013). The 
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combination of increased T cell activation and CCR5 expansion, especially 
in GALT, would clearly be an undesirable feature of an oral or topical PrEP 
regimen. As a consequence all rectal microbicide studies conducted to date 
have evaluated GALT T cell phenotype.  
5.8.2 Previous studies 
GALT T cell phenotype data have been generated using flow cytometry in 
the HPTN-056, RMP-01, and RMP-02 studies. HPTN-056 enrolled 16 
participants who underwent flexible sigmoidoscopy at baseline, + 2 weeks, 
and + 4 weeks. The purpose of the study was to generate pilot data on the 
biological variability within and between HIV negative and HIV positive male 
participants. GALT phenotypic data are also available from the RMP-01 and 
RMP-02/MTN-006 studies.  
 
Table 5-7 GALT T cell phenotype from previous studies 
GALT T Cell Phenotype  
Mean %  
HPTN-056 
(N = 4) 
RMP-01 
(N = 36) 
RMP-02/MTN-006 
(N = 18) 
Distance from anal verge 
10 
cm 
30 
cm 
10 
cm 
30 
cm 
15  
cm 
      
CD3+ 62.7 73.3 - - 58.6 
CD3+/CD4+ 38.1 45.0 42.8 47.2 34.4 
CD3+/CD8+ 27.1 30.1 - - 22.4 
CD3+/CD4+/CCR5+  65.1 65.5 70.2 75.5 52.1 
CD3+/CD4+/CXCR4+ 76.2 77.5 81.6 82.5 - 
CD3+/CD4+/CCR5+/CXCR4+ 45.3 48.7 57.6 62.9 - 
CD3+/CD4+/HLA-DR+ 9.8 11.7 16.5 20.4 10.3 
CD3+/CD4+/CD38+ 46.0 39.4 12.1 10.0 44.1 
CD3+/CD4+/HLA-DR+/CD38+ - - 2.28 2.44 5.65 
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GALT phenotypic data for the subgroup of HIV negative participants (who 
practiced RAI) from the HPTN-056 study and Baseline data from participants 
in the RMP-01 and RMP-02/MTN-006 rectal microbicide studies are 
presented in Table 5-7. 
5.8.3 Methods 
5.8.3.1 Isolation of mononuclear cells from intestinal biopsies 
Rectal biopsies were collected via anoscopy (ARB) and flexible 
sigmoidoscopy (FSB) from study participants. The biopsies were placed in 
complete RPMI 1640 transport medium which contained 7.5% heat-
inactivated fetal bovine serum and 1% antibiotic/antimycotic (Gibco® Life 
Sciences, Carlsbad, CA, USA) and transported to the laboratory. The 
biopsies were scissor-minced in 2 mL of digest solution consisting of 
complete RPMI transport medium as described above,  with the addition of 
0.5 mg/mL Collagenase II (Sigma, St. Louis, MO, USA) and 0.83 units/mL 
DNAse 1 (New England BioLabs, Ipswich, MA, USA).  Using a sterile 
pipette, the minced tissue was transferred into a 50 mL conical polystyrene 
tube containing 20 mL of pre-warmed digest solution. The tube was secured 
horizontally in a 37°C shaker incubator for 30 minutes and shaken at 250 
revolutions per minute (rpm). The minced tissue and cell suspension were 
filtered through a 40 M cell strainer (BD Falcon, Franklin Lakes, NJ, USA) 
into a sterile 50 mL conical tube. Cells were washed from the strainer into 
the 50 mL conical tube with D-PBS containing 2 mM EDTA (Gibco/Life 
Sciences, Carlsbad, CA, USA) and kept on ice. The remaining undigested 
tissue on the strainer was dislodged with 3 mL of digest solution and 
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transferred to a 50 mL conical tube with 20 mL of fresh digest solution. The 
50 mL conical tube was secured onto the shaker incubator as described 
above and incubated for an additional 30 minutes with shaking at 250 rpm. 
Following the second digestion, the tissue and cells were again filtered 
through the 40 M cell strainer into the 50 mL conical tube with wash buffer. 
If a third digestion was required, the tissue digestion and cell collection 
procedures were repeated. Cells obtained from all of the digestions were 
collected by centrifugation at 1000 x g. The supernatant fluid was removed 
and the cell pellet was resuspended in complete RPMI 1640 medium. Cell 
counts were obtained using a haemacytometer. 
5.8.3.2 Flow cytometry 
The steps used included the following: i) staining cells for viability, ii) setting 
up compensation tubes, iii) staining cells with monoclonal antibody and iv) 
establishing “fluorescence minus one” or FMO staining controls.  
 
Cell viability was assessed using the LIVE/DEAD® fixable dead cell stain kit 
(Invitrogen, Grand Island, NY, USA). Aqua fluorescent dye is reactive with 
cellular amines. In dead cells with compromised cell membranes, the dye 
reacts with the free amines in the interior of the cell resulting in a 50-fold 
greater fluorescence in dead cells compared to live cells.  
 
In multi-color flow cytometry, compensation is a process by which 
mathematical corrections are made for spectral overlap. If uncorrected, 
spectral overlap can lead to fluorochrome emission in an inappropriate 
detector. Lack of compensation could therefore result in misinterpretation of 
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data leading to false positive populations or artifacts on multi-color plots. By 
using controls for compensation, unwanted signals from spectral overlap can 
be removed electronically and accurate flow cytometric analysis of multi-
color stained cells can be achieved. Fluorescence compensation settings 
were optimized using BD™ CompBead particles (BD Biosciences, San Jose, 
CA, USA). The bead set provides two populations of microparticles; the 
BD™ CompBeads Anti-Mouse IGg, κ particles which bind any mouse kappa 
light chain-bearing immunoglobulin and the BD™ CompBeads negative 
control labeled with fetal bovine serum (FBS) which have no binding 
capacity.  
 
Compensation for the Aqua Blue fluorescent dye in the LIVE/DEAD® cell 
viability assay (Invitrogen, Grand Island, NY, USA) was performed 
separately using the ArC™ (Amine Reactive Compensation) Bead Kit 
(Invitrogen, Grand Island, NY, USA). The ArC™ kit contains two types of 
modified polystyrene microspheres to allow compensation with the 
LIVE/DEAD® kit. The ArC™ reactive microspheres (Component A) bind any 
amine-reactive dyes while the ArC™ negative microspheres (Component B) 
have no reactivity. 
 
MMCs were stained with monoclonal antibody/fluorochrome conjugates for 
eight cell surface markers (Table 5-8). Staining with monoclonal antibodies 
for the CD45 marker is used to select all cells of hematopoietic origin except 
for erythrocytes.  This common leukocyte marker reacts with all lymphoid 
cells. Monoclonal antibodies to CD3 bind to the transducing elements of the 
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T cell receptor complex and are thus used to identify T cells. Cells were 
stained for CD4, which is expressed on most thymocytes and about two 
thirds of peripheral blood T cells. The other third of all peripheral blood T 
cells are CD8 positive. CD69, a marker of T cell early activation, is widely 
expressed and is present on both CD4 and CD8-positive hematopoietic 
cells. It is not expressed in resting lymphocytes but is rapidly induced upon 
activation of B, T and natural killer cells.  CCR5 and CXCR4 are co-
receptors for HIV, and are expressed on CD4-positive lymphocytes.  
 
“Fluorescence minus one” (FMO) controls contain all antibodies in the panel 
except one. They are used to define the negative population gates for dim 
markers. FMO tubes were used to define the difference between positive 
and negative populations for CD69, CXCR4, and CCR5.  
 
 
Table 5-8 Flow cytometry monoclonal antibody reagents 
T cell 
phenotype Purpose Fluorochrome Supplier 
Catalogue 
number 
     
CD45 Leucocyte common 
antigen 
PerCP BD 340665 
CD3 T-cell co-receptor Pacific Blue BD 558117 
CD4 T-cell co-receptor PE-Cy7 BD 348789 
CD8 T-cell co-receptor APC-H7 BD 557834 
CCR5 HIV co-receptor FITC BD 555530 
CXCR4 HIV co-receptor APC BD 555976 
CD69 Early marker of T cell 
activation 
PE BD 555993 
     
BD; BD Biosciences 
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5.8.3.3 Flow cytometry protocol 
Flow cytometric analysis was performed on a BD™ LSRFortessa cytometer 
(BD Biosciences, San Jose, CA, USA).  All data were stored in list mode and 
analyzed with BD™ FACSDIVA operating system and Flow Jo (Tree Star, 
Inc., Ashland, OR, USA).  
5.8.3.4 Gating strategy 
Gating was undertaken to characterize a population of single lymphocytes 
based on morphological criteria and CD45+ staining (Figure 5-13). 
Subsequent gates defined viable CD3+ lymphocytes, CD4+ lymphocytes, 
CD8+ lymphocytes, and CCR5+, CXCR4+, CCR5+/CXCR4+, and CD69+ 
subsets of CD4+ and CD8+ lymphocytes. 
 
 
 
Figure 5-13 Gating strategy for MTN-007 
C
D
3
 
Viability 
 5.9 Statistical analysis 
Data were used from the 60 evaluable participants including the replacement 
participants. The association between the mucosal parameters and 
randomisation arm was explored for samples collected at 9 cm and 15 cm. 
Mucosal parameters were measured at the Baseline visit, the Treatment 1 
Visit, and the Final Clinic Visit. Differences in histology, fecal calprotectin, 
epithelial sloughing, rectal microflora and mucosal biomarkers were 
evaluated among participants who completed at least 5 doses of gels during 
the 7-day product use period and completed the Final Clinic Visit. Pairwise 
group comparisons were conducted across groups after adjustment for 
baseline variability for biomarkers measured after the single-dose use and 
for the 7-day use, separately. Cytokine/chemokine gene expression (RT-
PCR) data were transformed by log base 10. Microflora data were 
dichotomized by treating Grade 0 as “absence” and Grades 1-4 as 
“presence”.   
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Mucosal Safety Results 
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6 Mucosal safety results 
6.1 Histological assessment of rectal biopsies 
Rectal biopsies were collected via anoscopy (9 cm from the anal verge) and 
flexible sigmoidoscopy (15 cm from the anal verge). Biopsies were formalin 
fixed; paraffin embedded, sectioned, and stained with haematoxylin and 
eosin and scored using a semi quantitative score of mucosal damage in a 
blinded fashion by a single gastrointestinal pathologist (Section 5.2). 
6.1.1 Results 
Within the anorectal biopsy (ARB) samples, following seven exposures to 
study product, the histology score was significantly increased in the N9 arm 
(1.8) compared to the TFV (0.7, P = 0.01) and the HEC (1.1, P = 0.03) arms 
(Figure 6-1). Within the flexible sigmoidoscopy biopsy (FSB) samples, there 
were no significant differences between the study arms (Figure 6-2). 
6.1.2 Discussion 
Previous human studies have reported that rectal exposure to N9 is 
associated with increased rates of epithelial sloughing (Phillips et al., 2000; 
Phillips et al., 2004) and histological abnormalities including separation of 
the epithelium from the underlying mucosa (Phillips et al., 2004). In the 
HIVNET 008 study of N9 gel, 69% of the placebo recipients had slightly 
abnormal or abnormal histology compared to 89% of the N9 recipients 
(Tabet et al., 1999). Consequently, it is not surprising that N9 use in the 
MTN-007 study was associated with an increase in the histology damage 
score. However, it was interesting that the mucosal changes were only seen 
in the ARB samples suggesting that the exposure to N9 at the FSB site (15 
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cm from the anal margin) was insufficient to result in mucosal damage. No 
changes were seen in the TFV, HEC, or No Rx arms of the study although 
an exposure period of 7 days is still relatively brief for a product that could be 
used over extended periods of time.  
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Figure 6-1 Anorectal biopsy histological scores 
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Figure 6-2 Histology grade for the flexible sigmoidoscopy biopsies 
  
No treatment, HEC gel, Nonoxynol-9 gel, Tenofovir gel 
P< 0.05 
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6.2 Epithelial sloughing in rectal lavage fluid 
Cell pellets were isolated from lavage fluid obtained from participants 
following an isotonic enema. 2% paraformaldehyde (1 mL) was gently added 
to resuspend each pellet.  The cellular suspension was then added to a petri 
dish with 10 mL of PBS. The petri dish that was then scanned at using a 
dissecting microscope and the number of epithelial sheets >2 mm counted in 
each quadrant. The total number of epithelial sheets in all four quadrants 
was then submitted as the final score for the epithelial sloughing assay 
(Section 5.3).  
6.2.1 Results 
There were no significance differences in the epithelial sloughing score 
between study arms at any time point during the study (Figure 6-3). 
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Figure 6-3 Epithelial sloughing scores 
 
 
No treatment, HEC gel, Nonoxynol-9 gel, Tenofovir gel 
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6.2.2 Discussion 
Increases in epithelial sloughing following exposure to N9 have been 
previously reported in murine (Phillips & Zacharopoulos, 1998), NHP 
(Patton, Cosgrove Sweeney, Rabe, & Hillier, 2002) and human studies 
(Phillips et al., 2000; Phillips et al., 2004). We did not see significant 
changes in epithelial sloughing across any of the study arms. Indeed, we 
saw evidence of sloughing in 15-20% of baseline samples, a finding not 
documented in the studies by Phillips et al. (Phillips et al., 2000; Phillips et 
al., 2004). It is possible that the preparatory isotonic enema used in the 
MTN-007 study contributed to these divergent results. In the Phillips study, 
participants administered a 10 mL saline lavage (Phillips et al., 2000) 
whereas the MTN-007 preparatory enema was 120 mL of Normosol. The 
significantly larger volume in the MTN-007 study may have induced baseline 
epithelial sloughing. It is also possible that the processing of the lavage fluid 
in MTN-007 increased the sensitivity of the assay and created more 
background noise. Both the RMP-01 and RMP-02/MTN-006 Phase 1 rectal 
safety studies included epithelial sloughing assays and in both cases 
exposure to antiretroviral rectal microbicides was not associated with 
significant increases in epithelial sloughing (Anton et al., 2011; Anton et al., 
2012). 
6.3 Fecal calprotectin 
Stool samples were collected from study participants at each clinic visit and 
sent to a commercial laboratory for quantification of fecal calprotectin levels 
(Section 5.4). 
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6.3.1 Results 
There were no significance differences in the faecal calprotectin levels 
between study arms at any time point during the study (Figure 6-4). 
6.3.2 Discussion 
Quantification of fecal calprotectin is widely used in gastroenterology to help 
differentiate between patients with inflammatory or infectious colitis and 
patients with functional bowel disease in order to avoid unnecessary 
invasive diagnostic procedures such as colonoscopy (Abraham & Kane, 
2012). Fecal calprotectin has been used in previous rectal microbicide trials 
but has not been shown to be increased after exposure to UC781 or TFV 
gels (Anton et al., 2011; Anton et al., 2012). There were no significant 
increases in fecal calprotectin in the MTN-007 trial. One participant in the 
HEC gel arm had an unusually high fecal calprotectin level after a single 
dose of HEC (1,347 g/mL) but the values at the Baseline visit and after 7 
doses of HEC gel were both < 16 g/mL). Consequently, it is unlikely that 
this elevation was product related. In addition there were no gastrointestinal 
adverse events reported at this clinic visit and so it is most likely that this 
represents a laboratory error. 
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Figure 6-4 Fecal calprotectin levels 
 
 
6.4 Assessment of rectal microflora  
Rectal swabs were collected at each study visit and rectal microflora were 
characterized using semi-quantitative techniques (Section 5.5). 
6.4.1 Results 
There were relatively few significant changes in the rectal microflora 
following seven daily doses of study product. The prevalence of 
Streptococcus viridans (H2O2 producing) was significantly reduced in the 
TFV arm (20%) compared to the HEC (73%) and N9 (73%) arms (P = 
0.006). The prevalence of other gram positive cocci was increased in the N9 
arm (67%) compared to the no treatment arm (27%) (P = 0.03). Anaerobic 
gram positive rods were increased in the HEC arm (60%) compared to the 
TFV arm (13%) (Table 6-1).  
 
No treatment, HEC gel, Nonoxynol-9 gel, Tenofovir gel 
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Table 6-1 Rectal microflora culture data 
Bacteria No Rx HEC gel N9 gel TFV gel 
 BL  D7 BL  D7 BL  D7 BL  D7 
         
Lactobacillus (H2O2+) 33% 27% 27% 13% 33% 47% 67% 53% 
Lactobacillus (H2O2-) 27% 27% 7% 13% 20% 20% 27% 13% 
Gardnerella vaginalis 20% 13% 27% 27% 20% 13% 13% 7% 
Diptheroids 93% 93% 80% 87% 100% 80% 93% 93% 
Bacillus species 0% 7% 0% 7% 0% 0% 0% 0% 
Gram-positive rods, other 60% 53% 53% 73% 60% 47% 60% 80% 
Group B Streptococcus 40% 20% 27% 13% 33% 33% 47% 47% 
Enterococcus species 13% 40% 27% 33% 0% 33% 13% 20% 
Staphylococcus aureus 0% 0% 0% 0% 7% 0% 0% 0% 
Staphylococcus species 60% 40% 67% 27% 40% 53% 33% 40% 
Micrococcus species 0% 0% 13% 0% 7% 7% 0% 0% 
Streptococcus viridans (H2O2+) 33% 47% 53% 73% 47% 73% 47% 20%
Streptococcus viridans (H2O2-) 40% 47% 53% 53% 60% 47% 53% 53% 
Gram positive cocci, other 27% 27% 27% 60% 53% 67% 53% 40% 
Escherichia coli 87% 87% 100% 93% 73% 80% 73% 80% 
Proteus species 7% 7% 0% 0% 0% 0% 0% 0% 
Gram negative rod, other 7% 0% 0% 7% 7% 20% 27% 20% 
Bacteroides fragilis 100% 93% 100% 100% 100% 87% 100% 100%
Non-pigmented anaerobic 
GNR 
87% 80% 73% 73% 87% 80% 67% 47% 
Pigmented anaerobic GNR 87% 87% 87% 87% 87% 87% 93% 87% 
Anaerobic gram-positive cocci 47% 93% 73% 80% 100% 73% 73% 80% 
Anaerobic gram-positive rods, 
clostridium like 
53% 67% 67% 53% 40% 60% 67% 60% 
Anaerobic gram-positive rods, 
other 
60% 33% 47% 60% 67% 47% 73% 13% 
Yeast 0% 0% 0% 0% 0% 0% 0% 0% 
         
Statistically significant differences between rectal microflora across arms after seven daily 
doses are highlighted in red and described further in Section 6.4.1. 
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6.4.2 Discussion 
It is recognized that perturbations in vaginal microflora, such as those 
associated with bacterial vaginosis, may increase the risk of acquiring or 
transmitting HIV infection (Atashili et al., 2008; Cohen et al., 2012). As a 
consequence, semi-quantitative characterization of changes in vaginal 
microflora is an important component of the preclinical (Patton, Cosgrove 
Sweeney, & Paul, 2008) and clinical (Rosenstein et al., 1998) evaluation of 
candidate vaginal microbicides. A similar approach has been incorporated 
into the design of preclinical (Patton et al., 2009) and clinical (Anton et al., 
2011; Anton et al., 2012) rectal microbicide studies.  
 
In the MTN-007 study we demonstrated a significant decrease in 
Streptococcus viridans in the TFV gel arm (20%) compared to 73% in both 
the HEC and N9 gel arms although none of these arms were significantly 
different to the No Rx arm. Gram positive cocci were increased in the N9 gel 
arm (67%) compared to the No Rx arm (27%). Anaerobic gram positive rods 
were reduced in the TFV gel arm (13%) compared to the HEC gel arm. The 
biological or clinical significance of these findings is unclear as there were no 
significant differences in the prevalence of Grade 2 or higher gastrointestinal 
AEs across the arms of the study. There was a trend towards higher 
prevalence of flatulence in the TFV gel arm and other gastrointestinal AEs in 
the N9 gel arm. It is not clear how use of TFV gel might lead to a reduction in 
the prevalence of Streptococcus viridans and anaerobic gram positive rods 
as TFV gel does not have intrinsic antibacterial activity. The increase in 
gram positive cocci associated with N9 gel has previously been documented 
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in women receiving vaginal N9 (Rosenstein et al., 1998). MTN-007 did not 
collect rectal samples following a wash-out period and so it is unclear 
whether these perturbations persisted once product administration was 
stopped.  
 
There has been an increasing focus on the interactions between the gut 
microbiome and GALT in health and disease (Shanahan, 2013; Saxena et 
al., 2012).  This expansion of research has been driven by the development 
of culture-independent techniques to characterize gut microbiota. Examples 
of these techniques include terminal restriction fragment length 
polymorphism (T-RFLP), fluorescence in situ hybridisation (FISH), DNA 
microarrays, and next-generation sequencing of the 16S ribosomal (r) RNA 
(Fraher et al., 2012). These techniques have demonstrated the microbial 
diversity of the gut microbiota and have shown that changes in microbial 
composition and function can be associated with disease states such as 
obesity and inflammatory bowel disease (Shanahan, 2012). Culture-
independent techniques have recently been used in Phase 1 vaginal 
microbicide studies to characterize the vaginal microbiota (Ravel et al., 
2012). This approach was able to demonstrate a shift towards a microbial 
pattern seen in bacterial vaginosis. Use of similar techniques in Phase 1 
rectal microbicide studies may provide further insights into the gut microbial 
response to candidate microbicides. 
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6.5 Rectal secretion of cytokines and chemokines 
Rectal fluid samples were collected at each study visit and 
cytokines/chemokines of interest were quantified using Luminex® 
technology (Section 5.6) 
6.5.1 Results 
Rectal fluid TNF- levels following seven daily doses of study product were 
significantly higher in the HEC arm (2.7 pg/mL) compared to the no 
treatment arm (1.4 pg/mL; P = 0.04). Day 7 IL-8 levels were also significantly 
higher in the N9 arm (537.3 pg/mL) compared to the TFV arm (164.3; P = 
0.02). Following a single dose of study product MIP-1 levels were 
significantly lower in the TFV arm (2.6 pg/mL) compared to the No Rx arm 
(7.2 pg/mL; P = 0.03). RANTES levels were increased following a single 
dose of N9 gel (335.9 pg/mL) compared to the no treatment (33.1 pg/mL; P 
= 0.01), HEC (12.1 pg/mL; P = 0.0013), and TFV (8.3 pg/mL; P = 0.0036) 
arms of the study (Figures 6-5 and 6-6). 
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Figure 6-5 Luminex data (I) 
 
 
 
  
No treatment, HEC gel, Nonoxynol-9 gel, Tenofovir gel 
IFN- IL-1 
IL-6 TNF- 
IL-8 IL-17 
P< 0.05 
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Figure 6-6 Luminex data (II) 
 
 
 
6.5.2 Discussion 
The Luminex data from the MTN-007 study demonstrated a significant 
increase in TNF-secretion associated with exposure to HEC gel, an 
increase in IL-8 and RANTES associated with exposure to N9 gel, and a 
decrease in MI-1 associated with exposure to TFV gel. The HEC data are 
somewhat surprising as the HEC gel is generally regarded as inert and not 
associated with induction of mucosal responses (Tien et al., 2005; Schwartz 
No treatment, HEC gel, Nonoxynol-9 gel, Tenofovir gel 
MIP-1 MIP-1 
RANTES IL-12 
P< 0.05 
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et al., 2007; Cone et al., 2006; Richardson et al., 2013). However, N9 is 
known to be associated with induction of mucosal inflammation and release 
of inflammatory mediators such as IL-1 and IL-8 (Fichorova et al., 2001; 
Hillier et al., 2005). Reduced levels of cytokine/chemokine secretion 
following exposure to ARV gels have been seen in previous rectal 
microbicide trials. In the RMP-01 study, after single rectal dose exposure, 
there was a significant reduction in RANTES in the 0.1% UC781 gel arm 
(31.06 ± 17.2 pg/mL) compared to the placebo gel (71.79 ± 54.38 pg/mL) 
(Anton et al., 2011). In the RMP-02/MTN-006 study, after 7 days of dosing, 
there were significant cytokine reductions seen in the TFV gel compared to 
the HEC placebo gel: IL-1 (1.55 ± 1.64 vs. 5.43 ± 3.71 pg/mL), MIP-1 
(4.69 ± 10.78 vs. 11.76 ± 7.88 pg/mL), IL-6 (1.29 ± 1.48 vs. 4.13 ± 3.25 
pg/mL), and TNF-(4.57 ± 9.18 vs. 8.15 ± 9.49 pg/mL ) (Anton et al., 2012). 
The mechanism of action by which a topically applied microbicide might 
modulate secretion of cytokines/chemokines is uncertain. However, 
Melchjorsen et al. have demonstrated the ability of TFV to reduce 
lipopolysaccharide (LPS) induced cellular secretion of IL-8 and MIP-1 in 
U937 monocyte cells (Melchjorsen et al., 2011). 
 
Collection of biological samples for quantification of cytokines/chemokines 
has been widely used in vaginal microbicides studies (Fichorova, 2004) and 
has been adopted as a potential biomarker in rectal microbicide studies. 
However, some of the preliminary studies undertaken prior to 
implementation of quantification of cytokine/chemokines in vaginal studies 
have not been conducted in the rectal compartment. Fichorova et al. have 
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conducted multi-centre studies to determine the biological and technical 
variable associated with quantification of cytokine/chemokine levels in 
vaginal fluids (Fichorova, 2004). Dezzutti et al. have undertaken comparative 
assessment of different vaginal collection modalities (endocervical swabs, 
vaginal swabs, and cervicovaginal lavage fluid) and their influence on the 
quantity of cytokine/chemokine recovery (Dezzutti et al., 2011).  Studies 
have also been undertaken to characterize the baseline variation in vaginal 
cytokine/chemokine secretion in different populations (Fichorova et al., 
2011). Unfortunately, none of these studies have been conducted for studies 
involving collection of anorectal samples. A further complication is that the 
stability of plasma and serum cytokines/chemokines during prolonged 
storage is highly variable as is their response to freeze/thaw cycles (de et 
al., 2009) and there is a need to conduct similar studies for vaginal and 
rectal samples. 
6.6 Cytokine and chemokine gene expression in mucosal tissue 
RNA was isolated from rectal biopsies and reverse transcribed into cDNA. 
Quantitative real time PCR was then performed using standard curves 
generated from plasmid DNA for the targets of interest. All the gene 
expression data were transformed to log base 10 and normalised to the 
house keeping gene 2-microglobulin (2M) by calculating the ratio of the 
gene expression levels of the cytokine/chemokine of interest to 2M gene 
expression. In this analysis higher ratio numbers are associated with lower 
levels of gene expression. As one example, a ratio figure of -2.2 represents 
a one log higher level of gene expression than -3.2 (Section 5.7). 
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6.6.1 Results 
IL-1 gene expression in the ARB samples, following single dose exposure, 
was significantly increased in the N9 arm (-2.2) compared to the other study 
arms; No Rx (-3.2; P = 0.001), HEC (-2.9; P = 0.0007), and TFV (-2.9; P = 
0.0006). No significant differences were seen in the FSB samples (Figure 6-
7).  
 
IL-6 gene expression in the ARB samples, following single dose exposure, 
was significantly increased in the N9 arm (-3.1) compared to the other study 
arms; No Rx (-4.3; P = 0.004), HEC (-4.0; P = 0.003), and TFV (-4.2; P = 
0.00001). IL-6 expression in the FSB samples, following seven product 
exposures, was significantly increased in HEC arm (-4.0) compared to the 
N9 arm (-4.3; P = 0.02) (Figure 6-7). 
 
There were no significant changes in IFN- gene expression in the ARB 
samples, following single or multiple dose product exposure. IFN- gene 
expression in the FSB samples, following single dose exposure, was 
significantly increased in the HEC arm (-4.3) compared to the No Rx (-4.7; P 
= 0.04) and N9 (-4.4; P = 0.04) arms (Figure 6-7). 
 
TNF- gene expression in the ARB samples, following single dose 
exposure, was significantly increased in the N9 arm (-2.8) compared to the 
No Rx (-3.8; P = 0.003) and HEC (-3.5; P = 0.01) arms. There were no 
significant changes in TNF- gene expression in the FSB samples (Figure 6-
8). 
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IL-8 gene expression in the ARB samples, following single dose exposure, 
was significantly increased in the N9 arm (-2.1) compared to the other study 
arms; No Rx (-3.2; P = 0.005), HEC (-3.0; P = 0.0003), and TFV (-3.0; P = 
0.00004). There were no significant changes in IL-8 gene expression in the 
FSB samples (Figure 6-8). 
 
MIP-1 gene expression in the ARB samples, following single dose 
exposure, was significantly increased in the N9 arm (-2.8) compared to the 
other study arms; No Rx (-3.7; P = 0.003), HEC (-3.5; P = 0.003), and TFV (-
3.4; P = 0.003). There were no significant changes in MIP-1 gene 
expression in the FSB samples (Figure 6-8). 
 
MIP-1 gene expression in the ARB samples, following single dose 
exposure, was significantly increased in the N9 arm (-2.5) compared to the 
other study arms; No Rx (-3.3; P = 0.008), HEC (-3.0; P = 0.007), and TFV (-
2.9; P = 0.002). MIP-1 gene expression in the FSB samples, following 
single dose exposure, was significantly increased in the TFV arm (-3.0) 
compared to the N9 (-3.2; P = 0.02) arm (Figure 6-9). 
 
There were no significant changes in RANTES gene expression in the ARB 
samples, following single dose exposure. Variable changes were seen after 
seven product exposures. RANTES gene expression was increased in the 
N9 arm (-2.5) compared to the No Rx (-2.6; P = 0.02) and the TFV (-2.7; P = 
0.02) arms. However RANTES gene expression was increased in the HEC 
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arm (-2.4) compared to the N9 arm (-2.5; P = 0.03). In the FSB samples, 
following single dose exposure, there was a significant reduction in RANTES 
gene expression between the TFV arm (-2.5) and the No Rx arm (-2.5; P = 
0.01). After seven exposures, there was a significant increase in RANTES 
gene expression in the N9 arm (-2.2) compared to the TFV arm (-2.5; P = 
0.01) (Figure 6-9). 
 
IL-12p40 gene expression in the ARB samples, following single dose 
exposure, was significantly increased in the N9 arm (-4.4) compared to the 
No Rx arm (-5.2; P = 0.002). IL-12p40 gene expression in the FSB samples, 
following seven dose exposures, was significantly increased in the N9 arm (-
4.8 compared to the HEC arm (-4.9; P = 0.04). IL-12p40 gene expression 
was also significantly increased in the HEC arm (-4.9) compared to the TFV 
arm (-5.2; P = 0.006) (Figure 6-9). 
 
There were no significant changes in IL-17 gene expression in the ARB 
samples, following single dose exposure. After seven product exposures, IL-
17 gene expression was increased in the No Rx arm (-4.9) compared to the 
TFV (-4.9; P = 0.02) arm. In the FSB samples, following single dose 
exposure, there was a significant increase in IL-17 gene expression in the 
HEC arm (-4.4) compared to the No Rx arm (-5.2; P = 0.02) (Figure 6-10). 
 
IL-23 gene expression in the ARB samples, following single dose exposure, 
was significantly increased in the N9 arm (-3.6) compared to the No Rx (-4.6; 
P = 0.01) and HEC (-3.9; P = 0.02) arms. IL-23 gene expression in the FSB 
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samples, after seven product exposures, was significantly increased in the 
HEC arm (-3.9) compared to the No Rx arm (-4.7; P = 0.008) (Figure 6-10). 
 
CCR5 gene expression in the ARB samples, following single dose exposure, 
was significantly increased in the N9 arm (-3.9) compared to the No Rx (-4.6; 
P = 0.006) and HEC (-4.1; P = 0.03) arms. There were no significant 
changes in CCR5 gene expression in the FSB samples (Figure 6-10).  
6.6.2 Discussion 
Significant changes in gene expression were noted in 36 of 144 potential 
comparisons (25%). Changes were more common in the ARB samples 
(26/72; 36%) compared to the FSB samples (10/72; 14%) suggesting the 
possibility of a dose response effect. The majority of changes (30/36; 83%) 
resulted in increased gene expression and were associated with exposure to 
N9 and were more common in the ARB samples (25/26; 96%) compared to 
the FSB samples (5/10; 50%). N9 exposure was associated with increases 
in all of the cytokines/chemokines evaluated apart from IFN-. N9 exposure 
also resulted in increased expression of the HIV co-receptor CCR5. In 
contrast, changes associated with TFV were much more limited and 
included increased expression of RANTES compared to the HEC arm (FSB 
samples), reduced expression of IL-12 (FSB) compared to HEC, and 
reduced expression of IL-17 (ARB) compared to No Rx. HEC exposure 
resulted in increased expression of IFN- (FSB), IL-17 (FSB) and IL-23 
(FSB) compared to No Rx. The changes in gene expression associated with 
exposure to N9 are in keeping with previous studies that have demonstrated 
mucosal injury and increased secretion of proinflammatory cytokines (Hillier 
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et al., 2005). Dose dependent increased expression of RANTES has 
previously been documented in murine peritoneal macrophages exposed to 
TFV (Zidek, Frankova, & Holy, 2001) and it appears that TFV can inhibit 
inflammatory cytokine expression in cell lines (Melchjorsen et al., 2011). The 
changes associated with HEC are more surprising as HEC gel is regarded 
as an inert universal placebo (Schwartz et al., 2007).  The significance of the 
changes associated with HEC is unclear. A recent large Phase 2B trial 
(HPTN-035) confirmed that there were no significant differences in the 
clinical safety profile of women randomised to receive HEC gel (N= 771) 
compared to No Rx (N = 772) (Richardson et al., 2013). However, it is 
possible that the columnar epithelium of the distal colon is more susceptible 
to product related damage than the stratified squamous epithelium of the 
vaginal compartment. It was interesting that increased gene expression was 
more common in the ARB samples compared to the FSB samples 
suggesting product dilution by rectal fluid and or fecal matter might result in 
lower exposure to the more proximal sampling site. 
 
Previous rectal microbicide studies have included limited testing of mucosal 
gene expression (discussed in Section 5.7.2) and so the MTN-007 data set 
provides a more comprehensive assessment of changes in gene expression 
following product exposure. Another advantage of the qRT-PCR method 
used in the study is that gene expression data were normalised to a house 
keeping gene (2M). Prior to final data analysis, preliminary assessment was 
conducted for three other housekeeping genes (-actin, GAPDH, and 
CD45). Intra-class correlation (ICC) was calculated based on data from all 
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three visits for the four house-keeping genes (Table 6-2). Based on ICC, 2-
microglobulin was found to be the most stable housekeeping gene and was 
therefore used to normalise the cytokine/chemokine gene expression data.  
 
Table 6-2  Intraclass correlation for house-keeping genes 
 Log GAPDH  Log -actin  Log 2-microglobulin  Log CD45 
ARB samples 0.69 0.87 0.95 0.78 
FSB samples 0.79 0.84 0.92 0.70 
Combined 0.72 0.85 0.93 0.70 
 
In comparing the Luminex and qRT-PCR data there were more significant 
changes noted with qRT-PCR than with Luminex. This is not surprising as 
the qRT-PCR was able to detect down to 5 copies of the majority of the 
cytokines/chemokines (Figures 5-6 to 5-11). Neverthertheless, increases in 
expression of TNF-, IL-8, and RANTES noted by qRT-PCR were also seen 
in the Luminex data.  
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Figure 6-7 RT-PCR data (I) 
  No treatment, HEC gel, Nonoxynol-9 gel, Tenofovir gel 
Anorectal biopsies 
(9 cm) 
Flexible sigmoidoscopy biopsies 
(15 cm) 
IL-1 IL-1 
IL-6 IL-6 
IFN- IFN- 
P< 0.05 
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Figure 6-8 RT-PCR (II) 
 
 
 
No treatment, HEC gel, Nonoxynol-9 gel, Tenofovir gel 
Anorectal biopsies 
(9 cm) 
Flexible sigmoidoscopy biopsies 
(15 cm) 
TNF- TNF- 
IL-8 IL-8 
MIP-1 MIP-1 
P< 0.05 
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Figure 6-9 RT-PCR data (III) 
 
 
No treatment, HEC gel, Nonoxynol-9 gel, Tenofovir gel 
Anorectal biopsies 
(9 cm) 
Flexible sigmoidoscopy biopsies 
(15 cm) 
MIP-1 MIP-1 
RANTES RANTES 
IL-12p40 IL-12p40 
P< 0.05 
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Figure 6-10 RT-PCR data (IV) 
 
 
No treatment, HEC gel, Nonoxynol-9 gel, Tenofovir gel 
Anorectal biopsies 
(9 cm) 
Flexible sigmoidoscopy biopsies 
(15 cm) 
IL-17 IL-17 
IL-23 IL-23 
CCR5 CCR5 
P< 0.05 
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6.7 Flow cytometric analysis of mucosal T cells 
Mucosal mononuclear cells were liberated from intestinal biopsies by 
enzymatic digestion. They were then stained with monoclonal antibodies to a 
range of T cell markers. Flow cytometry was undertaken to quantify the 
prevalence of various GALT T cell populations before and after exposure to 
study products. Data are presented on the prevalence of the following T cell 
subsets; CD45+/CD3+, CD3+/CD4+, CD3+/CD8+, CD3+/CD4+/CCR5+, 
CD3+/CD4+/CXCR4+, CD3+/CD4+/CCR5+/CXCR4+, CD3+/ CD4+/CD69+, 
and CD3+/ CD4+/CD69+ T cells (Section 5.8). 
6.7.1 Results 
The prevalence of CD45+/CD3+ T cells in the ARB samples, following seven 
doses of study product, was significantly reduced in the HEC arm (41.0%) 
compared to the No Rx arm (57.7%; P = 0.006). There was a significant 
increase in CD45+/CD3+ T cells in the FSB samples, following seven doses 
of study product in the TFV arm (57.3%) compared to the HEC arm (42.8%; 
P = 0.04)(Figure 6-11).  
 
The prevalence of CD3+/CD4+ T cells in the ARB samples, following seven 
doses of study product, was significantly increased in the N9 arm (60.5%) 
compared to the No Rx (50.1%; P = 0.01) or HEC arms (53.8%; P = 0.04). 
There was no significant increase in CD3+/CD4+ T cells in the FSB samples 
(Figure 6-11).  
 
The prevalence of CD3+/CD8+ T cells in the ARB samples, following seven 
doses of study product, was significantly reduced in the N9 arm (27.5%) 
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compared to the No Rx arm (37.3%; P = 0.002). The prevalence of 
CD3+/CD8+ T cells in the FSB samples, following seven doses of study 
product, was also significantly reduced in the N9 arm (32.8%) compared to 
the No Rx arm (36.5%; P = 0.04) (Figure 6-11).  
 
There were no significant changes in CD3+/CD4+/CCR5+ T cells in the ARB 
or FSB samples in any of the study arms (Figure 6-12). 
 
The prevalence of CD3+/CD4+/CXCR4+ T cells in the ARB samples, 
following seven doses of study product, was significantly increased in the N9 
arm (59.6%) compared to the No Rx arm (38.2%; P = 0.02). There was no 
significant increase in CD3+/CD4+/CXCR4+ T cells in the FSB samples 
(Figure 6-12).  
 
There were no significant changes in CD3+/CD4+/CCR5+/CXCR4+ T cells 
in the ARB or FSB samples in any of the study arms (Figure 6-12). 
 
There were no significant changes in CD3+/CD4+/CD69+ T cells in the ARB 
or FSB samples in any of the study arms (Figure 6-13). 
 
The prevalence of CD3+/CD8+/CD69+ T cells in the ARB samples, following 
seven doses of study product, was significantly decreased in the N9 arm 
(69.5%) compared to the No Rx arm (83.4%; P = 0.02). The prevalence of 
CD3+/CD8+/CD69+ T cells in the FSB samples, following a single dose of 
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study product, was significantly decreased in the TFV arm (81.8%) 
compared to the No Rx arm (89.0%; P = 0.02) (Figure 6-13).  
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Figure 6-11 Flow cytometry data (I) 
  
Anorectal biopsies 
(9 cm) 
Flexible sigmoidoscopy biopsies 
(15 cm) 
CD3 CD3 
CD4 CD4 
CD8 CD8 
No treatment, HEC gel, Nonoxynol-9 gel, Tenofovir gel 
P< 0.05 
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Figure 6-12 Flow cytometry data (II) 
 
Anorectal biopsies 
(9 cm) 
Flexible sigmoidoscopy biopsies 
(15 cm) 
CCR5 CCR5 
CXCR4 CXCR4 
CCR5/CXCR CCR5/CXCR4 
No treatment, HEC gel, Nonoxynol-9 gel, Tenofovir gel 
P< 0.05 
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Figure 6-13 Flow cytometry data (III) 
  No treatment, HEC gel, Nonoxynol-9 gel, Tenofovir gel 
Anorectal biopsies 
(9 cm) 
Flexible sigmoidoscopy biopsies 
(15 cm) 
CD4/CD69 CD4/CD69 
CD8/CD69 CD8/CD69 
P< 0.05 
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6.7.2 Discussion 
The primary rationale for including flow cytometric assessment in the MTN-
007 study was the concern that repetitive exposure to rectal microbicides 
might be associated with changes in GALT that could lead to increased risk 
of HIV acquisition. Changes in T cell phenotype might include increased 
prevalence of CD4+ HIV target cells in the intestinal mucosa, increased 
prevalence of CD4+ T cells expressing CCR5 or CXCR4, and increased 
activation phenotype (CD69+) of those target cells.  
 
In the MTN-007 study we saw a reduction in CD45+/CD3+ cells in the HEC 
arm (ARB) after seven exposures compared to No Rx and conversely an 
increase in CD45+/CD3+ cells in the TFV arm (FSB) compared to the HEC 
arm after seven exposures. Exposure to N9 was associated with an increase 
in CD3+/CD4+ cells, a decrease in CD3+/CD8+ cells, an increase in 
CD3+/CD4+/CXCR4+ cells, and a decrease in CD3+/CD8+/CD69+ cells in 
both TFV (FSB) and N9 (ARB) arms compared to the No Rx arm.  
 
Flow cytometry did not identify any significant increases in CD3+/CD4+ T 
cells following exposure to TFV gel. In contrast, exposure to N9 did result in 
an increase in CD3+/CD4+ T cells. In a previous Phase 3 vaginal 
microbicide study (COL1492), repetitive exposure to an N9 gel did increase 
the rate of HIV acquisition in study participants (Van Damme et al., 2002). 
These women, who used 3-5 applicators per day, also had a high incidence 
of vaginal lesions with epithelial disruption. A possible increase in CD4+ T 
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cells could have also contributed to the risk of HIV acquisition in these 
women. 
 
There are a number of limitations associated with the flow cytometry 
approach used in MTN-007. The flow panels used in the study focused on T 
cell populations. Other mucosal cell populations such as macrophages, 
dendritic cells, and B cells all play important roles in the transmission of HIV 
infection (Haase, 2001) and were not characterized in this study. In addition 
we explored changes in the prevalence of various T cell populations but did 
not attempt to quantify these changes in absolute terms as is routinely 
undertaken in flow cytometric assessment of peripheral blood samples. 
Another issue that is often raised is the degree of sampling heterogeneity 
associated with random biopsies of the colon. As one example, a biopsy that 
samples a lymphoid aggregate in the mucosa may reveal a different 
population of cells compared to a biopsy that only samples lamina propria. 
The MTN-007 flow panels were derived from three individual rectal biopsies 
and so this would have reduced any bias associated with the sampling 
process. We were unable to demonstrate an increase in T cell activation 
defined by expression of the CD69 phenotype. Indeed, exposure to N9 and 
TFV was associated with a reduction in CD69 expression. CD69 is 
expressed early during T cell activation and was highly expressed at 
baseline in gut T cells (66-84%). Future studies should explore the 
differential expression of other activation markers such as CD38 and HLA-
DR. Recent studies of maraviroc have demonstrated changes in GALT 
phenotype including enhanced CCR5 expression and markers of T cell 
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activation (Hunt et al., 2013). These are not desirable features for a PrEP 
agent and so it will be important to continue to monitor GALT phenotype in 
future rectal microbicide studies involving maraviroc as well as other 
antiretroviral agents. 
6.8 Additional analyses of mucosal safety data 
6.8.1 Gender 
The MTN-007 study enrolled 45 men and 20 women. Data were evaluated to 
determine whether gender-specific significant differences across the range 
of mucosal biomarkers. Table 6-3 summarises mucosal parameters that 
reached significance. 
Table 6-3 Gender specific differences in mucosal biomarkers 
Biomarker Female vs. male difference SE P value 
    
Rectal microflora    
Anaerobic gram positive cocci 0.68 0.19 0.004 
Anaerobic gram positive rods -0.62 0.27 0.02 
    
Flow cytometry    
CD3+/CD8+/CD69+ 4.79 2.13 0.02 
    
Cytokine/chemokine RT-PCR    
IL-1 (ARB) 0.41 0.19 0.03 
IL-1(FSB) 0.35 0.17 0.04 
IL-23 (ARB) 0.53 0.26 0.04 
IL-23(FSB) 0.69 0.26 0.008 
CCR5 (ARB) 0.44 0.20 0.03 
    
Luminex    
TNF- -1.81 0.45 7e-5 
RANTES -37.54 17.56 0.03 
    
 
The analysis suggests potential differences between men and women with 
regards to rectal flora, T cell activation, and expression of 
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cytokines/chemokines. One limitation of the study is that, although women 
had to be sterilized or on effective contraception, we did not attempt to 
synchronize sample collection with a specific phase of the menstrual cycle or 
control for use of exogenous hormones. The MTN-007 study lacks adequate 
power to provide definitive evidence of such changes but provides 
hypothesis generating ideas that can be explored in future studies. There is 
increasing interest in how changes in hormonal levels associated with the 
menstrual cycle may influence women’s vulnerability to HIV infection through 
changes in innate or adaptive anti-HIV immune responses in the 
reproductive tract (Rodriguez-Garcia, Patel, & Wira, 2013). Vishwanathan et 
al. have also demonstrated increased risk of SHIV acquisition in NHP during 
the late luteal phase of the menstrual cycle when progesterone levels are 
high and local immunity may be low  (Vishwanathan et al., 2011). It is 
unclear whether similar changes may affect the gastrointestinal mucosa. 
However, estrogen receptors can be found in the colon (Campbell-
Thompson, Lynch, & Bhardwaj, 2001) and exogenous ethynyl estradiol has 
been to improve gut inflammation in transgenic HLA-B27 model of 
inflammatory bowel disease (Harnish et al., 2004) suggesting that the 
relationship between reproductive hormones and intestinal vulnerability to 
HIV infection should be further explored. 
6.8.2 Regional variation in mucosal parameters 
Histology, flow cytometry, and qRT-PCR data were evaluated to determine 
whether there were significant differences in mucosal parameters stratified 
by the site of sample collection. Parameters with significant differences are 
summarised in Table 6-4. 
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Table 6-4 Regional differences in mucosal parameters 
Biomarker ARB vs. FSB difference SE P value 
    
Flow cytometry    
CD3+/CD4+/CD69+ -3.34 0.98 7e-4 
CD3+/CD8+/CD69+ -4.52 1.02 1e-5 
    
Cytokine/chemokine RT-PCR    
IL-6 0.30 0.04 2e-10 
IL-8 0.23 0.05 7e-7 
MIP-1 0.14 0.03 7e-5 
MIP-1 0.11 0.03 7e-5 
RANTES -0.10 0.02 2e-6 
IL-12p40 0.13 0.03 3e-4 
IL-17 0.10 0.04 7e-3 
IL-23 0.09 0.02 1e-4 
    
 
T cell activation and cytokine/chemokine gene expression were found to 
vary by site. CD69 expression on both CD4+ and CD8+ T cells was reduced 
in the ARB compared to the FSB samples. In contrast, a broad range of 
cytokines/chemokines were increased in the ARB compared to the FSB 
samples. One of the goals of the MTN-007 study was to determine whether 
anoscopic sampling could provide adequate tissue for microbicide studies 
compared to the use of flexible sigmoidoscopy to collect the same samples. 
The practical limitations of this approach are that the maximum number of 
biopsies collected anoscopically (N = 5) is significantly lower than the 
number available through flexible sigmoidoscopy (N = 20 to 30). This has 
implications in terms of the breadth of mucosal assays that can be 
incorporated into studies. Another issue is whether tissue samples collected 
at 9 cm (ARB) and 15 cm (FSB) are equivalent. The data presented in Table 
6-4 suggest there are regional differences in a number of parameters. This 
phenomenon was seen in the HPTN-056 study where samples from 10 cm 
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and 30 cm were compared.  In this study, cells expressing CD3, CD4, CD8, 
CD4+/CCR5+, and HLA-DR+/ DC-SIGN lineage-negative cells were more 
common in the 30 cm samples. CD19+ cells (a marker of B cells) were more 
common in the 10 cm samples (McGowan et al., 2007). McElrath et al. have 
recently reported a 3-fold increase in CD68+ macrophages expressing 
CCR5 in rectal tissue (4 cm from the anal verge) compared to colon tissue 
(30 cm from the anal verge) (McElrath et al., 2013). Collectively, these 
studies suggest that there is significant regional heterogeneity in 
composition of GALT and that care must be taken in interpreting the results 
of studies where tissue samples have been collected at different anatomical 
sites within the colon.  
 
The optimal site for tissue sampling in rectal microbicide studies remains 
uncertain. Imaging studies by Louissaint et al. suggest that, for most 
participants, the highest colorectal concentration of semen and microbicide 
surrogates is found 10-20 cm above the anal verge (Louissaint et al., 2012). 
These data would appear to offer a rationale for flexible sigmoidoscopic 
collection of samples at 15 cm from the anal verge. This approach also 
provides the ability to safely collect the greatest number of tissue biopsies 
during one procedure. 
6.9 Summary 
In 1992, Joan Kreiss and her colleagues reported the results of a study 
evaluating the efficacy of an N9 contraceptive sponge in preventing 
heterosexual acquisition of HIV in a group of Nairobi prostitutes (Kreiss et 
al., 1992). Unfortunately, despite positive in vitro efficacy data, the Kreiss 
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study found that use of the N9 sponge increased the risk of HIV infection in 
this population with a hazard ratio of 1.7. Use of the N9 sponge was also 
associated with increased incidence of genital ulcers. Since this time, a 
critical concern in microbicide research has been whether candidate 
microbicides have the potential to increase, rather than decrease, the risk of 
HIV infection. The COL1492 study also demonstrated an increased risk of 
HIV infection associated with N9 use and again there was increased 
incidence of epithelial disruption associated with N9 use (Van Damme et al., 
2002). Not surprisingly, the key components of safety monitoring in vaginal 
microbicide trials include assessment of clinical symptoms and signs 
associated with product use (Poynten et al., 2009).  
 
In January 2007 a DSMB stopped a Phase 3 study of a cellulose sulphate 
(CS) gel study due to concerns of an increased risk of HIV infection in the 
active arm of the study. The interim hazard ratio was 2.23 (p = 0.02) and the 
trial was stopped (Van Damme et al., 2008). There was no obvious increase 
in genital signs or symptoms in participants receiving the CS gel compared 
to the placebo gel participants. However, subsequent in vitro studies 
demonstrated that CS had the ability to disrupt epithelial tight junctions and 
potentially increase the risk of HIV acquisition (Mesquita et al., 2009). 
Unfortunately, the CS study describes a scenario wherein significant product 
associated mucosal changes occurred in the absence of clinical signs or 
symptoms. This observation has increased the need to develop sensitive 
and specific mucosal safety biomarkers to identify and exclude harmful 
microbicide candidates at an early stage of clinical development. This 
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strategy obviously applies to the development of both vaginal and rectal 
microbicides.  
 
The design of MTN-007 reflects this concern about the need for mucosal 
biomarkers. Multiple candidate biomarkers were included in MTN-007. They 
were chosen because of their utility in previous microbicide trials or because 
they had proven useful in identifying inflammation in other settings e.g. the 
use of fecal calprotectin in IBD. This process has two major limitations. The 
first limitation is the selectivity applied to the choice of biomarkers. One 
example might be the decision to choose to characterize IL-17 gene 
expression rather than expression of IL-4. IL-17 may not be involved in the 
biological pathway of mucosal damage caused by candidate “X” whereas up 
or down regulation of IL-4 gene expression may be critical. Failure to see 
any change in IL-17 expression may provide the investigators with a false 
sense of security that candidate “X” is safe.  
 
A second and perhaps more important problem is that Phase 1 microbicide 
safety studies are usually powered based on the ability to discriminate 
differential rates of ≥ Grade 2 AEs across the arms of the studies. The 
sample size is routinely 15 participants per study arm. However, with the 
proliferation of biomarkers used in Phase 1 studies, the number of 
comparisons across study arms increases significantly. As one example, in 
the MTN-007 study there were a total of 84 biomarkers evaluated with 18 
statistical comparisons conducted for each biomarker. Using a Bonferroni 
correction to control for multiple comparisons the convention level of 
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significance (P = < 0.05) falls to 0.05/672 = < 0.00007. Few biomarkers will 
withstand this level of correction and so an argument can be made that, in 
the context of small trials, use of approaches such as the Bonferroni 
correction is unhelpful (Perneger, 1998). For the purpose of the MTN-007 
study we described changes in mucosal biomarkers with an unadjusted p 
value of < 0.05 as providing suggestive evidence of a difference in biomarker 
expression. 
 
In the absence of definitive safety biomarkers it is likely that microbicide 
trials will continue to evaluate novel safety biomarkers and, depending on 
the performance characteristics of these assays, decide whether to include 
them in future microbicide studies. Based upon recent experience in the 
RMP-01, RMP-02/MTN-006, and MTN-007 studies, investigators in this field 
have chosen to discard epithelial sloughing and fecal calprotectin from future 
studies. In addition, there is growing interest in adopting a more systems 
biology approach in characterising mucosal safety in microbicide trials. 
Rather than characterising specific microbes as part of a semi-quantitative 
assessment of vaginal microflora, Ravel et al. chose to use pyrosequencing 
to evaluate microbicide-induced changes in vaginal microbiota (Ravel et al., 
2012). MTN-007 is the first rectal microbicide study to incorporate microarray 
analysis of the entire mucosal transcriptome. This approach has generated 
provocative data on the impact of TFV gel on mucosal mitochondrial and 
immune function that are described in Chapter 7 of this thesis. 
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7 MTN-007 microarray analysis 
7.1 Introduction 
Currently, no validated biomarkers that reliably measure the potential 
mucosal toxicity of microbicides are available.  Certain cytokines and 
chemokines may in principle be suitable as mucosal biomarkers for 
microbicide-induced toxicity or inflammation.  The concentration of 
inflammatory cytokines in mucosal secretions has therefore been evaluated 
in prior microbicide studies.  However, these studies have their limitations. 
First, only a few genes/proteins can be studied from one sample.  Second, it 
is unclear what constitutes a meaningful change in cytokine concentration.  
 
Because of the described limitations when measuring individual biomarkers, 
it would be useful to develop assays that evaluate the cumulative impact of 
candidate microbicides on mucosal immune function as a whole.  To 
evaluate the global impact of microbicides on the mucosa, gene expression 
microarrays were performed on RNA isolated from mucosal biopsies taken 
before and after application of TFV, N9, or HEC placebo gels.  HumanHT12 
v4 Expression BeadChips (Illumina Inc., San Diego, CA, USA) permit the 
measurement of 48,000 mRNAs simultaneously on a single high-density 
oligonucleotide microarray.  This offers the opportunity to: (i) identify 
signature expression patterns of dozens or even hundreds of genes that 
correlate with microbicide side effects on the mucosa; (ii) interpret 
expression changes of a particular gene group, such as inflammatory 
cytokines, in relationship to other genes; and (iii) cross-validate the array 
results with measurements of mucosal gene expression by qRT-PCR and of 
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other techniques such as the measurement of cytokine/chemokine proteins 
in mucosal secretions by the Luminex technique. 
 
An expected outcome of the array studies in MTN-007 was the identification 
of groups of genes, in particular apoptotic, pro-inflammatory and/or innate 
immunity-related genes, which were modulated significantly from baseline in 
response to topical N9 application. In comparison, at the outset of the MTN-
007 study it was not clear whether such changes might be expected after 
exposure to TFV or HEC placebo gel application.  Another expected 
outcome of the array studies was the validation of any significant 
cytokine/chemokine/chemokine receptor changes found by qRT-PCR and 
Luminex measurements.  Similar results in all three assays (expression 
array, qRT-PCR, and Luminex) would underscore the potential usefulness of 
a biomarker to predict toxicity of a candidate microbicide.  Moreover, 
interpreting such a promising marker in the light of other gene expression 
changes in the microarray would provide an opportunity to better understand 
its biological significance.   
7.2 Methods 
7.2.1 Mucosal biopsy procedures 
Rectal biopsies for the microarray studies were obtained before treatment at 
enrollment (time point “0”), 30-60 minutes following application of the single 
gel dose (time point “I”), and again on the day following the last dose of the 
seven once-daily gel applications (time point “VII”).  Following an enema with 
Normosol-R pH 7.4, a flexible sigmoidoscope was inserted into the rectum 
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and biopsies were collected at 15 cm from the anal margin (FSB).  Following 
the sigmoidoscopy, a disposable anoscope was inserted into the anal canal 
with collection of rectal biopsies at 9 cm from the anal margin (ARB).  
Immediately after harvest, biopsies were immersed in RNAlater (Qiagen, 
Valencia, CA, USA), stored at 4°C overnight and transferred to a -80°C 
freezer for long-term storage prior to sample processing. 
7.2.2 RNA isolation and cRNA preparation  
RNA was isolated from the biopsies using the RNeasy Fibrous Tissue Mini 
Kit (Qiagen, Valencia, CA, USA) according to manufacturer’s instructions, 
treated with 27 Kunitz units of DNAse (Qiagen, Valencia, CA, USA) to 
remove genomic DNA contamination, and evaluated for integrity using the 
Agilent RNA 6000 Nano Kit (Agilent, Palo Alto, CA, USA) on an Agilent 2100 
Bioanalyzer.  All samples had a RIN score of 7 or greater.  200 ng of total 
RNA was amplified and labeled using the Illumina TotalPrep RNA 
Amplification kit (Ambion, Grand Island, NY, USA).  cRNA from a total of 192 
biopsy samples (8 men per study arm, 4 study arms, 3 time points and 2 
biopsy sites (9 and 15cm)) was hybridized to HumanHT12 v4 Expression 
BeadChips (Illumina, San Diego, CA, USA) according to the manufacturer’s 
protocols.  Each chip contained 47,323 probes, corresponding to 30,557 
genes.   
7.2.3 Quality control and processing of microarray data 
All chips used in the analysis passed standard quality control metrics 
assessed by GenomeStudio (Illumina, Inc., San Diego, CA, USA) as well as 
visual inspection for anomalies and artifacts.  Using GenomeStudio, a 
256 
 
detection P value was calculated for each probe, representing the 
confidence that a given transcript is expressed above background defined by 
negative control probes.  Further processing and statistical analysis of data 
was done using R/Bioconductor (Dudoit, Gentleman, & Quackenbush, 
2003). Data were pre-processed by robust spline normalization and variance 
stabilizing transformation using lumi (open source software available from 
www.bioconductor.org) (Baldi & Long, 2001; Long et al., 2001). The pre-
processed data were filtered to include only probes with detection threshold 
P values of < 0.05 in 100% of biopsies in at least one of the four study arms, 
and to remove probes that had a low standard deviation (≤ 0.5) across all 
arrays, using genefilter (open source software available from 
www.bioconductor.org).  Finally, probes without an Entrez ID were removed, 
leaving 1928 probes for further statistical analysis.   
7.3 Statistical analysis 
A Bayesian statistical framework, Cyber-T, was used to test for the effect of 
gel treatment on gene expression in paired comparisons between either time 
points I or VII and time point 0 (Long et al., 2001). Each study arm was 
considered separately.  The Benjamini Hochberg method estimating false 
discovery rates (FDR) was used to control for multiple comparisons 
(Benjamini & Hochberg, 1995).  Criteria for significance and relevance were 
an estimated FDR ≤ 0.05 and a log2 fold expression change of ≥ 0.5 (up-
regulation) or ≤ 0.5 (down-regulation), respectively.  For confirmation, the 
pre-processed but unfiltered data (all 47,323 probes) were statistically re-
analyzed for significant treatment effects using a double subtraction strategy, 
where the paired differences between time point 0 and time points I or VII 
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within each treatment arm were first calculated for each probe and study 
subject.  In a second step, the average paired differences for each probe 
within each of the three treatment arms were subtracted from the average 
paired differences for each probe within the no-treatment arm.  Analysis for 
significance was then performed using a linear fit model, Limma (Smyth, 
2005), with criteria for significance and relevance set at an estimated 
Benjamini Hochberg FDR ≤ 0.05 and a log2 fold difference to no-treatment of 
≥ 0.5 (up-regulation) or ≤ 0.5 (down-regulation), respectively.  Confirmatory 
Limma analysis greatly overlapped with the Cyber-T results.  The numbers 
of up- and down-regulated genes are based on the Cyber-T analysis.  Heat 
maps of differentially regulated genes were generated using MeV 4.8 within 
the TM4 Microarray Software Suite (Saeed et al., 2006), and hierarchically 
clustered according to selected gene ontologies found in the databases 
DAVID 6.7 (Huang et al., 2009; Huang, Sherman, & Lempicki, 2009), and 
InnateDB (Lynn et al., 2008). 
7.3.1 General statistics 
Correlation of log2 fold gene expression changes between ARB and FSB 
samples was tested by Spearman’s rank correlation coefficient.  Ratios of 
stimulated to suppressed genes were tested for a difference between 
cellular compartments using Chi-square statistics.  Differences in gene 
expression between study groups or between time points were tested by 
paired or unpaired, parametric or non-parametric statistical tests, and 
adjusted for multiple testing, as appropriate.   
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7.3.2 Pathway and network analysis of microarray data 
Entrez ID designations, assigned to the array probes by Illumina, were 
uploaded to the Innate DB database and a Gene Ontology (GO) over-
representation analysis was performed for gene groups signifying a 
particular molecular function or biological process, or occurring in specific 
cellular compartments (Lynn et al., 2008). The following strategy was used 
to determine which gene groups were enriched in the data set: separately for 
down- and up-regulated genes, ratios of the number of genes in a particular 
GO group to the total number of genes detected in the data set were 
compared to the ratios in the same GO group reported for the complete 
human genome using Fisher's exact test.  Ingenuity Pathways Analysis (IPA) 
(Ingenuity Systems, Redwood City, CA, USA) was used to visualize direct 
and indirect relationships between individual gene products and map their 
cellular localizations.   
7.3.3 Confirmation of microarray results 
A two-step RT droplet digital PCR (RT-ddPCR) was used to confirm 
microarray transcriptome data for selected genes of interest (Hindson et al., 
2011; Pinheiro et al., 2012). In a ddPCR assay, each sample is partitioned 
into approximately 20,000 droplets representing as many individual PCR 
reactions.  The number of target DNA copies present per sample can be 
quantified based on Poisson distribution statistics, because each individual 
droplet is categorized as positive or negative for a given gene.  cDNA was 
generated using the High Capacity cDNA Reverse Transcription Kit (Life 
Technologies, Grand Island, NY, USA).  ddPCR was carried out using the 
QX100 droplet digital PCR system (BioRad, Hercules, CA, USA) with cDNA 
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amplified in a duplex reaction using Primetime (Integrated DNA 
Technologies, Coralville, IA, USA) and Taqman (Life Technologies, 
Carlsbad, CA, USA) qPCR assays.  Reactions were set up using the 2X 
ddPCR Supermix for Probes (BioRad, Hercules, CA, USA), 20X 6-
carboxyfluorescein (FAM)-labeled target gene-specific qPCR assay 
(Integrated DNA Technologies or Life Technologies) and 20X VIC-labeled 
housekeeping haemoglobin B (HBB) gene-specific Taqman gene expression 
assay (Life Technologies, Carlsbad, CA, USA).  Each assembled ddPCR 
reaction mixture was loaded in duplicate into the sample wells of an eight-
channel disposable droplet generator cartridge (BioRad, Hercules, CA, USA) 
and droplet generation oil (BioRad, Hercules, CA, USA) was added.  After 
droplet generation, the samples were amplified to the endpoint in 96-well 
PCR plates on a conventional thermal cycler using the following conditions: 
denaturation/enzyme activation for 10 min at 95°C, 40 cycles of 30 sec 
denaturation at 94°C and 60 sec annealing/amplification at 60°C, followed by 
a final 10 min incubation step at 98°C.  After PCR, the droplets were read on 
the QXT100 droplet Reader (BioRad, Hercules, CA, USA).  Analysis of the 
ddPCR data was performed with QuantaSoft analysis software version 
1.3.1.0 (B BioRad, Hercules, CA, USA).   
7.3.4 Electron microscopy 
Formalin-fixed paraffin-embedded rectal biopsies were de-paraffinized and 
fixed overnight in half-strength Karnovsky’s fixative.  Staining, embedding, 
cutting and viewing on a JEOL 1400 SX transmission electron microscope 
were performed as previously described (Hladik et al., 2007; Hladik et al., 
1999). Twenty images per sample were acquired at 5,000X magnification.  
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Using ImageJ (available at http://rsbweb.nih.gov/ij/), the 2-dimensional sizes 
in µm2 of all individual mitochondria with a circularity index of ≥ 0.9 were 
calculated (for standardisation purposes, only mitochondria cut near 
perfectly along their minor axis were evaluated).  Ten images per sample 
were also acquired at 2,000X magnification, always including the epithelial 
cell brush border.  Using ImageJ, a grid of 1.32 µm2 squares of defined size 
was overlaid onto each image.  All mitochondria in the images were counted, 
except those in the first row of squares falling on the brush border and in 
squares along the image rims which only partially covered tissue), and the 
mean numbers of mitochondria per were calculated for each of the acquired 
2,000X images (range of counted squares per image: 23 to 50).  
Mitochondrial sizes and mean numbers per µm2were compared between 
time point 0 and time point VII using unpaired two-sided t tests.   
7.4 Results 
7.4.1 Microarray data 
A surprisingly large number of genes were altered by topical treatment with 
TFV gel, in particular after 7 days of treatment and in the biopsies closer to 
the anal margin (Figure 7-1).  TFV gel suppressed 505 genes and induced 
137 genes after 7 days of treatment, whereas N9 suppressed only 56 genes 
and induced 60 genes (Figure 7.2).  Changes induced by HEC gel were 
much lower (4 genes decreased and 12 genes increased) and comparable 
to the number of genes fluctuating between baseline and final biopsy in the 
No Rx arm (6 genes decreased and 17 genes increased).  Thus, TFV gel 
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had a profound effect on gene expression in the rectum, modulating many 
more genes than N9 gel.   
 
There was little overlap between the expression changes caused by TFV 
and N9.  After 7 days of treatment, only 15 genes decreased and 4 genes 
increased simultaneously in both arms, less than 5% of the genes affected 
by TFV (Figure 7-2), indicating that the effects of the TFV gel were quite 
specific and not caused by general irritation as is known to occur in 
response to N9.  Not unexpectedly, the effects of TFV gel were greater after 
7 days of treatment than after a single application (Figure 7.2).  This was 
more evident for suppression, with only 8 genes decreasing in expression 
after a single application.  In contrast, 70 genes increased in expression 
after a single tenofovir application, with 44 of these genes remaining up-
regulated after 7 treatment days.  Three kinetic patterns typified the genes 
that were up-regulated after 7 days of tenofovir treatment (Figure 7-3): no 
change or decrease after a single application followed by an increase after 7 
days; slight increase followed by further increase; and strong increase 
followed by sustained high expression.  Thus, by microarray analysis, TFV 
gel’s pronounced inhibitory effect on gene expression was mostly evident 
after seven applications, while some up-regulation could be observed 
immediately following the first application.   
 
The effects of TFV gel were less apparent in the 15 cm (FSB) than the 9 cm  
(ARB) biopsies.  277 genes were suppressed and 89 genes induced in the 
15 cm biopsies after seven daily applications (Figure 7-2).  While these were 
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markedly fewer genes than were impacted at 9 cm, the general pattern of 
expression changes was similar, in particular for suppressed genes.  237 of 
the 277 genes suppressed at 15 cm were also suppressed at 9 cm, and 32 
of the 89 genes induced at 15 cm were also induced at 9 cm.  The similarity 
of 9 and 15 cm expression changes of genes suppressed by TFV gel is 
underscored by the strong correlation between the expression changes of 
the 505 genes suppressed at 9 cm and the expression changes in these 
same genes at 15 cm (Spearman r = 0.4775; p < 0.0001) (Figure 7-4).   
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Figure 7-2 Venn diagram of changes in mucosal gene expression 
Numbers of significantly down- (circles in green hues) and up-regulated (red/brown hues) 
genes after tenofovir (TFV) gel treatment and their overlap with the other three study arms, 
Nonoxynol-9 (N-9), hydroxyethyl cellulose (HEC), and No Treatment (No tx).  When not 
otherwise labeled, circles depict TFV-induced changes.  All circles depict changes on Day 
VII at 9 cm, except where labeled as “Day I” and “15 cm”.  Circle area symbolizes the 
number of affected genes; size of overlapping area symbolizes the number of genes 
simultaneously affected by two or three conditions. 
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 Although many of the 505 genes were not identified as suppressed at 15 cm 
(FDR ≤ 0.05 and log2 fold expression change of ≤ 0.5), the direction of 
change at 15 cm for all of these genes was almost always downward. Thus, 
the gene expression changes caused by TFV gel exhibited similar patterns 
in 9 and 15 cm rectal biopsies, with fewer genes affected at 15 cm, likely 
reflecting dilution of the gel away from the application site and/or signifying 
higher sensitivity of the distal rectum to the drug.   
7.4.2 Expression patterns and functional pathways 
The surprisingly broad impact of TFV gel on rectal gene expression 
prompted an exploration of the patterns of expression changes and their 
predicted functional consequences.  Interestingly, while the overall effect of 
TFV gel was more suppressive than stimulatory, genes encoding for proteins 
known to be secreted from the cell were more often stimulated than 
suppressed (Figure 7-5).  After seven days of treatment, 50 genes encoding 
products that are secreted were differentially expressed in the 9 cm tissue 
samples. Of these, 35 genes were up-regulated and 15 were down-
regulated).  This contrasted significantly to the ratio of up-regulated to down-
regulated genes encoding for products known to localize to the cell nucleus. 
Of 163 such genes, 17 were up-regulated and 146 were down-regulated; χ2 
P <0.0001).  Particularly noteworthy among upregulated genes for secreted 
products were a number of chemokines, specifically CCL2, CCL19, CCL21, 
CCL23, CXCL9 and CXL13 (Figure 7-5).  Correspondingly, transcripts of a 
number of genes encoding for leukocyte-specific cell surface markers 
increased, specifically CD2, SLAMF6 (belonging to CD2 family), CD3D, 
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CD7, CD8A, CD19, CD52, CD53, CD196 (CCR6) and CD197 (CCR7).  
Consistent with increases in chemokines and immune cell presence, TFV 
gel suppressed IL-10, an essential secreted immunoregulator with anti-
inflammatory activity. 
 
Among suppressed genes with products localizing to the cell nucleus, we 
identified a large number of known or putative transcription factors, for 
example CREBBP (CREB-binding protein), a co-activator for IL-10 
transcription (Woodgett & Ohashi, 2005; Martin, Rehani, Jope, & Michalek, 
2005; Alvarez, Municio, Alonso, Sanchez, & Fernandez, 2009), (nuclear 
factor of activated T cells 5) (Neuhofer, 2010; Buxade et al., 2012; Trama, 
Go, & Ho, 2002) and many zinc finger proteins whose specific functions are 
still unknown (Figure 7-5).   
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 Figure 7-5: Ingenuity pathways analysis showing cellular localizations of and relationships 
between individual gene products.  Red symbols indicate up-regulation and green symbols 
down-regulation, at Day VII relative to baseline in 9 cm biopsies.  The diagram includes all 
significant genes in our data set identified by Ingenuity as primarily located in the 
extracellular space and the cell nucleus.  A few selected significant genes with products 
localizing to the plasma membrane (PM) or cytoplasm (CP) are also shown based on their 
putative functional roles.  Direct (solid lines) and indirect (dashed) interactions between 
gene products are indicated.  Line color is arbitrary. 
 
 Of note, TFV gel not only suppressed transcription of a large number of 
genes, but this suppression was also relatively strong, as the comparison 
with N9 demonstrates (P <0.0001) (Figure 7-6).  Thus, through suppression 
of the transcription of many genes, TFV gel appears to initiate a process 
whereby biological loops such as mediated through CREBBP and IL-10 
suppression lead to up-regulation of leukocyte-attracting chemokines.   
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individuals who were also enrolled in the TFV gel arm.  For this purpose, 
nine up-regulated and six down-regulated genes were selected based on a 
combined assessment of magnitude of change in the microarrays and/or 
their potential functional significance (Figure 7.6).  The up-regulated genes 
were matrix metallopeptidase 12 (MMP12), serine protease inhibitor of the 
Kazal type 4 (SPINK4), the chemokines CCL19, CCL21, CCL23 and 
CXCL9, and the leukocyte cell surface receptors CD7, CD19 and CCR7 
(Figure 7-8A).  The down-regulated genes were IL-10, NFAT5, p21-activated 
kinase (PAK2), desmoplakin (DSP), TGF-β receptor associated protein 1 
(TGFBRAP1) and tripartite motif-containing protein 5 (TRIM5) (Figure 7-8B).  
Because expression changes measured in the microarray assays were in 
general stronger in the 9 cm than in the 15 cm biopsies, RT-ddPCR 
confirmations were focused on the 9 cm biopsies.   
 
mRNA copy numbers of all genes tested by RT-ddPCR increased or 
decreased as predicted from the microarray data between baseline and 
following 7 days of TFV gel treatment.  For up-regulated genes, similar 
kinetic patterns were observed as seen in the microarray data, with one 
gene (CD7) being mostly flat across the seven subjects tested after a single 
TFV application and increasing thereafter, two genes (CXCL9 and MMP12) 
increasing after a single application and then staying mostly flat, and the 
remaining six genes increasing after a single application and then increasing 
further during seven days of treatment (Figure 7.3A).  For down-regulated 
genes, five of the six genes tested were also already inhibited after a single 
TFV PAK2 was mostly flat after a single application, before decreasing 
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strongly thereafter.  Of note, none of these six genes were identified as 
down-regulated after a single TFV gel application by microarray screening, 
which is mostly reflective of the stringent microarray analysis criteria, but 
also underscores the sensitivity and merit of the RT-ddPCR assays.  To 
evaluate the impact of TFV gel across all 15 study subjects in the TFV gel 
arm, microarray (8 subjects) and RT-ddPCR (7 subjects) expression data 
were combined and statistically tested for the fold-change after seven days 
of treatment compared to the normalized baseline (Figure 7-8).  Expression 
changes for all fifteen genes tested by microarray and RT-ddPCR assay 
were highly significant (Bonferroni-adjusted P <0.01 for all genes except 
TRIM5 [P = 0.02]).  Thus, the effect of TFV gel treatment on expression of 
these fifteen genes at 9 cm in the rectal mucosa was overall extremely 
consistent across all 15 study subjects.   
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Figure 7-8 Quantification of mRNA by ddPCR 
(A) mRNA copy numbers measured in 9 cm biopsies by reverse transcription (RT) droplet 
digital PCR (ddPCR) relative to hemoglobin beta (HBB) copy numbers for nine selected 
genes identified as up-regulated in the microarray data set.  Copy numbers at baseline (0), 
after a single TFV gel application (I) and after seven consecutive once-daily applications 
(VII) are shown.  Line colors signify each of the 7 subjects.  (B) mRNA copy numbers in 9 
cm biopsies for six select genes identified as down-regulated in the microarray data set.  (C) 
Normalized fold changes of gene expression at Day VII over baseline in all 15 individuals 
enrolled in the TFV gel arm of the study.  Red dots depict fold changes measured by 
microarray assay in 8 subjects, blue dots depict fold changes measured by RT-ddPCR in 
the 7 remaining subjects.  The horizontal line in each box denotes the median, the ends of 
the box denote the 25th and 75th percentiles, and the whiskers indicate 10th to 90th 
percentile.  Expression changes were tested for statistical significance using one-sided 
Wilcoxon tests and adjusted for multiple testing (p <0.01 for all genes except TRIM5 [P = 
0.02]).   
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7.4.4 Signs of mitochondrial toxicity 
The analysis of biological processes indicated an effect of TFV gel on 
mitochondria (Figure 7-9).  Because mitochondrial toxicity has been reported 
after systemic treatment with TFV (Herlitz et al., 2010; Lewis, Day, & 
Copeland, 2003; Perazella, 2010), this finding was further explored.  PNPT1 
was clearly inhibited in the microarray assays and has recently been 
characterized as a master regulator of RNA import into mitochondria, leading 
to visible changes of mitochondrial morphology when experimentally deleted 
(Wang et al., 2010; Wang et al., 2012). TFV-induced inhibition of PNPT1 
across all 15 subjects was therefore first confirmed by RT-ddPCR assays in 
the 9 cm and 15 cm rectal biopsies (Figure 7-9A).  Before treatment, the 
mean PNPT1 mRNA copy numbers were 140/1000 hemoglobin B copies 
(SD ± 78) at 9 cm and 76 (SD ± 42) at 15 cm (ANOVA Bonferroni post-test P 
<0.01).  After a single application of TFV gel, copy numbers decreased to 
106 (SD ± 106) at 9 cm (P = NS) and 50 (SD ± 43) at 15 cm (P < 0.01).  
After 7 days of treatment, copy numbers fell further to 10 (SD ± 19) at 9 cm 
(VII versus 0; P < 0.001) and 40 (SD ± 41) at 15 cm (VII versus 0; P < 
0.001).  Thus, the RT-ddPCR assays confirmed a strong inhibition of rectal 
PNPT1 transcription by TFV gel.   
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To assess whether TFV’s inhibition of PNPT1 and/or other genes leads to 
impairment of mitochondrial function, the transcription of ATP synthase F0 
subunit 6 (ATP6), a key component of the proton channel (Houstek et al., 
2006), was measured by RT-ddPCR assays across all 15 subjects in the 9 
cm biopsies (Figure 7-9B).  Because mitochondrial genes are not included 
on the microarray chips, there was no preexisting information on its 
expression.  Before treatment, the mean ATP6 mRNA copy numbers were 
64,446/1000 hemoglobin B copies (SD ± 57,731).  After a single application 
of TFV gel, copy numbers decreased to 22,500 (SD ± 15,390) (P < 0.01).  
After 7 days of treatment, copy numbers fell further to 11,701 (SD ± 13,030) 
(VII versus 0; P < 0.001).  In contrast, ATP6 copy numbers were stable in all 
15 subjects treated with 2% N9 gel (P = 0.4911) (Figure 7-6B).  These 
results indicate that TFV gel impaired mitochondrial function whereas N9 gel 
did not.   
 
Impairment of mitochondrial function can be accompanied by morphological 
changes that are visible by electron microscopy (Wang et al., 2010; 
Perazella, 2010). Although the only tissue samples available were formalin-
fixed biopsies, which do not optimally preserve ultrastructural details, 
mitochondrial number and size changes between baseline and after 7 days 
of topical TFV treatment were evaluated in two subjects.  In the first subject, 
the number of mitochondria / μm2 decreased significantly (P <0.001) 
whereas mitochondrial size did not change markedly (P = 0.098).  In the 
second subject, significant changes were seen for both parameters: the 
number of mitochondria decreased (P < 0.0001) and their size increased (P 
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< 0.0001) (Figures 7-9C & 7-9D).  In this subject, there were disorderly 
convoluted mitochondria, which were never seen at baseline or in the first 
subject (Figures 7-9E & 7-9F).  Taken together, these studies related to 
mitochondria suggest that TFV gel inhibits genes such as PNPT1 that are 
important for mitochondrial function and consequently leads to functional 
impairment as evidenced by a decrease in mitochondrial gene transcription 
and ultrastructural alterations.   
7.5 Discussion 
When the MTN-007 study was planned, it was anticipated that N9 gel would 
impact gene expression more strongly and across a larger number of genes 
than TFV gel.  Past clinical trials found TFV gel to be well tolerated and 
without overt toxicities (Mayer et al., 2006). It was therefore surprising to see 
the profound impact of TFV gel on the rectal transcriptome.  Indeed, TFV 
changed the expression of a much larger number of genes than N9 after one 
week of once-daily use.  Its broadly inhibitory effect was particularly striking, 
with approximately ten times as many rectal genes inhibited by TFV as by 
N9 and the magnitude of inhibition by TFV on average more pronounced 
than by N9.  The effects of TFV gel were also drug-specific, because few of 
the changes in rectal gene expression were shared between N9 and TFV.   
 
The specific effects of TFV gel on the rectal transcriptome affected several 
pathways that are likely relevant for gut immune and self-repair 
homeostasis, HIV transmission and stimulation of local immune memory 
responses by infection or vaccination.  As such, the data raise three principal 
questions.  Firstly, could topical TFV lead to changes that decrease the 
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mucosa’s natural resistance to HIV infection over time?  Secondly, could 
prolonged daily use of topical TFV cause irreversible side effects to the 
mucosa?  And thirdly, as preventative combination approaches of 
microbicides and vaccines are currently being considered, could topical 
tenofovir alter the mucosa’s response to an HIV vaccine?   
 
These findings indicate that TFV gel interferes on multiple levels with 
mucosal stress responses and tissue remodeling, which may in turn 
compromise the mucosa’s resistance to infection.  Two well-studied genes 
regulating these functions, NFAT5 and PAK2, were strongly inhibited by 
TFV.  Both genes also play important roles in development, as knocking out 
either is lethal during mouse embryogenesis (Mak et al., 2011; Hofmann, 
Shepelev, & Chernoff, 2004). It is well established that the same genes and 
pathways that mediate essential functions during embryogenesis often 
regulate and control self-renewing organs, such as the gut in adult 
organisms (Radtke, Clevers, & Riccio, 2006). NFAT5 has been identified as 
a central factor in cellular osmoregulation and appears necessary for Toll-
like receptor (TLR)-mediated signaling (Neuhofer, 2010; Buxade et al., 2012; 
Trama et al., 2002). PAK2 is a central effector molecule downstream of 
Cdc42 and Rac, which are ancient, highly conserved Rho GTPases 
mediating extracellular signals that trigger reorganization of the actin 
cytoskeleton (Cotteret & Chernoff, 2002). TFV gel also inhibited other 
effector molecules mediating downstream effects of Cdc42 and Rac on 
regulation of actin polymerization, specifically WHAMM (Wiskott-Aldrich 
syndrome homolog associated with actin, golgi and microtubules) 
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(Campellone, Webb, Znameroski, & Welch, 2008) and Pi5K1B 
(phosphatidylinositol 4-phosphate-5 kinase type I beta) (Cotteret & Chernoff, 
2002). PAK2 also links Rho GTPases to MAP kinase pathways (Cotteret & 
Chernoff, 2002). MAP kinases can translocate to the nucleus where they 
phosphorylate transcription factors such as c-Fos, c-Jun and STAT-3 to 
regulate their activities (Pearson et al., 2001), and they direct cellular 
responses to stress such as hyperosmosis, heat shock and radiation.  
Besides PAK2, a second activator of MAP kinase pathways, TAOK1 (TAO 
kinase 1) was also significantly inhibited by TFV gel.  Thus, via suppressive 
effects on NFAT5, PAK2 and other related genes, TFV gel likely impairs the 
response of the rectal mucosa to stress stimuli, including the hyperosmotic 
formulation of the gel, as well as its capacity to remodel actin following 
alterations in cellular shape and cell matrix adhesion or during cell migration 
and cell-cell synapse formation.   
TFV gel also impacted genes that are likely important for maintaining 
mucosal integrity, potentially worsening problems arising from capacity 
constraints to mucosal remodeling and stress responses resulting from 
NFAT5 and PAK2 inhibition.  DSP (desmoplakin) and DST (dystonin or 
bullous pemphigoid antigen 1), which participate in hemi-desmosomal 
adhesive junctions in epithelia (Lai Cheong, Wessagowit, & McGrath, 2005; 
Hatsell & Cowin, 2001; Sonnenberg & Liem, 2007) were strongly inhibited.  
Additionally, expression of MMP12, an elastase involved in the break-down 
of extracellular matrix (Feinberg et al., 2000; Shipley, Wesselschmidt, 
Kobayashi, Ley, & Shapiro, 1996; Belaaouaj et al., 1995), was induced.  
Taken together, the above described effects of topical TFV may lead to an 
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overall decrease in the rectal mucosa’s repair ability and a higher likelihood 
of loss of epithelial integrity.  It is conceivable that these effects could 
facilitate HIV virion penetration into the mucosa.  Once suitable target cells 
are reached by HIV, their permissiveness to infection might be increased by 
the observed inhibition of the HIV restriction factor TRIM5 by TFV (Stremlau 
et al., 2004; Nisole, Stoye, & Saib, 2005). 
Another category of genes inhibited by TFV gel is involved in signaling 
initiated by TGF-β, a central anti-inflammatory mediator in the gut that by 
itself was not altered by TFV (Konkel & Chen, 2011; Surh & Sprent, 2012). 
This group included the TGFBRAP1 (Wurthner et al., 2001), spectrin (Baek 
et al., 2008), and 14-3-3 epsilon genes (McGonigle, Beall, Feeney, & 
Pearce, 2001). Other inhibited anti-inflammatory factors were IL-10 
(interleukin 10), mucin 12 and IRAK1BP1 (interleukin-1 receptor-associated 
kinase 1 binding protein 1) (Conner, Smirnova, Moseman, & Poltorak, 2010). 
This blockade of immuno-dampening pathways/effectors does not 
necessarily signify that TFV gel directly induces inflammation in the rectal 
mucosa.  Indeed, up-regulation of classic inflammatory markers such as IL-
1, IL-6, IL-8, IL-12, TNF-α, or MIP-1 was not detected.  However, TFV gel 
did increase the expression of a number of chemokine genes, most 
prominently among them CXCL13, which is selectively chemotactic for B 
lymphocytes (Ansel, Harris, & Cyster, 2002), and CCL19 and CCL21, both 
ligands of CCR7 on T lymphocytes and dendritic cells (Forster, Davalos-
Misslitz, & Rot, 2008). Correspondingly, CCR7 was strongly up-regulated, 
confirming the chemotactic effects of CCL19 and CCL21.  The B cell marker 
CD19 and the T cell markers CD2, CD3D, and CD7 were also up-regulated, 
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indicating that chemokine induction by TFV indeed enhanced lymphocytic 
infiltration or retention in the rectal mucosa.   
In concert, the changes to the expression patterns of gut immune 
homeostasis genes suggest that TFV creates a state of potential hyper-
responsiveness to external pro-inflammatory stimuli rather than directly 
causing inflammation.  Particularly in populations with a high incidence of 
mucosal infections and associated immune activation, this could negate the 
protective effect of topical TFV prophylaxis over time (Naranbhai et al., 
2012). Intriguingly, recent findings in CAPRISA 004 participants support this 
notion: while pericoital vaginal TFV gel was overall protective (Abdool et al., 
2010), when inflammation did occur within the TFV arm it dramatically 
increased the risk of HIV infection, much more so than within the placebo 
arm (Jo-Ann Passmore; personal communication).  It is tempting to 
speculate that daily use of the gel in VOICE created an even more pro-
inflammatory state than the pericoital use in CAPRISA 004, and ultimately 
enhanced HIV infection and contributed to the observed futility of the gel in 
VOICE (Celum & Baeten, 2012; van der Straten et al., 2012). 
A third category of genes inhibited by TFV gel was associated with 
mitochondrial function.  Most prominently among these, TFV strongly and 
consistently inhibited expression of the PNPT1 gene, which encodes what is 
more commonly named polynucleotide phosphorylase or PNPASE.  
PNPASE is a master regulator of RNA import into mitochondria, including 
RNAs that control the transcription and translation of electron chain transport 
proteins encoded by the mitochondrial genome (Wang et al., 2010). In 
PNPT1 knock-out mice, mitochondrial morphology and respiratory capacity 
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is disrupted (Wang et al., 2010; Wang et al., 2012) in a manner quite similar 
to what has been observed in renal proximal tubular cells in patients with 
TFV-induced nephrotoxicity (Perazella, 2010), which is thought to be a 
disease of mitochondrial dysfunction (Fernandez-Fernandez et al., 2011). 
Strikingly, in the MTN-007 study, just one week of once-daily application of 
TFV gel strongly impaired mitochondrial function as measured by 
transcription of two mitochondrial genes encoding electron chain transport 
proteins, ATP6 (ATP synthase F0 subunit 6) and COX1 (cytochrome c 
oxidase subunit I), and by morphological swelling of mitochondria.  These 
findings suggest that the negative effect of TFV on PNPT1 expression may 
underlie its reported, but heretofore unexplained, mitochondrial toxicity.   
 
Mitochondrial respiratory capacity has been identified as a critical regulator 
of CD8+ T cell memory development and maintenance (van der Windt et al., 
2012; Pearce et al., 2009). Thus, TFV could negatively affect mucosal 
memory T cell generation after vaccination.  Moreover, the observed 
suppression of immune-dampening factors such as IL-10 and signaling 
effectors downstream of TGF-β could intensify the reactivity of the mucosa 
to antigenic stimuli and increase the likelihood that vaccine vector-specific 
responses paradoxically increase HIV susceptibility, as has been observed 
in individuals with pre-existing Ad5-specific immunity in the Step Study 
(Buchbinder et al., 2008; Moodie et al., 2005). Local immune homeostasis 
could also be altered by the stimulatory effect of TFV gel on the expression 
of CCL19 and CCL21, leading to retention of CCR7+ naive and central 
memory T cells (TCM) and CCR7+ dendritic cells in the mucosa rather than 
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allowing their migration to mucosal lymph nodes (Debes et al., 2005; 
Bromley, Thomas, & Luster, 2005). This could alter the kinetics or impede 
the generation of primary antigen-specific T cell responses to vaccination, or 
change the secondary response of TCM cells to HIV exposure following 
vaccination (Pepper & Jenkins, 2011). Thus vaccination/topical tenofovir 
combination studies need to be designed in light of the possibility that TFV 
interferes with vaccination outcomes.   
 
Finally, some of the genes impacted by TFV have been implicated in 
carcinogenesis and tumor metastasis, although a clear pattern predicting 
either lower or higher risk could not be discerned.  Inhibition of PAK2 and 
TAOK1 also interferes with cellular apoptosis in response to DNA damage, 
potentially resulting in a tumourigenic effect (Cotteret & Chernoff, 2002). 
Additional tumourigenic pressure could arise from up-regulation of UBD 
(ubiquitin D), which has been reported to increase mitotic non-disjunction 
and chromosome instability and which appears highly upregulated in 
gastrointestinal cancers (Lee et al., 2003; Ren et al., 2006; Ren, Wang, Gao, 
Mehta, & Lee, 2011). 
One uncertainty in our study was the discrepancy of gel vehicle osmolarities 
between the slightly hyperosmolar TFV gel (836 mOsmol/kg) and the 
isotonic HEC control gel (304 mOsmol/kg).  Thus, it is not certain that all the 
effects observed in response to TFV were drug-related.  In particular, some 
of the immediate effects observed after a single gel application could have 
been caused by the hyperosmolarity of the gel.  However, the N9 gel was 
also hyperosmolar (1406 mOsmol/kg) and therefore effects occurring due to 
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gel hyperosmolarity should have been observed in both the N9 and the TFV 
gel arms.  Since only minimal overlap existed between the N9 and TFV 
arms, we conclude that the active drugs rather than the gel vehicles were 
mostly causing the gene expression changes.  Furthermore, the powerful 
blocking effect of TFV gel on a much larger number of genes than were 
inhibited by the N9 gel is consistent with the known off-target inhibition of 
cellular DNA polymerase by nucleoside reverse transcriptase inhibitors (De 
& Holy, 2005). Perhaps the strongest indicator that many of the effects 
observed in the TFV gel arm of the study were due to the active drug and 
not the gel vehicle is the pronounced inhibitory effect of TFV gel on 
mitochondrial function, whereas no such inhibition was observed with N9 
gel.  Mitochondrial toxicity is a well-documented side effect of TFV and other 
nucleoside reverse transcriptase inhibitors (Lewis et al., 2003; Perazella, 
2010; Gallant & Deresinski, 2003), strongly suggesting that the mitochondrial 
dysfunction in our study was directly caused by TFV.   
 
While the observed impact of seven once-daily applications of TFV gel on 
the rectal transcriptome was strong and broad, and allowed for predictions of 
its functional consequences, many questions remain.  Would the gut regain 
its homeostasis after longer periods of gel use or become even more 
imbalanced?  Does the cervicovaginal mucosa react to the gel in a similar 
way to the rectal mucosa?  Does TFV actually cause the functional changes 
predicted by the transcriptome data, such as, in broad categories, hyper-
responsiveness to inflammatory stimuli, impaired aerobic respiration in 
mitochondria, aberrant mucosal self-renewal, and perhaps even 
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carcinogenesis?  The first two questions can be answered in currently 
planned clinical trials. MTN-014 will compare vaginal and rectal TFV gel in 
the same women in a crossover format. MTN-017 will apply rectal TFV gel 
daily or pericoitally over a period of 8 weeks. Extending the current findings 
by similar investigations in these trials is important.  Addressing the last 
question requires a step back to basic science, studying the short- and 
longer-term functional impact of TFV on mucosal cells and tissues in vitro, 
ex vivo, and in animal models.  While TFV has been proven safe as an orally 
administered systemic drug, this does not necessarily imply its safety as a 
topical drug applied repeatedly at high concentrations to relatively small, 
circumscribed mucosal areas.   
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8 Discussion and conclusions 
8.1 The need for rectal microbicides 
Epidemiological studies have confirmed that RAI is a common practice 
among MSM in the Global North (Wolitski & Fenton, 2011; Hart & 
Williamson, 2005). Unfortunately, a sizeable proportion of RAI among MSM 
is unprotected (Chen, Gibson, Weide, & McFarland, 2003; Begley, Chan, 
Jeganathan, Batterham, & Smith, 2008) and contributes to the growing 
number of new infections among MSM (Beyrer et al., 2010). More recent 
data have clearly identified at risk MSM in the Global South (Beyrer et al., 
2012; Baral et al., 2012). Unfortunately this prevalence of URAI also 
appears, at least in MSM, to be associated with high prevalence and 
incidence of HIV infection as well as other STIs (Beyrer et al., 2012). These 
observations emphasize the need to develop new prevention strategies, 
including rectal microbicides, in populations at risk of HIV infection through 
URAI who are unable or unwilling to use a condom. The prevalence of HIV 
infection in transgender women (i.e. male to female transgender persons) is 
equal or greater than that seen in other high-risk groups such as MSM 
(Herbst et al., 2008). In a systematic review of 29 U.S. studies of 
transgender women, the average laboratory confirmed HIV prevalence was 
28% (Herbst et al., 2008). This high prevalence of HIV infection was 
associated with an equally high prevalence of URAI with multiple male 
partners, psychological health problems, and alcohol/substance use 
(Brennan et al., 2012). Similar patterns emerge in recent studies from 
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Thailand and Peru (Newman, Lee, Roungprakhon, & Tepjan, 2012; Silva-
Santisteban et al., 2012) and provide a clear rationale for the inclusion of 
transgender women in microbicide studies. MTN-017 as well as future MTN 
rectal microbicide studies will include transgender women. 
8.2 Alternatives to rectal microbicides for HIV prevention 
Rectal microbicide development is occurring within a broader field of HIV 
prevention research. Other strategies may offer alternative approaches to 
HIV prevention for individuals at risk of HIV infection associated with URAI.  
8.2.1 Treatment as prevention 
It is clear that the risk of HIV transmission is directly correlated to an infected 
individual’s plasma viral load; the higher the viral load the greater the greater 
risk of HIV transmission (Quinn et al., 2000). Reducing an individual’s viral 
load through the use of antiretroviral therapy should reduce their 
infectiousness and in 2011, Cohen et al. demonstrated that this strategy did 
indeed dramatically reduce rates of HIV transmission among serodiscordant 
couples enrolled in the HPTN-052 study (Cohen et al., 2011). Inevitably, this 
observation has led to a vigorous debate about the public health benefits of 
an HIV treatment strategy versus a HIV prevention strategy (Cohen et al., 
2012). Proponents of the “treatment as prevention” strategy argue that 
treating HIV infected individuals has both personal and public health benefits 
whereas prevention efforts only shift limited resources away from treatment - 
an argument that is particularly relevant in the developing world.  Key 
limitations of a treatment strategy are (i) the fact that roll out of antiretroviral 
therapy cannot, and may never, keep pace with new HIV infections, (ii) 
identification of early HIV infections is challenging and account for a 
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significant number of new infections (Hurt et al., 2012), and (iii) once HIV 
infected individuals are identified they may not be able to access or sustain 
antiretroviral treatment. In the United States it is estimated that the treatment 
“cascade” results in only 19-25% of the HIV infected population actually 
achieving virological suppression (Mugavero, Amico, Horn, & Thompson, 
2013). Rather than debating for treatment or prevention, the debate should 
probably focus on how resources can be found to adequately fund 
comprehensive treatment and prevention strategies - especially in the 
developing world setting. 
8.2.2 Oral pre-exposure prophylaxis 
The iPrEx study demonstrated that MSM and transgender women receiving 
PrEP with Truvada were significantly protected from HIV infection (Grant et 
al., 2010). These data together with data from the Partners PrEP study 
(Baeten et al., 2012) led to the FDA approving use of Truvada for the 
prevention of HIV infection (http://www.truvadapreprems.com/#). Although 
PrEP is now available in the US, uptake by physicians and individuals at risk 
of HIV infection has been quite limited (Mimiaga, White, Krakower, Biello, & 
Mayer, 2013). Moreover, the iPrEx study, like many other PrEP studies had 
quite poor adherence to antiretrovirals. Anderson et al. demonstrated in a 
case control study nested within the iPrEx study that only 8% of the HIV 
seroconverters and 44% of the case controls had detectable levels of drug 
(Anderson et al., 2012). PrEP will only work when taken and it is clear that 
there is a need for alternative strategies that increase the likelihood of 
product adherence. 
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associated with protection from explant infection. Preliminary data from this 
study suggest that rilpivirine does indeed provide significant protection from 
colorectal explant infection (Figure 8-1) and provides a rationale for further 
evaluation of this HIV prevention strategy in MSM and transgender women. 
 
An integrase inhibitor (GSK1265744) (Spreen et al., 2013) is also being 
evaluated as a possible long acting injectable PrEP agent (Spreen, Margolis, 
& Pottage, Jr., 2013). A nanoparticle suspension of GSK1265744 
(GSK744LAP) has been evaluated in an NHP rectal challenge model 
(Andrews et al., 2013). A total of 16 macaques received either GSK744LAP 
(50mg/kg; N = 8) or no treatment (N = 8). The animals were challenged with 
50 TCID50 of SHIV162p3 weekly for eight weeks. All of the GSK744LAP 
were protected from SHIV infection whereas all the macaques who did not 
receive GSK744LAP became infected over a 1-7 week period.  
 
In a more recent study the same group have conducted a study to determine 
the plasma levels of GSK744LAP at which protection is maintained and lost 
during repeated low-dose rectal SHIV challenges in male rhesus macaques 
(Andrews et al., 2014). Of the twelve GSK744LA-treated RM, none had 
detectable systemic viremia following the first 4 weekly challenges 
confirming that monthly administration of GSK744LA protects an additional 
twelve male rhesus macaques against repeated rectal low-dose SHIV 
challenges. The GSK744LA-treated animals became infected after six to 
seventeen challenges compared with one to seven challenges for the twelve 
placebo controls (four current and eight historical). None of the SHIV 
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challenges resulted in infection when plasma levels of GSK744LAP were 
>3X protein-adjusted (PA) IC90, compared with one of twenty two challenges 
when plasma levels were between 1X to 3X PAIC90 and eleven of forty 
challenges when plasma levels were <1X PAIC90.These TMC278LA and 
GSK744LAP data suggest that injectable PrEP should be further evaluated 
as a means of preventing rectally acquired HIV infection. 
8.3 The results of the MTN-007 study 
The MTN-007 study demonstrated that a reduced glycerin formulation of 
TFV gel was safe and acceptable to men and women with a history of RAI. 
Importantly, use of this formulation was not associated with the frequent 
gastrointestinal adverse events seen with the hyperosmolar formulation of 
TFV 1% gel used in the RMP-02/MTN-006 study (Anton et al., 2012) 
Adverse events that occurred in the MTN-007 study were uncommon, 
predominately graded as mild or modest, and occurred mainly in the N9 arm. 
The study included a comprehensive array of mucosal safety assays. 
Changes were seen in a number of mucosal parameters but again these 
changes were mainly confined to the N9 arm of the study.  
 
One of the most important findings in the MTN-007 study was the 
demonstration of altered mucosal gene expression associated with exposure 
to TFV gel. The incorporation of microarray assessment of gene expression 
in rectal biopsies obtained from MTN-007 participants resulted in the 
generation of novel data suggesting that TFV gel has the potential to induce 
significant changes in mucosal biology including activation of innate 
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immunity pathways, suppression of mitochondrial function, and modulation 
of gene expression associated with carcinogenesis.  
The MTN-007 microarray data have important ramifications for the manner 
in which mucosal safety is assessed in microbicide trials. A priori selection of 
mucosal biomarkers such as T cell phenotypic markers or 
cytokines/chemokines to characterize mucosal safety may miss alternative 
or unanticipated pathways of mucosal injury. As a consequence, future 
rectal microbicide studies are increasingly adopting a more holistic / systems 
biology approach to the assessment of mucosal safety. Transcriptomic and 
proteomic assays have been included in rectal microbicide trials being 
conducted within Project Gel (Section 2.8) and the CHARM Program 
(Section 2.9). Data from the Project Gel and CHARM-01 studies, in which 
participants also received 7 daily rectal doses of TFV gel, may confirm or 
refute the results from the MTN-007 study.  
 
At this point in time, the clinical significance of these changes in the mucosal 
transcriptome is uncertain as there were no overt safety signals seen in 
participants receiving TFV gel in the MTN-007 study. Future studies such as 
MTN-017 where participants will receive 8 weeks rather than 1 week of TFV 
gel may provide further insights into these changes. A subset of 36/186 
participants in the MTN-017 study will undergo intensive tissue evaluation 
(18 participants in Pittsburgh, Pennsylvania, USA and 18 participants in 
Bangkok, Thailand) including mucosal safety and compartmental PK. These 
studies will allow the exploration of the relationship between PK and 
potential changes in the mucosal transcriptome/proteome. 
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In addition, proteomic and immunohistochemical studies are currently being 
conducted on residual tissue samples from the MTN-007 study. Preliminary 
proteomic data derived from rectal fluid samples have also demonstrated 
significant changes associated with exposure to TFV gel (Figure 8-2). 
 
Limitations of the MTN-007 study included the fact that the participants were 
sexually abstinent during the study and so it was not possible to determine 
product safety and acceptability in the context of RAI. Product adherence 
was based upon self-report which often overestimates actual product use.  
In addition the sample size and period of product exposure were both 
relatively small. During the development of the MTN-007 protocol, a decision 
was made not to include multicompartmental PK and PD assays as these 
data had already been collected in the RMP-02/MTN-006 study (Anton et al., 
2012). In retrospect, this decision was unfortunate as it is now not possible 
to confirm product use based on PK parameters and to correlate the 
microarray data with tissue specific levels of TFV. Preliminary evidence of a 
dose-response relationship between tissue levels of TFV and outcomes 
such as mitochondrial dysfunction would increase the significance of this 
observation. However, these data will be available from the CHARM-01 
study in which participants received exposure to three different formulations 
of TFV 1% gel (the CAPRISA 004 formulation, the formulation used in the 
MTN-007 study, and a new rectal-specific formulation) in a cross-over 
fashion.  
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8.4 Further development of TFV gel as a rectal microbicide 
Successful completion of the RMP-02/MTN-006 and MTN-007 studies of 
TFV gel has positioned the MTN to initiate MTN-017, an expanded safety 
study of the RG-TFV gel. The MTN-017 study will enroll 186 participants 
from a total of eight sites in the US (Pittsburgh, Boston, San Francisco, and 
San Juan), South Africa (Cape Town), Peru (Lima), and Thailand (Chiang 
Mai and Bangkok). Each participant will progress through a randomised 
sequence of eight week blocks of oral Truvada and rectal TFV gel (daily and 
associated with RAI). The study will assess the safety and acceptability of 
Truvada and TFV gel and PK/PD/mucosal safety in a subset of 36 
participants at the Pittsburgh and Bangkok sites. It is anticipated that MTN-
017 will complete follow-up in Q1 2015 allowing the possible initiation of a 
Phase 3 study in 2016. Given the recent approval of an HIV PrEP indication 
by the US FDA, the design of the Phase 3 TFV gel study will have to allow 
access to Truvada.  
 
In addition to completing MTN-017 and potentially initiating a Phase 3 TFV 
gel study, the portfolio of Phase 1 TFV rectal studies will be expanded. 
Studies that explore the influence of sexual activity on product delivery and 
compartmental PK exposure will be developed. In previous Phase 1 rectal 
microbicide studies the microbicide was delivered directly into the rectal 
compartment using an applicator. In non-clinical settings it is more likely that 
individuals will apply microbicide product to the receptive partner’s anorectal 
area as well as the insertive partner’s penis. Whether this form of product 
application can deliver adequate TFV concentrations to the rectal 
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compartment is an important scientific question. Although this type of mixed 
behavioral/product assessment study is logistically challenging, the MTN has 
previously obtained approval for, and is currently undertaking, a similar study 
in heterosexual HIV negative/HSV-2 seroconcordant couples (MTN-011; 
http://clinicaltrials.gov/: NCT01687205) which explores the impact of coitus 
on the PK of TFV gel in the female genital tract. It is anticipated that this 
study will be completed in advance of initiating a Phase 3 evaluation of TFV 
gel as this will allow more nuanced discussions and advice to participants 
about product use in the study.  
8.5 Moving forward with rectal microbicide research 
In order to move beyond TFV gel, rectal microbicide development will 
require new active compounds, formulations, and clinical trials. The 
dichotomous separation between vaginal and rectal microbicide products 
and development pathways is neither rationale nor scientific and there is a 
clear need to develop products that can be used in either compartment. The 
discussion of the microbicide pipeline (Section 8.5.1 and Table 8-1) is 
therefore not broken out by anatomical site. Another fundamental issue is 
whether rectal microbicides will need to be given daily, irrespective of sexual 
activity, or whether they could be given in a peri-coital fashion analogous to 
the regimen used in the CAPRISA 004 study. Daily versus peri-coital 
delivery of TFV gel will be explored in the MTN-017 study. However, it is 
likely that the PK/PD profile needed for an effective peri-coital dosing 
regimen (rapid accumulation and persistent of active drug in the rectal 
tissue) may differ from a product that is effective when given on a daily 
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basis. It may be that a coformulation of two distinct APIs with a rapid and a 
more delayed PK release profile may be needed to achieve this goal. 
8.5.1 The rectal microbicide pipeline 
The current microbicide pipeline is presented below starting with products 
that are already in clinical development followed by products that are still in 
preclinical development, but are poised to move into clinical trials, and ends 
with a brief discussion of products that are in the very earliest stages of 
development but which provide insight into new mechanisms of action that 
could be exploited to develop microbicides.  
8.5.1.1 Clinical candidates 
Dapivirine (DPV) is a di-amino-pyrimidine NNRTI with potent activity against 
wild type and mutant HIV (Van et al., 2004). Prevention of vaginal 
transmission of HIV has been demonstrated in a humanized severe 
combined immunodeficient mouse model using DPV gel (Di Fabio et al., 
2001; Di Fabio et al., 2003). IPM and the MTN are currently developing DPV 
as a microbicide. Initial Phase 1 studies evaluated a gel formulation (Nel et 
al., 2010; Nel, Smythe, Habibi, Kaptur, & Romano, 2010) but efforts are now 
focused on the development of an intravaginal ring, which offers the 
possibility of once monthly application (Malcolm et al., 2005; Woolfson et al., 
2006). Following completion of Phase 1/2 studies of a matrix vaginal ring 
(IPM 024, 013, and 015), development has now advanced to Phase 3 (IPM 
027 and MTN-020). A penile tolerance study (MTN-012/IPM 010) and a 
combination DPV/MVC vaginal ring study (MTN-013/IPM 026) have recently 
been completed. Protocols for additional safety and PK studies in 
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adolescents (MTN-023) and post-menopausal women (MTN-024) are in 
development. 
 
Maraviroc (MVC) is a CCR5 co-receptor antagonist that prevents the 
interaction of HIV gp120 and CCR5 necessary for CCR5-tropic HIV to enter 
cells. It is also currently licensed for the treatment of chronic HIV infection 
(Selzentry®, ViiV Healthcare). Since CCR5 is known to be the primary co-
receptor involved in sexual transmission of HIV, MVC has good potential as 
a topical microbicide and both gel and ring formulations have been shown to 
be efficacious in vaginal NHP models (Veazey et al., 2010; Malcolm et al., 
2012). In addition, MVC is not widely used in the treatment of HIV-1 infection 
enhancing its potential use as a microbicide. MTN-013 is the first study to 
evaluate intravaginal delivery of MVC alone and in combination with DPV. 
An initial NHP study evaluating oral MVC for prevention of SHIV infection 
following rectal challenge did not demonstrate any protection despite high 
tissue levels of MVC (Massud et al., 2013). More encouragingly, a second 
NHP study, that evaluated rectal administration of MVC prior to SHIV 
challenge, did demonstrate significant protection (Dobard et al., 2013). 
Rectal specific formulations of MVC have been developed and will be 
evaluated in the CHARM-03 Phase 1 study. 
8.5.1.2 Preclinical and discovery candidates 
MIV-150 is an NNRTI initially developed as a therapeutic that is currently 
being developed by the Population Council as a potential microbicide. After 
initial demonstration of in vitro efficacy (Fernandez-Romero et al., 2007), 
MIV-150 was shown to be active in NHP rectal and vaginal challenge studies 
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(Singer et al., 2011; Kenney et al., 2011; Kenney et al., 2012). The 
Population Council is currently developing gel and ring formulations of MIV-
150 in combination with zinc, carageenan, and hormonal contraceptives. 
 
IQP-0528 is an antiretroviral pyrimidinedione NNRTI with nanomolar activity 
against HIV (Watson, Yang, & Buckheit, Jr., 2011) being developed by 
ImQuest Biosciences Inc. with support from the NIAID/DAIDS IPCP 
Program. Vaginal gels, films, and intravaginal rings have been manufactured 
(Mahalingam et al., 2011; Ham et al., 2012; Ham et al., 2012; Dezzutti et al., 
2012) and preliminary supportive safety data have been generated for the 
intravaginal ring in the NHP model (Johnson et al., 2012).  
 
PSC-RANTES is a synthetic CCR5 antagonist. As these molecules target 
the host co-receptor and not the HIV envelope, it is hoped that they will 
retain activity against all HIV clades, and in vitro studies using peripheral 
blood mononuclear cell targets confirm this (Torre et al., 2000).  Recently, 
studies in the rhesus vaginal challenge model demonstrated that blocking 
CCR5 by PSC-RANTES provided high level protection against vaginal 
challenge with the SHIV162P4 isolate (Lederman et al., 2004).  
 
Concern that manufacturing costs might limit the utility of PSC-RANTES in 
the developing world has led to the production of two PSC-RANTES 
derivatives (5P12-RANTES and 6P4-RANTES) that appear stable, lack the 
ability to induce cell proliferation (Cerini et al., 2008), and are active in the 
macaque challenge model (Veazey et al., 2009). 
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Griffithsin (GRFT) is a product discovered by scientists at the National 
Cancer Institute that targets HIV envelope glycoproteins. A lectin derived 
from red algae, GRFT has extremely potent inhibitory activity against HIV 
with an EC50 of 40 pM, activity in the cervical explant model, and against 
multiple viral clades. Importantly, GRFT does not appear to induce cell 
activation or proliferation (Kouokam et al., 2011). Similar to cyanovirin-N, 
GRFT has been manufactured using transgenic plant technology (O'keefe et 
al., 2009). GRFT was safe in a rabbit vaginal irritation study (O'keefe et al., 
2009) and in a 28-day rectal safety study in rabbits (Personal 
communication; Ian McGowan). Another attractive feature of GRFT is its 
activity against hepatitis C virus (HCV) infection (Meuleman et al., 2011). 
HCV is emerging as an important public health issue among HIV positive 
MSM (Larsen et al., 2011). A rectal microbicide with activity against HIV, 
HSV, and HCV would be of great value for MSM unwilling or unable to use 
condoms. 
 
A range of other candidates, summarized in Table 8-1, are moving through 
early preclinical evaluation. They may emerge as viable candidates for 
Phase 1 studies during the next funding period of the MTN.  
 
The majority have only been evaluated in in vitro systems but some, such as 
glycerol monolaurate, retrocyclin, and the S-acyl-2-mercaptobenzamide 
thioester have demonstrated antiviral efficacy in a NHP model (Li et al., 
2009; Cole et al., 2010; Cheng-Mayer et al., 2011).  
304 
 
 
A key challenge for these products is finding the resources to conduct IND 
enabling studies and to manufacture adequate amounts of GMP API to 
support Phase 1 studies. 
 
Table 8-1 Summary of preclinical candidates 
Product Mechanism of 
Action 
Reference 
 
Raltegravir Integrase inhibitor (Dobard et al., 2011) 
   
4’E-2FdA Nucleoside reverse 
transcriptase inhibitor 
(Murphey-Corb et al., 2012) 
   
BMS793 Entry inhibitor  
   
S-acyl-2-
mercaptobenzamide 
thioester 
Zinc finger inhibitor (Cheng-Mayer et al., 2011) 
   
Glycerol monolaurate Anti-inflammatory (Li et al., 2009) 
   
4E10 and VRC01 Anti-HIV monoclonal 
antibodies 
(Veselinovic, Preston, Mulder, & 
Akkina, 2012) 
   
Retrocyclin (RC101) gp41 binding (Cole et al., 2010) 
   
PD 404, 182 Virion disruption (Chamoun et al., 2012) 
   
PIE12 trimer Pocket specific entry 
inhibitor 
(Welch, VanDemark, Heroux, Hill, 
& Kay, 2007) 
   
C5A Virion disruption (Maskiewicz et al., 2012) 
Peptide triazoles Entry inhibitor (McFadden et al., 2012) 
   
DARPins CD4 binding (Pugach et al., 2010) 
   
Bioengineered microbicides Dependent on 
peptide 
(Lagenaur & Berger, 2005) 
   
Toll like receptor inhibitors 
(TLR7 & 9)  
Inhibition of TLR 
induced inflammation 
(Fraietta et al., 2010) 
   
siRNA Gene silencing (Katakowski & Palliser, 2011) 
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8.5.2 The need for alternative formulations 
The first two Phase 1 rectal safety studies of antiretroviral microbicides 
evaluated gel formulations developed for vaginal use (Anton et al., 2011; 
Anton et al., 2012). While UC781 vaginal gel was well tolerated in the 
rectum, usage of the vaginal formulation of TFV gel was associated with a 
significant increase in GI adverse events. This observation led to 
development of rectal specific formulations (Wang et al., 2011) that are 
currently being evaluated in the CHARM IPCP grant (Section 2.8). It remains 
to be seen whether rectal specific formulations that are well tolerated will 
also be acceptable for vaginal use. The reduced glycerin (RG)-TFV gel was 
included in the MTN-007 study after use of the original TFV gel by 
participants in RMP-02/MTN-006 was associated with gastrointestinal 
adverse events. While still a vaginal formulation, due to the low pH, it was 
acceptable to persons using it rectally. The first vaginal use of the RG-TFV 
gel will be in the MTN-014 study that is anticipated to start in Q4 2013.  
 
Qualitative and clinical studies have suggested that acceptable rectal 
formulations could include gels, suppositories, or douches (Carballo-Dieguez 
et al., 2008; Carballo-Dieguez et al., 2008; Leyva et al., 2013).  Gels were 
considered more acceptable than suppositories (Carballo-Dieguez et al., 
2008) and a volume escalation of a placebo gel demonstrated that up to 35 
mL of gel, with the physical properties of Femglide® (transparent and 
odorless), was acceptable to the majority of participants (Carballo-Dieguez 
et al., 2007).   
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The current generation of rectal microbicides is delivered into the rectum 
using a vaginal applicator. It is not clear whether this strategy will be 
acceptable and or effective in longer term studies. An alternative approach 
might be to use rectal suppositories or rapid dissolving tablets.  There is an 
urgent need to evaluate novel placebo formulations in Phase 1 safety and 
acceptability trials. Mahan et al. have described innovative and quantitative 
techniques to capture product preferences for vaginal products and this 
approach could be adapted for rectal microbicides (Mahan, Morrow, & 
Hayes, 2011). 
8.5.3 Ongoing rectal microbicide studies 
As of September 2013, there are active clinical trials related to Project Gel 
(Section 2.8) and the CHARM Program (Section 2.9). Recruitment and 
follow up is complete for Project Gel apart from a cohort of male sex workers 
and data analysis is ongoing. The CHARM-01 and CHARM-02 studies have 
completed enrolling participants. CHARM-03, a Phase 1 evaluation of oral 
and rectal-specific formulations of MVC is in protocol development with an 
estimated start date of Q4 20I4. Building upon experience from previous 
studies the design of these studies will incorporate safety, acceptability, PK, 
and PD components. The mucosal safety component will be expanded to 
include transcriptomic and proteomic assessments in a subset of study 
participants.  
8.5.4 Rectal microbicide studies to be conducted by the MTN 
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The portfolio of rectal microbicide studies planned to be conducted by the 
MTN over the next seven years is summarised in Table 8-2 and discussed 
below. As with all drug development not all proposed studies will be 
conducted but the studies outlined in Table 8.2 reflect the state of the 
science as proposed by the MTN in their network recompetition submitted to 
the NIH in October 2012. 
8.5.4.1 MTN-027 
It is unclear how rectal microbicides will be used if they are licensed. To 
date, rectal microbicide trials have required product to be inserted directly 
into the rectum with an applicator. However, it is possible that individuals 
may wish to use the rectal microbicide as a sexual lubricant and apply it to 
the insertive partner’s penis and the receptive partner’s perianal area 
(Kinsler et al., 2010). The MTN-027 will explore the PK correlates of different 
routes of product application. It is anticipated that these data will be 
important in informing the choice of dosing strategies, and associated 
counseling, in future studies. 
8.5.4.2 MTN-026, MTN-029, MTN-033, and MTN-044 
The MTN plans to conduct Phase 1 evaluation of novel compounds that will 
characterize the rectal safety, acceptability, and PK/PD profile of dapivirine, 
MIV-150, 5P12 RANTES, and GRFT.  
8.5.4.3 MTN-035/HVTN-117 
It is likely that a Phase 2B/3 rectal microbicide effectiveness study will be 
conducted at the same time that effectiveness studies of HIV vaccines will 
be ongoing. Building upon the experience of working with the HVTN on the 
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MTN-022/HVTN-095 study exploring interactions between oral/vaginal PrEP 
and HIV vaccines, the MTN proposes to conduct a similar study in 
approximately 120 MSM and transgender women in the US and Peru. This 
study will evaluate the safety and potential impact or oral/rectal TFV on HIV 
vaccine immunogenicity. The proposed HIV vaccine is the Geovax Clade B 
HIV vaccine. 
 
Table 8-2 Summary of proposed MTN rectal microbicide studies 
Study Phase Population Product(s) N Reference 
 
MTN-026 1 Men/Women Dapivirine 24  
      
      
MTN-027 1 Men/Women TFV gel 45  
      
MTN-029 1 Men/Women MIV-150 gel 45 (Singer et al., 2011) 
      
MTN-030 2B/3 
MSM and  
Transgender 
women 
TFV gel 5,000  
MTN-033 1 Men/Women 5P12-RANTES 45 
(Hartley et al., 
2004; Lederman 
et al., 2004) 
      
MTN-035/ 
HVTN 117 1 
MSM and  
Transgender 
women 
Oral 
TDF/FTC 
TFV gel 
HIV vaccine 
120  
      
      
MTN-044 1 Men/Women Griffithsin 45 (Emau et al., 2007) 
      
 
8.5.5 Preparing for rectal microbicide efficacy studies 
Contingent upon appropriate safety, acceptability, and PK/PD from MTN-
017, the MTN is proposing to conduct a randomised, multi-site, double-
blinded, placebo-controlled trial of rectal TFV gel. The main challenge in the 
design of this efficacy trial is the potential use of oral TFV/FTC (Truvada) or 
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TFV (Viread) as PrEP.  Truvada is licensed for a PrEP indication in the US 
and we assume that oral PrEP will be available in other communities or 
potentially provided as part of the standard prevention package. As a 
preliminary exploration of the sample size requirements, the number of 
events needed to detect and rule out various levels of effectiveness with 
90% power and = 0.05 was calculated (Table 8-3). These calculations 
were based on a log rank test and show the number of events needed to 
detect the effectiveness given by the columns while ruling out the level of 
effectiveness indicated in the rows, where effectiveness is defined as 1 
minus the relative risk (product infection rate/placebo infection rate). For 
example, 113 infections would be required to detect a minimum 55% 
reduction in HIV infections and rule out a 15% or smaller reduction. 
 
Table 8-3 HIV endpoint analysis for a Phase 3 study 
Effectiveness 
Detect
50% 55% 60% 65% 70% 
Rule Out 
0% 93 72 56 44 35 
5% 109 82 63 49 39 
10% 130 95 72 55 42 
15% 160 113 83 62 47 
20% 204 139 98 72 53 
25% 275 177 120 85 61 
 
 
In all HIV prevention studies, the required number of participants is 
influenced by a number of factors that are challenging to predict, particularly 
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the incidence rate of new HIV infections.  The introduction of an approved 
oral PrEP agent and expanded treatment makes this even more challenging 
as observed incidence rates at participating sites may decrease. To estimate 
the sample size, a background infection rate of 5% in the placebo arm is 
assumed. 
 
A trial designed to detect a 55% reduction in the infection rate and rule out a 
15% reduction would require 3,997 person-years of follow-up.  Assuming the 
uniform accrual of 3500 participants over one year, it would take 
approximately 17 months from the start of randomization to reach 113 
endpoints. 
 
Assuming that a 64% effective PrEP product becomes available to half the 
study population, a 3.6% incidence rate per year is expected which would 
require 4329 person-years of follow-up or 21 months assuming 3500 
participants are enrolled over one year. Given the uncertainty about how 
provision of oral PrEP will evolve and whether participants will be able or 
want to use oral PrEP a 5,000 participant study would probably be 
necessary.   
8.5.6 Social marketing and microbicide development 
The FEM-PrEP and VOICE studies demonstrated that despite counseling, 
the majority of participants were unwilling or unable to use the study product 
(Van Damme et al., 2012; Marrazzo et al., 2013). Moreover, based on PK 
data, the majority of these women were also unwilling or unable to give an 
accurate account of their pattern of non-adherence. Other studies such as 
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iPrEx and CAPRISA 004 have also demonstrated significant levels of non-
adherence (Grant et al., 2010; Abdool et al., 2010). For an HIV prevention 
strategy (including rectal microbicides) to succeed it will be necessary to 
market the concept so that the best (adherent) participants are enrolled into 
clinical trials and that the licensed product / behaviour is attractive to 
potential consumers. Social marketing strategies set out to change 
behaviour by influencing the real and perceived benefits and costs that may 
result from a specific behaviour such as use of a rectal microbicide. The 
marketing approach focuses on four key domains (often known as the 4Ps); 
product, price, place, and promotion. Key issues include how attractive is the 
product, how expensive is the product, is it easily available (place), and how 
is the behaviour being promoted. This approach has been used successfully 
to increase STI and HIV knowledge and testing behaviour (Pedrana et al., 
2012). The NIH is planning to convene a meeting in May 2014 to explore 
whether social marketing could be used to help create desire for 
microbicides, improve patterns of adherence in clinical trials, and enhance 
the likelihood of operational success in rolling out a licensed product. 
8.5.7 Implementation of rectal microbicides for HIV prevention 
The current generation of rectal microbicides under development are all 
antiretroviral gels. They could only be used by HIV negative individuals and 
would have to be distributed through a health care system. Unintended 
exposure to an antiretroviral rectal microbicide by an individual with 
untreated HIV infection would likely result in the development of HIV 
resistance. This might generate subsequent challenges in providing an 
effective ARV regimen for treatment of HIV infection and also present 
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broader public health issues in terms of dissemination of resistant virus 
throughout at-risk populations. Consequently, provision of ARV rectal 
microbicides will require extensive voluntary counseling and testing for HIV 
infection as well as ongoing surveillance of individuals using these products. 
These issues may limit the social desirability of these products unless there 
is a carefully orchestrated public health campaign that targets rectal 
microbicides to those individuals who could gain the most to benefit from 
their use. Characterizing this population will be challenging but necessary to 
focus limited prevention resources to individuals who really need rectal 
microbicides. Parameters may include a history of frequent unprotected RAI 
and perhaps anorectal STIs. Such individuals may also benefit from using 
both oral and topical PrEP. Ongoing Phase 1 rectal microbicides studies will 
hopefully provide data on the pharmacological consequences of using both 
oral and topical PrEP as well as preliminary data on the relative efficacy of 
single or dual therapy using ex vivo explant challenge studies (Elliott et al., 
2009). Successful roll out of rectal microbicides will also probably require 
focused marketing and the development of more user friendly delivery 
devices.  
8.5.8 Advocacy for rectal microbicides 
The increasing momentum of rectal microbicide development is encouraging 
and has been driven to a large extent by community advocacy as well as by 
the reality of the US HIV epidemic that is now clearly concentrated in young 
ethnic minority MSM (Sifakis et al., 2007; Sifakis et al., 2010). The efforts of 
groups such as the International Rectal Microbicide Advocates (IRMA) have 
played a key role in educating the community about advances in RM 
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development. IRMA is composed of a diverse group of community 
advocates, clinicians, sponsors, and scientists working on rectal 
microbicides. Through their website (http://www.rectalmicrobicides.org), 
frequent interactive teleconferences, and satellite conferences, IRMA plays a 
critical role in maintaining momentum in rectal microbicide research. Marc-
André LeBlanc and Jim Pickett, both members of IRMA, have recently 
published a chapter on community engagement in rectal microbicide 
development which provides a comprehensive account of the productive 
engagement between community activists and research scientists in the 
development of rectal microbicides (André LeBlanc and Jim Pickett, 2014). 
8.6 Conclusions 
HIV infection associated with URAI remains a significant public health issue 
in both the developed and developing world. Recent studies have 
demonstrated the effectiveness of oral PrEP in serodiscordant couples, 
MSM, heterosexuals at high risk of HIV infection, and most recently in 
injecting drug users. In the majority of studies adherence levels were less 
than 100% and in many cases significantly less than 100% suggesting that 
there is still a need to develop alternative HIV prevention strategies including 
rectal microbicides.  
 
Proof of concept that rectal microbicides are a viable strategy comes from 
NHP studies documenting that ARV gels can provide high levels of 
protection in the SIV/SHIV challenge model as well as in vitro and ex vivo 
colorectal explant challenge studies that have also demonstrated significant 
inhibition of HIV infection in explant tissue. TFV gel has advanced from 
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preclinical evaluation to Phase 2 assessment and is poised to enter a Phase 
3 effectiveness study. 
 
The design of Phase 1 rectal microbicide studies has evolved to allow 
integration of safety, acceptability, PK, and PD assessments in parallel 
which provides the most efficient mechanism to undertake early clinical 
evaluation of candidate microbicides. The microarray data from MTN-007 
are intriguing and will require further evaluation in future studies. However, it 
is clear that mucosal safety assessments in Phase 1 microbicide studies 
need to adopt a more holistic approach and include transcriptomic and 
proteomic evaluation of tissue samples. 
 
Despite these advances, significant challenges remain. The VOICE study 
was unable to demonstrate effectiveness of daily TFV gel in protecting 
women from HIV infection. The FACTS-01 study of a peri-coital TFV regimen 
is currently ongoing. If this study also fails to demonstrate the effectiveness 
of TFV gel it is uncertain whether funders will be willing to undertake further 
studies of a TFV gel. It is unclear whether participants will be willing to use 
TFV gel on a daily basis, whether this is necessary, and whether daily use of 
a TFV gel may lead to significant changes in mucosal function. Many of 
these questions will be addressed in the MTN-017 Phase 2 study but the 
outcome of this study is far from certain.  
 
Building upon the experience of the VOICE study, the MTN-017 will now use 
“real-time” PK monitoring to try and improve participant adherence to study 
315 
 
products. Participants will be counseled that the study is monitoring drug 
levels in their blood and they will receive PK data every four weeks as part of 
a scheduled interview. Hopefully this approach will lead to better product 
adherence and generation of data that will support progression to a Phase 3 
effectiveness study. 
 
To quote the late Senator Edward Kennedy, “The work goes on, the cause 
endures, the hope still lives, and the dream shall never die.” Certainly, the 
need for effective interventions to prevent HIV infection, including rectal 
microbicides, is greater than ever.   
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9.1 Appendix 1: DAIDS rectal toxicity table 
Addendum 3 Rectal Grading Table for Use in Microbicide Studies 
Clarification dated May 2012. 
PARAMETER GRADE 1
Mild 
GRADE 2
Moderate 
GRADE 3
Severe 
GRADE 4
Potentially 
Life- 
threatening 
Anal         
Bruising (in 
absence of 
thrombocytopenia) 
≤ 25% of 
perianal 
tissue 
> 25% of 
perianal 
tissue 
NA NA 
Hemorrhoids No symptoms 
or symptoms 
not requiring 
medical 
intervention 
Symptomatic 
with medical 
intervention 
indicated 
Symptoms 
causing inability 
to perform usual 
social & 
functional 
activities with 
surgical 
intervention 
indicated 
NA 
Anorectal pruritus Itching 
localized AND 
relieved 
spontaneously 
or with ≤ 48 
hours 
treatment 
Itching 
requiring > 
48 hours 
treatment 
Symptoms 
causing 
inability to 
perform usual 
social & 
functional 
activities 
NA 
Anal edema ≤25% of 
perianal 
tissue with 
edema
>25% of 
perianal 
tissue w/ 
edema
NA NA 
Anal erythema ≤25% of 
perianal 
tissue with 
erythema 
>25% of 
perianal 
tissue 
erythema 
NA NA 
Epithelial 
disruption, NOS 
(e.g. abrasions) 
≤25% of 
circumference 
small 
superficial 
disruptions 
>25% of 
circumference 
small 
superficial 
disruptions 
Symptoms 
causing inability 
to perform usual 
social & 
functional 
activities 
NA 
Anal fissure Superficial 
fissure 
Deep fissure Symptoms 
causing inability 
to perform usual 
social & 
functional 
activities 
NA 
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PARAMETER GRADE 1 GRADE 2 GRADE 3 GRADE 4 
Incontinence NA Incontinence 
with or without 
the need for 
medical 
treatment or 
use of a pad 
Symptoms 
causing inability 
to perform usual 
social & 
functional 
activities, 
operative 
intervention 
indicated
Bowel 
diversion 
indicated 
External anal 
condyloma 
(new onset or 
increased 
size/extent) 
New lesions 
covering ≤25% 
of perianal 
tissue 
New lesions 
covering >25 
of perianal 
tissue 
Lesions  causing 
obstruction with 
surgical 
intervention 
indicated 
NA 
Internal anal 
condyloma 
(new onset or 
increased 
size/extent) 
New lesions 
covering ≤25% 
of 
circumference 
New lesions 
covering >25% 
of 
circumference 
Lesions  causing 
obstruction with 
surgical 
intervention 
indicated 
NA 
Anal intraepithelial 
neoplasia (by 
biopsy) 
AIN1 AIN2 AIN3/CIS Anal 
squamous 
carcinoma 
Anal cytology 
(when anal biopsy 
not available) 
ASCUS/LSIL HSIL CIS Anal 
squamous 
carcinoma 
Colorectal         
Colitis, confirmed No symptoms, 
regardless of 
pathologic or 
radiographic 
evidence of 
inflammation 
Abdominal 
pain; 
mucus or 
blood in stool 
Abdominal pain, 
fever, 
change in bowel 
habits with ileus; 
peritoneal signs 
Life 
threatening 
consequences 
(e.g., 
perforation, 
bleeding, 
ischemia, 
necrosis, toxic 
megacolon) 
Constipation Occasional or 
intermittent 
symptoms, 
occasional use 
of stool 
softeners, 
laxatives, 
dietary 
modifications, 
or enema 
Persistent 
symptoms with 
regular use of 
laxatives or 
enemas 
indicated 
Symptoms 
causing 
inability to 
perform usual 
social & 
functional 
activities 
Life 
threatening 
consequences 
(e.g., 
obstruction, 
toxic 
megacolon) 
Diarrhea Transient or 
intermittent 
episodes of 
unformed 
stools OR 
Increase of ≤ 3 
stools over 
baseline per 
24-hour period 
Persistent 
episodes of 
unformed to 
watery stools 
OR Increase of 
4 – 6 stools 
over baseline 
per 24-hour 
period 
Bloody diarrhea 
OR Increase of 
≥ 7 stools per 
24-hour period 
OR IV fluid 
replacement 
indicated 
Life-
threatening 
consequences 
(e.g., 
hypotensive 
shock) 
PARAMETER GRADE 1
 
GRADE 2
 
GRADE 3
 
GRADE 4
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Discharge Visible 
discharge 
Discharge 
requiring 
the use of 
pads 
NA NA 
Distension or 
bloating 
Symptoms 
causing no 
or minimal 
interference 
with usual 
social & 
functional 
activities 
Symptoms 
causing 
greater than 
minimal 
interference 
with usual 
social & 
functional 
activities 
Symptoms 
causing 
inability to 
perform usual 
social & 
functional 
activities 
NA 
Flatulence Symptoms 
causing no 
or minimal 
interference 
with usual 
social & 
functional 
activities 
Symptoms 
causing 
greater than 
minimal 
interference 
with usual 
social & 
functional 
activities 
NA NA 
Urgency +/- 
incontinence 
Symptoms 
causing no 
or minimal 
interference 
with usual 
social & 
functional 
activities 
Symptoms 
causing 
greater than 
minimal 
interference 
with usual 
social & 
functional 
activities 
Symptoms 
causing 
inability to 
perform usual 
social & 
functional 
activities 
NA 
Hematochezia 
(rectal 
bleeding) 
Mild-
intermittent 
without 
transfusion 
Persistent 
without 
transfusion 
Requiring 
transfusion 
Life-
threatening 
consequences 
Endoscopic 
colorectal 
mucosal 
abnormality 
Minimal small 
superficial 
disruptions of 
the mucosa 
Moderate 
superficial 
and/or 
scattered deep 
disruption(s) of 
the mucosa 
Severe 
extensive deep 
disruption(s) of 
the mucosa 
NA 
Tenesmus Symptoms 
causing no 
or minimal 
interference 
with usual 
social & 
functional 
activities 
Symptoms 
causing 
greater than 
minimal 
interference 
with usual 
social & 
functional 
activities 
Symptoms 
causing 
inability to 
perform usual 
social & 
functional 
activities 
NA 
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PARAMETER GRADE 1
 
GRADE 2
 
GRADE 3
 
GRADE 4 
Proctalgia Symptoms 
causing no 
or minimal 
interference 
with usual 
social & 
functional 
activities 
Symptoms 
causing 
greater than 
minimal 
interference 
with usual 
social & 
functional 
activities 
Symptoms 
causing 
inability to 
perform usual 
social & 
functional 
activities and/or 
fecal 
incontinence 
NA 
Painful defecation Symptoms 
causing no 
or minimal 
interference 
with usual 
social & 
functional 
activities 
Symptoms 
causing 
greater than 
minimal 
interference 
with usual 
social & 
functional 
activities 
Symptoms 
causing 
inability to 
perform usual 
social & 
functional 
activities 
NA 
Perforation, 
colon/rectum 
NA NA Medical/surgical 
intervention 
indicated 
Life-
threatening 
consequences 
Other GI Events         
GI Bleed Mild not 
requiring 
intervention 
other than iron 
supplement 
Moderate 
requiring 
endoscopic 
intervention 
Requiring 
transfusion 
Life-
threatening 
consequences 
Melena, confirmed NA No transfusion 
required 
Requiring 
transfusion 
Life-
threatening 
consequences 
Abscess, indicate 
site 
Perianal 
abscess with 
fluctuance 
Abscess that is
draining or 
needs incision 
and drainage 
Abscess that 
requires 
more severe 
surgical 
intervention 
Necrotizing 
fasciitis 
from abscess 
Fistulae, indicate 
site 
Dry fistulae Draining 
fistulae 
Fistulae 
requiring 
medical/surgical 
intervention 
Life-
threatening 
consequences 
Abdominal pain Pain causing 
no or 
minimal 
interference 
with usual 
social & or 
functional 
activities 
Pain causing 
greater 
than minimal 
interference 
with usual 
social & or 
functional 
activities 
Pain causing 
inability to 
perform usual 
social & or 
functional 
activities 
Disabling pain 
causing 
inability to 
perform basic 
self-care OR 
Hospitalization 
(other than 
emergency 
room visit) 
indicated 
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PARAMETER GRADE 1 GRADE 2 GRADE 3 GRADE 4 
STIs         
HSV Present but no 
treatment 
required 
Treatment 
required 
Complicated 
disease 
requiring 
medical/surgical 
intervention 
NA 
Chlamydia NA Treatment 
required 
Complicated 
disease 
requiring 
medical/surgical 
intervention 
NA 
Syphilis NA Treatment 
required 
Complicated 
disease 
requiring 
medical/surgical 
intervention 
NA 
Gonorrhea NA Treatment 
required 
Complicated 
disease 
requiring 
medical/surgical 
intervention 
NA 
Lymphogranuloma 
venereum 
NA Treatment 
required 
Complicated 
disease 
requiring 
medical/surgical 
intervention 
NA 
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the study. Suggestive evidence of differences was seen in histology, mucosal gene expression, protein expression, and T cell
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Conclusions: The reduced glycerin formulation of tenofovir 1% gel was safe and well tolerated rectally and should be
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Introduction
Rectal microbicides (RM) are currently being developed to
prevent or at least significantly reduce the risk of HIV acquisition
associated with unprotected receptive anal intercourse (RAI) [1].
RAI is a common sexual practice among men who have sex with
men (MSM) [2]. Recent epidemiological data have suggested that
RAI is also common among men and women in the developed and
developing world [3–6]. As a consequence there is an urgent need
to develop a safe and effective RM. Attention is currently focused
on the development of tenofovir (TFV) gel as a potential RM. The
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vaginal formulation of TFV that was used in the CAPRISA 004
study [7] has been evaluated in a Phase 1 rectal safety study
(RMP-02/MTN-006) [8]. Use of the gel was associated with mild
to moderate gastrointestinal symptoms including bloating, pain,
urgency, and diarrhea. The vaginal formulation of TFV is
hyperosmolar (3111 mOsmol/kg) and it is possible that these
symptoms were linked to product osmolality [9]. Consequently,
the TFV used in the MTN-007 study was formulated with a lower
glycerin concentration (5% w/w mg rather than the 20% w/w in
the vaginal formulation) that results in a product osmolality of 836
mOsmol/kg [10]. It was anticipated this formulation would be
better tolerated by study participants.
In the two phase 1 trials of antiretroviral rectal microbicides
conducted to date, product use was not associated with any
significant change in mucosal safety parameters [8,11]. Whilst this
is reassuring, the possibility exists that the range of parameters
used in these studies was too narrow and might have missed
unanticipated or subtle but important mucosal changes. To
mitigate this situation, the MTN-007 study included microarray
assessment of mucosal gene expression. In addition, a nonoxynol-9
(N-9) arm was included to help determine the utility of individual
mucosal safety assays in detecting mucosal injury. Rectal use of N-
9 in humans has been associated with transient mild gastrointes-
tinal discomfort as well as minor histological abnormality [12] and
has been associated with induction of proinflammatory responses
in cervical epithelial cells [13]. It was hoped that these additional
assessments would help provide a more comprehensive assessment
of mucosal safety.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics Statement
The study was designed by the investigators with collaborative
input from CONRAD and the NIAID/DAIDS/Prevention
Sciences Integrated Preclinical-Clinical Program (IPCP) for HIV
Topical Microbicides, as stipulated in the award notice and
reviewed by the U.S. Food and Drug Administration (FDA). The
study was approved by the University of Pittsburgh Institutional
Review Board (IRB) as well as the University of Alabama IRB and
the Fenway Health IRB. All subjects provided written informed
consent. The trial is registered at ClinicalTrials.gov, number
#NCT01232803 and is in compliance with the CONSORT 2010
recommendations for reporting of trial results (www.consort-
statement.org) [14,15].
Study Schema
The primary objective of MTN-007 was to evaluate the safety of
TFV gel when applied rectally. Secondary objectives included
evaluation of the acceptability of TFV gel, the safety of the
hydroxyethyl cellulose (HEC) placebo gel, and determining
whether the use of either TFV or N-9 gels was associated with
rectal mucosal damage. MTN-007 was a Phase 1, double blind,
placebo-controlled trial in which participants were randomized to
receive rectal TFV, N-9, HEC gels or No Rx (1:1:1:1) at three
clinical sites (Pittsburgh, PA; Birmingham, AL; and Boston, MA).
The study protocol was approved by IRBs at all three sites and
informed consent was received from all participants. Enrollment
began in October 2010 and the last participant completed the
study in July 2011. The target sample size is 60, equally split to 15
in each arm, which ensures a 79% probability to observe at least
one Grade 2 or higher adverse event in an arm when the true
event rate is 10%. Five additional enrollees were recruited to
preserve the study power in the case of participants using less than
5 doses in the 7-day dosing period or fail to complete the final
clinical visit. A blinded statistician from The Statistical Center for
HIV/AIDS Research & Prevention (SCHARP), University of
Washington, Seattle, WAS, USA created lists containing randomly
generated unique three-digit codes for study product randomiza-
tion for each clinical site. Participants, study staff, pharmacists,
clinicians and statisticians were blinded to study assignments.
Study Population
The study population consisted of healthy, RAI-abstinent, HIV-
uninfected, adults (male and female) aged 18 or older at time of
screening. Female participants were required to be using an
acceptable form of contraception (e.g., barrier method, intra
uterine device, hormonal contraception, surgical sterilization, or
vasectomization of the male partner). Individuals with abnormal-
ities of the colorectal mucosa, significant gastrointestinal symptoms
(such as a history of rectal bleeding), evidence of anorectal
Chlamydia trachomatis (CT) or Neisseria gonorrhea (GC) infection,
chronic hepatitis B infection, or a requirement to use drugs that
were likely to increase the risk of bleeding following mucosal
biopsy were excluded from the study.
Study Products
Reduced glycerin (RG)-TFV 1% gel was supplied by CON-
RAD (Arlington, VA, USA). 2% N-9 was provided as Gynol IIH
(Johnson & Johnson, Fort Washington, PA). HEC gel, known as
the ‘‘Universal Placebo Gel’’ [16], and used in a previous Phase 1
rectal safety study of the UC781 gel [11], was also supplied by
CONRAD (Arlington, VA, USA). Each participant was assigned a
carton of applicators, based on the randomization number. At the
Treatment 1 Visit the participant’s first dose of study product was
administered by the clinic staff. During the period of daily
administration study participants were instructed to insert one
dose of gel into the rectum once daily throughout the 7-day period.
Rectal administration of study product occurred in the evening or
before the longest period of rest. All study products were provided
in identical opaque HTI polypropylene pre-filled applicators (HTI
Plastics, Lincoln, NE) containing 4 mL of study product.
Study Procedures
There were a total of five study visits and two follow-up phone
calls. After obtaining informed consent all participants were
screened with a thorough medical history, a targeted physical
examination, a digital rectal examination, and collection of swabs
for CT/GC nucleic acid amplification testing (NAAT). Urine was
also collected for CT/GC NAAT and for pregnancy testing in the
female participants (pregnancy testing was repeated at all
subsequent clinical visits). Blood was collected for safety labs
(complete blood count, urea nitrogen, creatinine, alanine amino-
transferase, and aspartate aminotransferase) and serology (syphilis,
HIV-1, hepatitis B, and herpes simplex 1 and 2). Participants who
met the inclusion and exclusion criteria during the Screening Visit
proceeded to an Enrollment Visit. At the Enrollment Visit
participants were randomized, a behavioral questionnaire was
administered and a rectal examination and a focused physical
examination were performed. Swabs were collected for assessment
of rectal microflora and quantification of cytokines/chemokines in
rectal secretions. Participants then received a Normosol-R pH 7.4
enema and effluent was collected for evidence of epithelial
sloughing and a sample of feces collected for measurement of
fecal calprotectin. A flexible sigmoidoscope was then inserted into
MTN-007 Phase 1 Study
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the rectum and 7 biopsies were collected at 15 cm from the anal
margin. A disposable anoscope was inserted into the anal canal
and high resolution anoscopy (HRA) of the anorectum was
performed at 166magnification with collection of 7 rectal biopsies
at 9 cm from the anal margin. Biopsies were used for histology,
qRT-PCR, microarray analysis, and flow cytometry. At the
Treatment 1 Visit (performed within 7–28 days of the Enrollment
visit), all participants randomized to receive gel product had a
single applicator of study gel inserted into the rectum. Within 30
minutes, swabs were collected for microflora and cytokines. An
enema was administered and the same rectal samples, including
biopsies, were collected as occurred during the Enrollment Visit.
At the Treatment 2 Visit (performed at least 7 days after
Treatment Visit 1) participants randomized to receive gel product
were provided with 7 applicators of study product to take home
and asked to insert the contents of one applicator daily for 7 days.
The Final Clinic Visit occurred no more than 21 days after
Treatment Visit 2 and was identical to the Enrollment Visit except
that anogenital testing (CT/GC) was only performed if clinically
indicated.
Clinical Safety and Laboratory Assessments
Emergent adverse events (AEs) were graded using the Division
of AIDS Table for Grading the Severity of Adult and Pediatric
Adverse Events, Version 1.0, December 2004 as well as
Addendum 1 and 3 (Female Genital and Rectal Grading Table for Use
in Microbicide Studies (http://rsc.tech-res.com/
safetyandpharmacovigilance/). In cases where an AE was covered
in both tables, the Female Genital or Rectal Grading Table for Use in
Microbicide Studies was the grading scale utilized.
Product Acceptability
Overall product like (or dislike) and likelihood of gel use in the
future were assessed using an internet based computer assisted self-
interview (CASI). To monitor adherence, participants were asked
to use a phone reporting system after each episode of gel use.
Mucosal Safety
Histology. A qualitative scoring system developed for inflam-
matory bowel disease (IBD) research [17] and adapted for use in
rectal microbicide trials [18] was used to characterize potential
product associated injury with a scale of 1 (normal) to 5 (mucosal
erosion or ulceration).
Fecal calprotectin. Fecal calprotectin was measured using a
commercial assay (Genova Diagnostics, Asheville, NC, USA) [19].
Epithelial sloughing. Epithelial sloughing was evaluated
using a modification of a previously described technique [20].
Briefly, lavage fluid, collected following the Normosol enema was
spun at 1000 rpm for 5 minutes. The cell pellet was resuspended
in 1 mL of 2% paraformaldehyde. The suspension was placed in a
petri dish that had previously been marked with quadrants. Each
quadrant of the petri dish was scanned with a dissecting
microscope at a magnification of 406. The total number of
.2 mm epithelial sheets in each quadrant of the petri dish were
recorded.
Rectal microflora. Rectal microflora were characterized
using previously described semi-quantitative culture analysis
techniques [21,22] that have been used in other rectal microbicide
Phase 1 studies [8,11].
Mucosal T cell phenotype. Mucosal mononuclear cells were
isolated from rectal biopsies using a combination of mechanical
and enzyme digestion as previously described [11]. Flow
cytometric analysis was performed on a BDTM LSRFortessa
cytometer (BD Biosciences, San Jose, CA). All data were stored in
list mode and analyzed with BDTM FACSDIVA operating system
and Flow Jo (Tree Star, Inc., Ashland, OR). All antibodies were
purchased from BD Biosciences, San Jose, CA (PerCP-CD45,
Clone 2D1; Pacific Blue-CD3, Clone UCHT1; PE-Cy7-CD4,
Clone SK3; APC-H7-CD8, Clone SK1; FITC-CD69, Clone
FN50; APC-CD184 (CXCR4), Clone 12G5 and PE-CD195
(CCR5)) and titrated under assay conditions to determine an
optimum saturating dilution. Cells were first stained with LIVE/
DEADH Fixable Aqua stain fluorescence (Life Technologies,
Eugene, OR).
Cytokine and chemokine mRNA expression. Rectal
biopsies were homogenized in the presence of 0.5 mm RNase-
free zirconium beads with the aid of a Bullet Blender homogenizer
(Next Advance Inc., Averil Park, NY). RNA was then purified on
columns using an RNAqueousH-4PCR kit (Applied Biosystems/
Ambion, Foster City, CA). The extracted total RNA was eluted in
a volume of 100 ml and DNase 1- treated. 1000 ng of total RNA
from biopsy samples were converted to cDNA using Multi-
ScribeTM reverse transcriptase and TaqManH Reverse Transcrip-
tion reagents (Applied Biosystems, Roche Molecular Systems, Inc.,
Branchburg, NJ). Oligo dT(20) was used to prime the reverse
transcription (RT) reaction and reactions were run on the Applied
Biosystems VeritiTM Dx Thermal Cycler (Life Technologies
Corporation, Carlsbad, CA). Three reference genes (GAPDH,
b-actin, and b2 Microglobulin b2M) were used to normalize
mucosal gene expression of CD45, IL-1b, IL-6, IL-12p40, IL-8,
IL-17, IFN-c, MIP-1a, MIP-1b, TNF-a, IL23, CCR5 and
RANTES (Table S1). All qRT-PCR experiments were performed
on a Bio-Rad CFX96 Real Time PCR System (Bio-Rad,
Hercules, CA).
Luminex analysis of rectal secretions. LuminexH was
used to measure IFN-c, IL-1b, IL-6, IL-8, IL-12 (p40), IL-17,
MIP-1a, MIP-1b, RANTES and TNF-a in rectal secretions
(MILLIPLEX MAP kit; Millipore, Billerica, MA).
Microarray analysis. RNA was extracted from colorectal
biopsies taken from 32 male study participants (8 men per study
arm, including the no-treatment arm) using the RNeasy Mini Kit
(Qiagen, Valencia, CA). 200 ng of total RNA was amplified and
labeled using the Illumina TotalPrep RNA Amplification kit
(Ambion, Grand Island NY). cRNA was hybridized to Hu-
manHT12 v4 Expression BeadChips (Illumina Inc., San Diego,
CA).
Analysis of Outcomes
Adverse events were evaluated for the full study cohort that
included all participants that were randomized into the study. All
adverse events were classified using the MedDRA organ system
class/preferred term. The proportion of participants having at
least one AE event was compared across arms using the Chi
Square test or Fisher’s exact test when counts are small. Product
acceptability was determined through a CASI interview and was
operationalized as intentionality of product use with RAI having a
rating in the upper one third of a 10-point Likert scale (values of 7–
10). Histology, fecal calprotectin, epithelial sloughing, rectal
microflora, and mucosal biomarkers were summarized for each
arm by mean and standard deviation among participants who
completed at least 5 doses of gels during the 7-day product use
period and completed the Final Clinic Visit. Using linear
regression, pairwise group comparisons were conducted across
groups after adjustment for baseline variability for biomarkers
measured after the single-dose use and for the 7-day use,
separately. Multiple testing in mucosal biomarkers was adjusted
for by using Bonferroni correction to control family wise error
rate, as well as using the Benjamini-Hochberg procedure to
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control false discovery rate (FDR) [23]. Microarray data were pre-
processed using robust spline normalization and variance stabiliz-
ing transformation. Unexpressed or low variability probes were
filtered out, leaving 1928 probes for analysis of treatment effects
versus control using a Bayesian statistical framework Cyber-T and
Benjamini-Hochberg false discovery rate (FDR) significance
adjustment [23]. Criteria for significance and relevance were an
FDR #0.05 and a log2 fold expression change of $0.5 (up-
regulation) or #0.5 (down-regulation), respectively.
Results
Enrollment, Retention, and Participant Disposition
A total of 65 participants were enrolled and randomized in the
study (TFV, n=16; N-9, n=17; HEC, n=16; and No Rx, n=16)
(Figure 1). The majority of participants were white males (Table 1).
There is no statistical difference between arms in age distribution
(p-value 0.79, ANOVA test), in gender composition (p-value 0.75,
Fisher’s exact test), nor in the proportion of white participants (p-
value 0.54, Chi-square test). One participant in the N-9 arm
withdrew from further participation after the enrollment visit
(before receiving any study product), due to an unrelated adverse
event. After completing their single-dose exposure, two partici-
pants did not receive products for the 7-day exposure. One
participant in the HEC group had major depression, was placed
on product hold, and was subsequently removed from the study.
The other participant in the TFV arm missed the Treatment Visit
2. Averaged across all study visits, the proportion of participants
who completed expected visits was 95% or above for all four study
arms.
Adherence and Acceptability
Among 46 participants who received products for the 7-day use
of gel, two participants had at least one product hold but later
resumed product use; one was due to moderate elbow cellulitis
after the Treatment visit 1 (N-9) and the other was due to
prohibited medication. Accounting for these product holds, only 1
participant in the N-9 arm reported using less than 80% of the
assigned doses between the Treatment Visit 2 and Final visit
(Table S2). Among 46 participants who were assigned to use gel
and completed the acceptability question, reported likelihood of
future product use (acceptability) was 93% (HEC), 87% (TFV,
Fisher exact test p-value = 1.0 when compared to the HEC group),
and 63% (N-9, Fisher exact test p-value = 0.08 when compared to
the HEC group).
Adverse Events
Adverse events were generally mild (Grade 1, N=121, 80% of
all AEs) or moderate (Grade 2, N= 27, 18% of all AEs). Two
Grade 3 events occurred in the No Rx arm and one Grade 4
psychiatric event (the major depression episode mentioned above)
occurred in the HEC arm prior to 7-day product use; all Grade 3
and 4 AEs were unrelated to product. Gastrointestinal adverse
events were common but the vast majority were mild (Table 2).
There were no significant differences in the proportion of
participants with $ Grade 2 or higher adverse events across the
arms of the study: 3/16 (19%) in the TFV arm, 7/17 (41%) in the
N-9 arm, 5/16 (31%) in the HEC arm, and 6/16 (38%) in the No
Rx arm; when compared to the No Rx arm, one sided Fisher exact
test yielded p-value 0.94 for the TFV arm, 0.56 for the N-9 arm,
and 0.77 for the HEC arm.
Mucosal Safety
Histology, fecal calprotectin, and epithelial
sloughing. There was suggestive evidence of increase in the
histology scores for the N-9 and HEC arms compared to the TFV
arm at the 9 cm site at the Final Visit (Table 3). In contrast, there
were no significant differences between the fecal calprotectin levels
or epithelial sloughing scores (data not shown).
Rectal microflora. There were no significant changes in
rectal microflora between the Baseline and Final Visits in any of
the gel arms (data not shown).
Mucosal T cell phenotype, cytokine and chemokine
mRNA expression, and Luminex analysis of rectal
secretions. Forty-five participants who completed more than
5 doses during the 7-day product use period as well as fifteen
Figure 1. Flow diagram of participant progress through the MTN-007 study.
doi:10.1371/journal.pone.0060147.g001
MTN-007 Phase 1 Study
PLOS ONE | www.plosone.org 4 April 2013 | Volume 8 | Issue 4 | e60147
participants in the No Rx arm who completed the Final Clinic
Visit were included in these biomarker analyses. Table 3 shows
biomarkers that have pairwise comparison nominal p-values less
than 0.05. Only two tests remain significant after Bonferroni
multiple testing correction (the comparisons of N-9 versus TFV for
IL-6 and IL-8 gene expression after the single-dose treatment).
Eight more comparisons meet the more lenient false discovery rate
cut-off 0.1 using the Benjamini-Hochberg procedure. The
Table 1. Baseline demographics of each treatment group.
All Arms Tenofovir Gel N-9 Gel HEC Placebo Gel No Treatment
Participants Enrolled 65 16 17 16 16
Age (Years) Mean (STD) 35.7 (11.0) 35.3 (8.7) 37.0 (9.9) 36.8 (12.6) 33.5 (13.0)
p-value 0.79
Gender Male 45 (69%) 10 (63%) 13 (76%) 12 (75%) 10 (63%)
Female 20 (31%) 6 (38%) 4 (24%) 4 (25%) 6 (38%)
p-value 0.75
Race White 44 (68%) 10 (63%) 13 (76%) 9 (56%) 12 (75%)
Non-white 21 (32%) 6 (37%) 4 (24%) 7 (44%) 4 (25%)
p-value 0.54
HEC, hydroxyethyl cellulose; N-9, Nonoxynol-9.
doi:10.1371/journal.pone.0060147.t001
Table 2. Participants reporting adverse events by study arm.
All Arms Tenofovir Gel N-9 Gel HEC Placebo Gel No Treatment
Participants enrolled 65 16 17 16 16
Total number of AEs 151 32 51 34 34
Grade 1 (Mild) 121 (80.1%) 29 (90.6%) 44 (86.3%) 26 (76.5%) 22 (64.7%)
Grade 2 (Moderate) 27 (17.9%) 3 (9.4%) 7 (13.7%) 7 (20.6%) 10 (29.4%)
Grade 3 (Severe) 2 (1.3%) 0 0 0 2 (5.9%)
Grade 4 (Potentially life-threatening)* 1 (0.7%) 0 0 1 (2.9%) 0
Grade 5 (Death) 0 0 0 0 0
Participants with one or more AEs
Grade 1 (Mild) 30 (46.2%) 7 (43.8%) 10 (58.8%) 7 (43.8%) 6 (37.5%)
Grade 2 (Moderate) 18 (27.7%) 3 (18.8%) 7 (41.2%) 4 (25.0%) 4 (25.0%)
Grade 3 (Severe) 2 (3.1%) 0 0 0 2 (12.5%)
Grade 4 (Potentially life-threatening) 1 (1.5%) 0 0 1 (6.3%) 0
Grade 5 (Death) 0 0 0 0 0
Participants with gastrointestinal AEs
Abdominal distension (G1/G2) 5 (7.7%) 1 (6.3%) 2 (11.8%) 2 (12.5%) 0
Abdominal pain (G1) 3 (4.6%) 1 (6.3%) 0 1 (6.3%) 1 (6.3%)
Anal pruritus (G1) 3 (4.6%) 1 (6.3%) 1 (5.9%) 1 (6.3%) 0
Defecation urgency (G1) 6 (9.2%) 0 5 (29.4%) 1 (6.3%) 0
Diarrhea (G1/G2/G3**) 9 (13.8%) 1 (6.3%) 4 (23.5%) 1 (6.3%) 3 (18.8%)
Flatulence (G1/G2) 13 (20%) 6 (37.5%) 2 (11.8%) 2 (12.5%) 3 (18.8%)
Haematochezia (G1) 1 (1.5%) 0 0 1 (6.3%) 0
Haemorrhoids (G1) 2 (3.1%) 0 1 (5.9%) 1 (6.3%) 0
Intestinal polyp (G1) 1 (1.5%) 0 0 0 1 (6.3%)
Painful defecation (G1) 2 (3.1%) 0 2 (11.8%) 0 0
Proctalgia (G1) 3 (4.6%) 1 (6.3%) 2 (11.8%) 0 0
Proctitis (G1) 1 (1.5%) 0 1 (5.9%) 0 0
Rectal polyp (G1) 3 (4.6%) 1 (6.3%) 1 (5.9%) 0 1 (6.3%)
HEC, hydroxyethyl cellulose; N-9, Nonoxynol-9; AEs, adverse events, *Grade 4 event was a participant who experienced a psychiatric AE (major depression) that occurred
prior to 7-day product use **Grade 3 diarrhea occurred in 1 participant in the No Treatment arm.
doi:10.1371/journal.pone.0060147.t002
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Table 3. Mucosal immunology assays with suggestive evidence of changes with nominal pairwise comparison p-value less than
0.05.
Tenofovir
Gel (T)
N-9 Gel
(N9)
HEC Placebo
Gel (H)
No Treatment
(N) p-Value
Participants analyzed 15 15 15 15
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Histology score
at 9 cm
Enrollment 0.7 (0.5) 1.0 (0.0) 1.1 (0.6) 0.9 (0.4)
Treatment 1 1.1 (0.6) 1.1 (0.7) 1.4 (0.8) 1.5 (1.0)
Final visit 0.7 (0.5) 1.8 (1.2) 1.1 (0.6) 1.4 (0.6) T:N9, 0.01, N9:H, 0.03
Flow cytometry
at 9 cm
Final Visit
CD45/CD3 (%) 51.7 (19.3) 48.5 (17.4) 41.0 (15.9) 57.7 (14.8) N9:H, 5.723
CD3/CD4 (%) 60.5 (9.0) 60.5 (7.9) 53.8 (10.8) 50.1 (11.1) N9:H, 0.04; N9:N, 0.01
CD4/CXCR4 (%) 48.0 (20.4) 59.6 (20.8) 49.4 (25.6) 38.2 (25.7) N9:N, 0.02
CD3/CD8 (%) 27.4 (8.6) 27.5 (7.6) 31.2 (8.6) 37.3 (10.4) N9:N, 1.623ˆ
CD8/CD69 (%) 71.3 (14.1) 69.5 (8.8) 75.0 (12.8) 83.4 (9.8) N9:N, 0.02
Flow cytometry
at 15 cm
Treatment 1
CD8/CD69 (%) 81.8 (9.1) 80.5 (14.3) 82.5 (11.5) 89.0 (5.4) T:N, 0.02
Final visit
CD45/CD3 (%) 57.3 (10.6) 47.2 (16.0) 42.8 (15.5) 50.8 (18.9) T:H, 0.04
CD3/CD8 (%) 31.2 (8.5) 32.8 (10.8) 30.3 (8.7) 36.5 (12.8) N9:N, 0.04
CD8/CCR5 (%) 90.0 (6.0) 84.7 (8.7) 80.3 (15.4) 80.8 (10.7) T:N, 0.01
qRT-PCR+ at 9 cm
Treatment 1
IL-1b 22.9 (0.6) 22.2 (0.8) 22.9 (0.8) 23.2 (0.6) N9:H, 6.824ˆ; N9:N,1.323ˆ
IL-6 24.2 (0.7) 23.1 (0.6) 24.0 (0.8) 24.3 (1.1) N9:T, 1.325*ˆ; N9:H, 3.024ˆ; N9:N,
4.323
TNF-a 23.3 (0.9) 22.8 (0.7) 23.5 (0.9) 23.8 (0.5) N9:H, 0.01; N9:N, 2.823
IL-8 23.0 (0.7) 22.1 (0.9) 23.0 (0.8) 23.2 (0.7) N9:T, 4.225*ˆ; N9:H, 2.824ˆ; N9:N,
4.923
MIP-1a 23.4 (0.7) 22.8 (0.7) 23.5 (0.8) 23.7 (0.6) N9:T, 2.724ˆ; N9:H, 2.523; N9:N,
2.623
MIP-1b 22.9 (0.8) 22.5 (0.7) 23.0 (0.8) 23.3 (0.5) N9:T, 1.823ˆ; N9:H, 7.423; N9:N,
8.023
IL-12p40 24.9 (0.8) 24.4 (0.8) 25.0 (1.0) 25.2 (0.7) N9:N, 0.02
IL-23 24.4 (1.1) 23.6 (1.0) 23.9 (0.7) 24.6 (0.9) N9:H, 0.02; N9:N, 0.01
CCR5 24.6 (0.8) 23.9 (0.6) 24.1 (0.6) 24.6 (0.7) N9:H, 0.03; N9:N, 6.023
Final visit
RANTES 22.7 (0.9) 22.5 (0.8) 22.4 (0.5) 22.6 (0.7) N9:T, 0.02; N9:H, 0.03; N9:N, 0.02
IL-17 24.9 (1.0) 24.4 (0.8) 24.5 (0.6) 24.9 (0.8) T:N, 0.02
qRT-PCR+ at 15 cm
Treatment 1
IFN-c 24.6 (0.6) 24.4 (0.8) 24.3 (0.6) 24.7 (0.4) N9:H, 0.04; N9:N, 0.04
RANTES 22.5 (0.9) 22.1 (0.7) 22.2 (0.6) 22.5 (0.6) T:N, 0.01
IL-17 24.8 (0.9) 24.4 (0.9) 24.4 (0.8) 25.2 (0.5) H:N, 0.02
Final visit
IL-6 24.5 (0.7) 24.3 (0.7) 24.0 (0.5) 24.5 (0.7) N9:H, 0.02
MIP-1a 23.4 (0.7) 23.6 (0.7) 23.6 (0.6) 23.9 (0.6) T:N, 0.04
RANTES 22.6 (1.0) 22.2 (0.7) 22.3 (0.5) 22.5 (0.7) N9:T, 0.01
IL-12p40 25.2 (0.9) 24.8 (1.1) 24.9 (0.7) 25.2 (0.6) T:H, 6.323; N9:H, 0.04
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majority of these changes involved upregulation of cytokine/
chemokine expression in the N-9 arm.
Microarray analysis. A single application of N-9 or TFV
up-regulated 24 genes and 70 genes, and down-regulated 30 and 8
genes, respectively. At the Final Visit, N-9 up-regulated 60 and
down-regulated 56 genes, whereas TFV up-regulated 137 and
down-regulated 505 genes (Figure 2). Background fluctuations in
the HEC and no-treatment arms were negligible (manuscript in
preparation).
Gender Specific and Regional Variations in Mucosal
Biomarkers
MTN-007 enrolled 20 women (31% of the study population) all
of whom reported RAI. Suggestive differences in T cell phenotype
(CD8+/CD69+) and mucosal cytokine/chemokine gene expres-
sion (TNF-a and IL-23) were also present when the data were
stratified by gender (manuscript in preparation). Regional
differences were seen in T cell phenotype (CD3+/CD8+,
CD8+/CD69+, CD4+/CD69+, CD4+/CXCR4+) and mucosal
cytokine/chemokine gene expression (IL-1b, IL-6, IL-8, MIP-1a,
MIP-1b, RANTES, IL-12p40, IL-17, and IL-23) between samples
collected at 9 cm and 15 cm (manuscript in preparation).
Discussion
This study demonstrates that the RG formulation of TFV gel is
safe and acceptable when administered for up to seven days in
sexually abstinent participants with a history of RAI. Gastrointes-
tinal AEs such as abdominal pain, rectal urgency, diarrhea, and
flatulence were the most common AEs seen but generally mild or
moderate. The preparatory enema and subsequent flexible
sigmoidoscopy may have contributed to these symptoms. Howev-
er, the overall rates of these symptoms were less than those seen in
the RMP-02/MTN-006 study which evaluated a more hyperos-
molar formulation of TFV gel [8]. Use of TFV gel did not appear
to be associated with mucosal damage as assessed by a broad range
of histological, immunological, and microbiological parameters.
Significant changes in gene expression were identified in the TFV
gel arm using microarray technology. The biological significance
of these changes, and more importantly whether they represent a
mucosal safety signal, is not clear and will require further
evaluation. A recent preclinical study identified intestinal injury
associated with in vitro exposure of colorectal explants to the
hyperosmolar vaginal formulation of TFV [9]. However, similar
histopathological changes were not seen in the TFV gel arm of the
MTN-007 study.
The inclusion of N-9 as a positive control was associated with
evidence of mild mucosal injury but was not associated with
significant changes in epithelial sloughing. Indeed epithelial
sloughing was seen at baseline in several participants. Non-human
primate studies of rectal exposure to N-9 also failed to demonstrate
epithelial sloughing [24]. Fecal calprotectin was also not elevated
Figure 2. Number of genes in rectal biopsies (9 cm) with
significant expression changes between baseline and after 7
days of treatment. The four ellipses represent each of the four
treatment arms, Nonoxynol 9 (N-9) gel, tenofovir (TFV) gel, hydro-
xyethylcellulose (HEC) gel or no gel (No Rx). The numbers of genes
changing expression exclusively in one study arm are indicated in fields
of the diagram that do not overlap with another field (N-9, 93 genes;
TFV, 608 genes; HEC, 11 genes; No Rx 12 genes). When identical genes
changed in more than one treatment arm, their number is placed into
the respective overlapping fields of the diagram. Choice of colors is
arbitrary to help visually distinguish each separate field of the diagram.
cRNA preparation, gene chip hybridization, and data significance
analysis was carried out as described in the Materials and Methods
section of the paper.
doi:10.1371/journal.pone.0060147.g002
Table 3. Cont.
Tenofovir
Gel (T)
N-9 Gel
(N9)
HEC Placebo
Gel (H)
No Treatment
(N) p-Value
IL-23 24.5 (1.1) 24.0 (1.1) 23.9 (0.7) 24.7 (1.0) H:N, 7.523
Luminex assay
Treatment 1
IL-8 164.3 (229.9) 537.3 (421.9) 510.9 (570.9) 303.5 (498.4) N9:T, 0.02
MIP-1a 2.6 (1.1) 4.1 (3.1) 5.0 (5.2) 7.2 (7.7) T:N, 0.03
RANTES 8.3 (10.1) 335.9 (429.1) 12.1 (10.6) 33.1 (74.6) N9:T, 3.623; N9:H, 1.323ˆ; N9:N,
0.01
Final visit
TNF-a 3.0 (4.0) 2.2 (1.9) 2.7 (2.1) 1.4 (1.0) H:N, 0.04
HEC, hydroxyethyl cellulose; N-9, Nonoxynol-9, qRT-PCR, quantitative reverse transcriptase PCR, RANTES; Regulated upon activation normal T cell expressed.
+Data expressed as logarithm (base 10) transformation of the number of copies of gene of interest/the number of copies of b2 microglobulin in the same sample.
*p-values that are significant after controlling for family-wise error rate at 0.05 using Bonferroni correction.
pˆ-values that are significant after controlling for false discovery rate at 0.1 using the Benjamini-Hochberg procedure.
doi:10.1371/journal.pone.0060147.t003
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throughout the study. This assay is useful in discriminating
between irritable bowel syndrome and IBD [19] but appears to
have limited utility in the evaluation of RM. Based on these data,
the MTN will not use these two assays in future Phase 1/2 studies
of candidate RM.
It is unclear whether the changes in mucosal gene expression
assessed by microarray are related to the TFV or its associated
formulation. Future RM studies may answer this question. The
CHARM-01 study (NCT01575405) will explore the impact of
three different TFV formulations on rectal safety and acceptabil-
ity. Each formulation has a different osmolality ranging from 479
to 3111 mOsmol/kg) and the study should be able to evaluate the
impact of osmolality on mucosal safety. The MTN-017 study
(NCT01687218) will be a Phase-2 RM study in which participants
will receive 8 weeks of TFV gel (either daily or with sex) followed
by 8 weeks of oral TruvadaH. This study will provide information
on the consequences of extended exposure to rectal TFV as well as
a crossover comparison of oral and topical exposure to TFV. Both
studies are expected to start in 2013.
Importantly, 31% of the participants in MTN-007 were women;
emphasizing the need for RM for both men and women. We
observed some modest gender specific differences in mucosal
safety biomarkers but a larger study would be required to provide
more definitive data on the impact of gender on the gastrointes-
tinal mucosa. Differences in mucosal safety parameters between
the 9 cm and 15 cm samples were more marked and in keeping
with previous studies demonstrating regional heterogeneity in
colonic mucosal biology [18,25].
This study demonstrated that it is possible to collect adequate
mucosal samples for Phase 1 RM studies via anoscopy. This
observation will potentially simplify the design and execution of
future Phase 1 RM studies although it is difficult to collect more
than 7 rectal biopsies via anoscopy and so studies requiring
collection of rectal samples for mucosal safety, pharmacokinetic,
and pharmacodynamic assessment may still require flexible
sigmoidoscopy.
It is encouraging that the RG formulation of TFV is well
tolerated as the vaginal formulation used in previous studies was
associated with a high frequency of gastrointestinal side effects
when given rectally [8]. This safety profile together with evidence
from the RMP-02/MTN-006 study showing that rectal use of
TFV is associated with ex vivo/in vitro inhibition of HIV-1 viral
replication [8] provides a compelling rationale for progression of
this product into Phase 2 development. Collectively, these data will
determine the longer term safety profile of this product and help
decide whether it is a suitable agent to take into Phase 3
effectiveness studies.
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